

2021 HEDIS Aggregate Report for Michigan Medicaid

October 2021





Table of Contents

Introduction 1-1 Summary of Performance. 1-3 Limitations and Considerations. 1-9 2. How to Get the Most From This Report. 2-1 Introduction 2-1 Michigan Medicaid Health Plan Names. 2-1 Summary of Michigan Medicaid HEDIS MY 2020 Measures. 2-1 Data Collection Methods. 2-4 Data Sources and Measure Audit Results. 2-6 Calculation of Statewide Averages 2-6 Calculation of Statewide Averages 2-6 Introduction 2-12 Measure Results. 2-6 Calculation of Statewide Averages 2-6 Interpreting Results Presented in This Report. 2-12 Measure Changes Between HEDIS MY 2019 MWA and HEDIS MY 2020 2-13 Measure Changes Between HEDIS MY 2019 MWA and HEDIS MY 2020 2-14 Introduction 3-1 Measure-Specific Findings. 3-1 Measure-Specific Findings. 3-1 Measure-Specific Findings 4-1 Murmary of Findings. 5-1 Measure-Specific Findings 5-1 Introduction 5-1 Measure-S	1.	Executive Summary1-1
Limitations and Considerations. 1-9 2. How to Get the Most From This Report. 2-1 Introduction 2-1 Michigan Medicaid Health Plan Names 2-1 Summary of Michigan Medicaid HEDIS MY 2020 Measures. 2-1 Data Collection Methods. 2-4 Data Sources and Measure Audit Results. 2-6 Calculation of Statewide Averages. 2-6 Evaluating Measure Results. 2-6 Measure Changes Between HEDIS MY 2019 MWA and HEDIS MY 2020. 2-13 3. Child & Adolescent Care 3-1 Introduction 3-1 Measure Specific Findings. 3-3 Summary of Findings. 3-4 Measure-Specific Findings. 4-4 Measure-Specific Findings. 4-4 Measure-Specific Findings. 5-4 Momen—Adult Care 4-1 Introduction 5-1 Summary of Findings. 5-1 Measure-Specific Findings. 5-1		Introduction1-1
2. How to Cet the Most From This Report. 2-1 Introduction 2-1 Michigan Medicaid Health Plan Names 2-1 Summary of Michigan Medicaid HEDIS MY 2020 Measures. 2-1 Data Collection Methods. 2-4 Data Sources and Measure Audit Results. 2-6 Calculation of Statewide Averages. 2-6 Evaluating Measure Results. 2-6 Interpreting Results Presented in This Report. 2-12 Measure Changes Between HEDIS MY 2019 MWA and HEDIS MY 2020. 2-13 3. Child & Adolescent Care 3-1 Introduction. 3-1 Summary of Findings. 3-1 Measure-Specific Findings. 3-1 Mutouction. 4-1 Nutroduction. 4-1 Summary of Findings. 4-1 Summary of Findings. 4-3 Summary of Findings. 5-1 Introduction. 5-1 Introduction. 5-1 Summary of Findings. 5-1 Measure-Specific Findings. 5-1 Measure-Specific Findings. 5-1 Measure-Specific Findings. 6-1 M		Summary of Performance1-3
Introduction 2-1 Michigan Medicaid Health Plan Names 2-1 Summary of Michigan Medicaid HEDIS MY 2020 Measures 2-1 Data Collection Methods 2-4 Data Sources and Measure Audit Results 2-6 Calculation of Statewide Averages 2-6 Evaluating Measure Results 2-6 Interpreting Results Presented in This Report. 2-12 Measure Changes Between HEDIS MY 2019 MWA and HEDIS MY 2020 2-13 3. Child & Adolescent Care 3-1 Introduction 3-1 Summary of Findings 3-1 Measure Specific Findings 3-5 4. Women—Adult Care 4-1 Introduction 4-1 Summary of Findings 4-3 5. Access to Care 5-1 Introduction 5-1 Introduction 5-1 Summary of Findings 5-4 6. Obesity 6-1 Introduction 6-1 Summary of Findings 6-1 Introduction 6-1 Neasure-Specific Findings 6-3 7. Pregnancy Care 7-1 <t< th=""><th></th><th>Limitations and Considerations</th></t<>		Limitations and Considerations
Introduction 2-1 Michigan Medicaid Health Plan Names 2-1 Summary of Michigan Medicaid HEDIS MY 2020 Measures 2-1 Data Collection Methods 2-4 Data Sources and Measure Audit Results 2-6 Calculation of Statewide Averages 2-6 Evaluating Measure Results 2-6 Interpreting Results Presented in This Report. 2-12 Measure Changes Between HEDIS MY 2019 MWA and HEDIS MY 2020 2-13 3. Child & Adolescent Care 3-1 Introduction 3-1 Summary of Findings 3-1 Measure Specific Findings 3-5 4. Women—Adult Care 4-1 Introduction 4-1 Summary of Findings 4-3 5. Access to Care 5-1 Introduction 5-1 Introduction 5-1 Summary of Findings 5-4 6. Obesity 6-1 Introduction 6-1 Summary of Findings 6-1 Introduction 6-1 Neasure-Specific Findings 6-3 7. Pregnancy Care 7-1 <t< th=""><th>2.</th><th>How to Get the Most From This Report2-1</th></t<>	2.	How to Get the Most From This Report2-1
Summary of Michigan Medicaid HEDIS MY 2020 Measures. .2-1 Data Collection Methods. .2-4 Data Sources and Measure Audit Results. .2-6 Calculation of Statewide Averages. .2-6 Evaluating Measure Results. .2-6 Interpreting Results Presented in This Report. .2-12 Measure Changes Between HEDIS MY 2019 MWA and HEDIS MY 2020. .2-13 3. Child & Adolescent Care .3-1 Introduction .3-1 Summary of Findings. .3-1 Measure-Specific Findings. .3-5 4. Women—Adult Care .4-1 Introduction .4-1 Summary of Findings. .4-3 5. Access to Care .5-1 Introduction .5-1 Measure-Specific Findings. .5-1 Measure-Specific Findings. .5-4 6. Obesity .6-1 Introduction .5-1 Measure-Specific Findings. .5-4 7. Pregnancy Care. .7-1 Introduction .6-1 Introduction .6-1 Measure-Specific Findings. <th></th> <th></th>		
Summary of Michigan Medicaid HEDIS MY 2020 Measures. .2-1 Data Collection Methods. .2-4 Data Sources and Measure Audit Results. .2-6 Calculation of Statewide Averages. .2-6 Evaluating Measure Results. .2-6 Interpreting Results Presented in This Report. .2-12 Measure Changes Between HEDIS MY 2019 MWA and HEDIS MY 2020. .2-13 3. Child & Adolescent Care .3-1 Introduction .3-1 Summary of Findings. .3-1 Measure-Specific Findings. .3-5 4. Women—Adult Care .4-1 Introduction .4-1 Summary of Findings. .4-3 5. Access to Care .5-1 Introduction .5-1 Measure-Specific Findings. .5-4 6. Obesity .6-1 Introduction .5-1 Measure-Specific Findings. .5-4 8. Living With Illness .7-1 Measure-Specific Findings. .7-1 Measure-Specific Findings. .7-1 Measure-Specific Findings. .7-1 Measure-Specific Findings. .7-1		Michigan Medicaid Health Plan Names2-1
Data Collection Methods. 2-4 Data Sources and Measure Audit Results. 2-6 Calculation of Statewide Averages 2-6 Interpreting Results Presented in This Report. 2-12 Measure Changes Between HEDIS MY 2019 MWA and HEDIS MY 2020. 2-13 3. Child & Adolescent Care 3-1 Introduction 3-1 Introduction 3-1 Measure-Specific Findings. 3-1 Measure-Specific Findings. 4-1 Introduction 5-1 Introduction 5-1 Introduction 5-1 Summary of Findings 5-4 6. Obesity 6-1 Introduction 6-1 Introduction 6-3 Summary of Findings 6-3 7. Pregnancy Care 7-1 Introduction 6-1 Introduction 6-3		
Calculation of Statewide Averages 2-6 Evaluating Measure Results 2-6 Interpreting Results Presented in This Report. 2-12 Measure Changes Between HEDIS MY 2019 MWA and HEDIS MY 2020 2-13 3. Child & Adolescent Care 3-1 Introduction 3-1 Measure Specific Findings 3-5 4. Women—Adult Care 4-1 Introduction 4-1 Summary of Findings 4-1 Measure-Specific Findings 4-3 5. Access to Care 5-1 Introduction 5-1 Numary of Findings 5-4 6. Obesity 6-1 Introduction 6-1 Summary of Findings 6-3 7. Pregnancy Care 7-1 Introduction 7-1 Summary of Findings 6-3 7. Pregnancy Care 7-1 Introduction 7-1 Measure-Specific Findings 7-3 8. Living With Illness 7-3 8. Living With Illness 8-1		
Evaluating Measure Results. .2-6 Interpreting Results Presented in This Report. .2-12 Measure Changes Between HEDIS MY 2019 MWA and HEDIS MY 2020 .2-13 3. Child & Adolescent Care .3-1 Introduction .3-1 Summary of Findings. .3-1 Measure-Specific Findings .3-5 4. Women—Adult Care .4-1 Introduction .4-1 Summary of Findings. .4-1 Measure-Specific Findings .4-3 5. Access to Care .5-1 Introduction .5-1 Summary of Findings. .5-1 Sum		Data Sources and Measure Audit Results2-6
Interpreting Results Presented in This Report. 2-12 Measure Changes Between HEDIS MY 2019 MWA and HEDIS MY 2020. 2-13 3. Child & Adolescent Care 3-1 Introduction 3-1 Summary of Findings. 3-1 Measure-Specific Findings. 3-5 4. Women—Adult Care 4-1 Introduction 4-1 Summary of Findings. 4-1 Summary of Findings. 4-3 5. Access to Care 5-1 Introduction 5-1 Summary of Findings. 5-1 Measure-Specific Findings 5-1 Summary of Findings. 5-1 Measure-Specific Findings 5-1 Introduction 5-1 Summary of Findings. 5-1 Measure-Specific Findings 5-1 Measure-Specific Findings 5-1 Measure-Specific Findings 6-1 Ntroduction 6-1 Summary of Findings. 6-3 7. Pregnancy Care. 7-1 Introduction 7-1 Summary of Findings. 7-3 8. Living With Illness. 8-		Calculation of Statewide Averages
Measure Changes Between HEDIS MY 2019 MWA and HEDIS MY 2020 2-13 3. Child & Adolescent Care 3-1 Introduction 3-1 Summary of Findings 3-1 Measure-Specific Findings 3-5 4. Women—Adult Care 4-1 Introduction 4-1 Summary of Findings 4-1 Measure-Specific Findings 4-3 5. Access to Care 5-1 Introduction 5-1 Summary of Findings 5-1 Measure-Specific Findings 5-1 Measure-Specific Findings 5-1 Measure-Specific Findings 5-1 Measure-Specific Findings 5-4 6. Obesity 6-1 Introduction 6-1 Summary of Findings 6-3 7. Pregnancy Care 7-1 Introduction 7-1 Summary of Findings 7-1 Measure-Specific Findings 7-3 8. Living With Illness 8-1 Introduction 8-1 Summary of Findings 7-3 8. Living With Illness 8-1 Sum		Evaluating Measure Results
3. Child & Adolescent Care 3-1 Introduction 3-1 Summary of Findings 3-1 Measure-Specific Findings 3-5 4. Women—Adult Care 4-1 Introduction 4-1 Summary of Findings 4-1 Measure-Specific Findings 4-3 5. Access to Care 5-1 Introduction 5-1 Summary of Findings 5-1 Measure-Specific Findings 5-1 Summary of Findings 5-1 Measure-Specific Findings 5-1 Measure-Specific Findings 6-1 Introduction 6-1 Summary of Findings 6-3 7. Pregnancy Care 7-1 Introduction 7-1 Summary of Findings 7-1 Measure-Specific Findings 7-3 8. Living With Illness 8-1 Introduction 8-1 Summary of Findings 7-3 8. Living With Illness 8-1 Summary of Findings 7-3 8. Living With Illness 8-1 Summary of Findings 8-1		
Introduction 3-1 Summary of Findings. 3-1 Measure-Specific Findings. 3-5 4. Women—Adult Care 4-1 Introduction 4-1 Summary of Findings. 4-1 Measure-Specific Findings. 4-3 5. Access to Care. 5-1 Introduction 5-1 Summary of Findings. 5-1 Measure-Specific Findings. 5-1 Summary of Findings. 5-1 Measure-Specific Findings. 5-4 6. Obesity 6-1 Introduction 6-1 Summary of Findings. 6-3 7. Pregnancy Care. 7-1 Introduction 7-1 Summary of Findings. 6-3 7. Pregnancy Care. 7-1 Measure-Specific Findings. 7-3 8. Living With Illness. 8-1 Introduction 8-1 Summary of Findings. 7-3 8. Living With Illness. 8-1 Summary of Findings. 8-1		Measure Changes Between HEDIS MY 2019 MWA and HEDIS MY 20202-13
Introduction 3-1 Summary of Findings. 3-1 Measure-Specific Findings. 3-5 4. Women—Adult Care 4-1 Introduction 4-1 Summary of Findings. 4-1 Measure-Specific Findings. 4-3 5. Access to Care. 5-1 Introduction 5-1 Summary of Findings. 5-1 Measure-Specific Findings. 5-1 Summary of Findings. 5-1 Measure-Specific Findings. 5-4 6. Obesity 6-1 Introduction 6-1 Summary of Findings. 6-3 7. Pregnancy Care. 7-1 Introduction 7-1 Summary of Findings. 6-3 7. Pregnancy Care. 7-1 Measure-Specific Findings. 7-3 8. Living With Illness. 8-1 Introduction 8-1 Summary of Findings. 7-3 8. Living With Illness. 8-1 Summary of Findings. 8-1	3.	Child & Adolescent Care
Summary of Findings. 3-1 Measure-Specific Findings. 3-5 4. Women—Adult Care 4-1 Introduction 4-1 Summary of Findings. 4-1 Measure-Specific Findings. 4-1 Measure-Specific Findings. 4-3 5. Access to Care. 5-1 Introduction 5-1 Summary of Findings. 5-1 Measure-Specific Findings. 5-1 Measure-Specific Findings. 5-1 Measure-Specific Findings. 5-1 Measure-Specific Findings. 6-1 Introduction 6-1 Nummary of Findings. 6-1 Measure-Specific Findings. 6-3 7. Pregnancy Care. 7-1 Introduction 7-1 Summary of Findings. 7-1 Measure-Specific Findings. 7-3 8. Living With Illness. 8-1 Introduction 8-1 Summary of Findings. 8-1		
Measure-Specific Findings 3-5 4. Women—Adult Care 4-1 Introduction 4-1 Summary of Findings 4-1 Measure-Specific Findings 4-3 5. Access to Care 5-1 Introduction 5-1 Summary of Findings 5-1 Measure-Specific Findings 5-1 Measure-Specific Findings 5-1 Measure-Specific Findings 5-1 Measure-Specific Findings 5-4 6. Obesity 6-1 Introduction 6-1 Summary of Findings 6-1 Measure-Specific Findings 6-3 7. Pregnancy Care 7-1 Introduction 7-1 Numary of Findings 7-3 8. Living With Illness 8-1 Introduction 8-1 Summary of Findings 7-3 8. Living With Illness 8-1 Summary of Findings 8-1		Summary of Findings
4. Women—Adult Care 4-1 Introduction 4-1 Summary of Findings 4-1 Measure-Specific Findings 4-3 5. Access to Care 5-1 Introduction 5-1 Summary of Findings 5-1 Measure-Specific Findings 5-1 Summary of Findings 5-1 Measure-Specific Findings 5-4 6. Obesity 6-1 Introduction 6-1 Summary of Findings 6-1 Measure-Specific Findings 6-3 7. Pregnancy Care 7-1 Introduction 7-1 Summary of Findings 7-1 Measure-Specific Findings 7-3 8. Living With Illness 8-1 Introduction 8-1 Summary of Findings 8-1		
Introduction4-1Summary of Findings4-1Measure-Specific Findings4-35. Access to Care5-1Introduction5-1Summary of Findings5-1Measure-Specific Findings5-46. Obesity6-1Introduction6-1Summary of Findings6-1Introduction6-1Summary of Findings6-1Neasure-Specific Findings6-37. Pregnancy Care7-1Introduction7-1Summary of Findings7-38. Living With Illness8-1Introduction8-1Summary of Findings8-1	4	
Summary of Findings.4-1Measure-Specific Findings4-35. Access to Care5-1Introduction5-1Summary of Findings5-1Measure-Specific Findings5-46. Obesity6-1Introduction6-1Summary of Findings6-1Measure-Specific Findings6-1Summary of Findings6-1Summary of Findings6-37. Pregnancy Care7-1Introduction7-1Summary of Findings7-38. Living With Illness8-1Introduction8-1Summary of Findings8-1	4.	
Measure-Specific Findings 4-3 5. Access to Care 5-1 Introduction 5-1 Summary of Findings 5-1 Measure-Specific Findings 5-4 6. Obesity 6-1 Introduction 6-1 Summary of Findings 6-1 Measure-Specific Findings 6-1 Summary of Findings 6-1 Measure-Specific Findings 6-3 7. Pregnancy Care 7-1 Introduction 7-1 Summary of Findings 7-1 Neasure-Specific Findings 7-3 8. Living With Illness 8-1 Introduction 8-1 Summary of Findings 8-1		
5. Access to Care 5-1 Introduction 5-1 Summary of Findings 5-1 Measure-Specific Findings 5-4 6. Obesity 6-1 Introduction 6-1 Summary of Findings 6-1 Measure-Specific Findings 6-1 Neasure-Specific Findings 6-3 7. Pregnancy Care 7-1 Introduction 7-1 Summary of Findings 7-1 Neasure-Specific Findings 7-3 8. Living With Illness 8-1 Introduction 8-1 Summary of Findings 8-1		
Introduction 5-1 Summary of Findings 5-1 Measure-Specific Findings 5-4 6. Obesity 6-1 Introduction 6-1 Summary of Findings 6-1 Summary of Findings 6-1 Neasure-Specific Findings 6-3 7. Pregnancy Care 7-1 Introduction 7-1 Summary of Findings 7-1 Neasure-Specific Findings 7-1 Summary of Findings 7-3 8. Living With Illness 8-1 Introduction 8-1 Summary of Findings 8-1	-	
Summary of Findings. 5-1 Measure-Specific Findings. 5-4 6. Obesity 6-1 Introduction 6-1 Summary of Findings. 6-1 Measure-Specific Findings. 6-1 Measure-Specific Findings. 6-3 7. Pregnancy Care. 7-1 Introduction 7-1 Summary of Findings. 7-1 Neasure-Specific Findings. 7-1 Summary of Findings. 7-3 8. Living With Illness 8-1 Introduction 8-1 Summary of Findings. 8-1	5.	
Measure-Specific Findings 5-4 6. Obesity 6-1 Introduction 6-1 Summary of Findings 6-1 Measure-Specific Findings 6-3 7. Pregnancy Care 7-1 Introduction 7-1 Summary of Findings 7-1 Neasure-Specific Findings 7-1 Summary of Findings 7-3 8. Living With Illness 8-1 Introduction 8-1 Summary of Findings 8-1		
6. Obesity		
Introduction .6-1 Summary of Findings. .6-1 Measure-Specific Findings .6-3 7. Pregnancy Care. .7-1 Introduction .7-1 Summary of Findings. .7-1 Measure-Specific Findings. .7-1 Measure-Specific Findings. .7-3 8. Living With Illness. .8-1 Introduction .8-1 Summary of Findings. .8-1		Measure-Specific Findings
Summary of Findings6-1Measure-Specific Findings6-37. Pregnancy Care7-1Introduction7-1Summary of Findings7-1Measure-Specific Findings7-38. Living With Illness8-1Introduction8-1Summary of Findings8-1	6.	Obesity
Measure-Specific Findings .6-3 7. Pregnancy Care. .7-1 Introduction .7-1 Summary of Findings. .7-1 Measure-Specific Findings. .7-3 8. Living With Illness. .8-1 Introduction. .8-1 Summary of Findings. .8-1		
7. Pregnancy Care		
Introduction .7-1 Summary of Findings .7-1 Measure-Specific Findings .7-3 8. Living With Illness .8-1 Introduction .8-1 Summary of Findings .8-1 Summary of Findings .8-1		Measure-Specific Findings
Introduction .7-1 Summary of Findings .7-1 Measure-Specific Findings .7-3 8. Living With Illness .8-1 Introduction .8-1 Summary of Findings .8-1 Summary of Findings .8-1	7.	Pregnancy Care
Measure-Specific Findings		
8. Living With Illness		Summary of Findings7-1
Introduction		Measure-Specific Findings
Introduction	8.	Living With Illness
Summary of Findings		



9.	Health Plan Diversity9-1
	Introduction
	Summary of Findings
10.	Utilization10-1
	Introduction10-1
	Summary of Findings10-1
	Measure-Specific Findings
11.	HEDIS Reporting Capabilities—Information Systems Findings11-1
	HEDIS Reporting Capabilities—Information Systems Findings11-1
12.	Glossary
	Glossary
An	oendix A. Tabular Results
	Child & Adolescent Care Performance Measure Results
	Women—Adult Care Performance Measure Results
	Access to Care Performance Measure Results
	Obesity Performance Measure Results
	Pregnancy Care Performance Measure Results
	Living With Illness Performance Measure Results
	Health Plan Diversity and Utilization Measure Results
Арј	bendix B. Trend TablesB-1
Ap	bendix C. Performance Summary StarsC-1
	IntroductionC-1
	Child & Adolescent Care Performance Summary Stars
	Women—Adult Care Performance Summary Stars
	Access to Care Performance Summary Stars
	Obesity Performance Summary Stars
	Pregnancy Care Performance Summary StarsC-10
	Living With Illness Performance Summary Stars
	Utilization Performance Summary StarsC-14



Introduction

During 2020, the Michigan Department of Health and Human Services (MDHHS) contracted with 10 health plans to provide managed care services to Michigan Medicaid members. MDHHS expects its contracted Medicaid health plans (MHPs) to support claims systems, membership and provider files, as well as hardware/software management tools that facilitate valid reporting of the Healthcare Effectiveness Data and Information Set (HEDIS[®])¹⁻¹ measures. MDHHS contracted with Health Services Advisory Group, Inc. (HSAG), to calculate statewide average rates based on the MHPs' rates and evaluate each MHP's current performance level, as well as the statewide performance, relative to national Medicaid percentiles.

MDHHS selected HEDIS measures to evaluate Michigan MHPs within the following eight measure domains:

- Child & Adolescent Care
- Women—Adult Care
- Access to Care
- Obesity
- Pregnancy Care
- Living With Illness
- Health Plan Diversity
- Utilization

Of note, all measures in the Health Plan Diversity domain and some measures in the Utilization domain are provided within this report for information purposes only as they assess the health plans' use of services and/or describe health plan characteristics and are not related to performance. Therefore, most of these rates were not evaluated in comparison to national percentiles, and changes in these rates across years were not analyzed by HSAG for statistical significance.

The performance levels are based on national percentiles and were set at specific, attainable rates. MHPs that met the high performance level (HPL) exhibited rates that were among the 90th percentile in comparison the national average. The low performance level (LPL) was set to identify MHPs that were among the 25th percentile in comparison to the national average and have the greatest need for improvement. Details describing these performance levels are presented in Section 2, "How to Get the Most From This Report."

¹⁻¹ HEDIS[®] is a registered trademark of the National Committee for Quality Assurance (NCQA).



In addition, Section 11 ("HEDIS Reporting Capabilities—Information Systems Findings") provides a summary of the HEDIS data collection processes used by the Michigan MHPs and the audit findings in relation to the National Committee for Quality Assurance's (NCQA's) information system (IS) standards.¹⁻²


Due to the possible effect of coronavirus disease 2019 (COVID-19) on HEDIS hybrid measures, specifically an MHP's ability to collect medical record data, NCQA allowed MHPs to report their audited HEDIS 2019 (measurement year [MY] 2018) hybrid rates if they were better than their HEDIS 2020 (MY 2019) hybrid rates. MHPs were not required to rotate all hybrid measures but were required to rotate entire measures when there were multiple indicators (e.g., Comprehensive Diabetes Care). NCQA's Interactive Data Submission System (IDSS) was not configured to capture rotation decisions, meaning that even when a hybrid measure was rotated, the MY would still say 2019. For HEDIS MY 2020, NCQA did not allow MHPs to report their audited HEDIS MY 2019 hybrid rates if they were better than their HEDIS MY 2020 hybrid rates.

¹⁻² National Committee for Quality Assurance. *HEDIS*[®] MY 2020, *Volume 5: HEDIS Compliance Audit*TM: *Standards, Policies and Procedures*. Washington D.C.



Summary of Performance

Figure 1-1 compares the Michigan Medicaid program's overall rates with NCQA's Quality Compass[®] national Medicaid HMO percentiles for HEDIS MY 2020, which are referred to as "percentiles" throughout this report.¹⁻³ For measures that were comparable to percentiles, the bars represent the number of Michigan Medicaid Weighted Average (MWA) measure indicator rates that fell into each percentile range.



Of the 64 reported rates that were comparable to national Medicaid percentiles, 16 of the MWA rates fell below the 25th percentile and a total of 40 rates (about 63 percent) were below the 50th percentile. These results demonstrate a general statewide decline in performance in comparison to the MY 2019 rates, which showed approximately 35 percent of the rates falling below the 50th percentile. A summary of MWA performance for each measure domain is presented on the following pages.

¹⁻³ Quality Compass[®] is a registered trademark for the National Committee for Quality Assurance (NCQA).



Child & Adolescent Care

For the Child & Adolescent Care domain, the Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication—Initiation Phase and Continuation and Maintenance Phase measure was an area of strength. Both measure indicators ranked above the 50th percentile and demonstrated improvements. Priority ranked above the 50th percentile for the most measures within the Child & Adolescent Care domain (Childhood Immunization Status—Combinations 2–10, Lead Screening in Children, and Immunizations for Adolescents—Combination 1 and Combination 2). Total Health and Blue Cross were the only MHPs to rank above the HPL for one indicator each within the Follow-Up Care for Children Prescribed ADHD Medication measure.

The MWA demonstrated a significant decline for the *Childhood Immunization Status*—*Combinations 2, 3, 4, 5,* and 7, *Lead Screening in Children,* and *Immunizations for Adolescents*—*Combination 1 and Combination 2* indicators, decreasing by over two percentage points. *Lead Screening in Children* had the highest number of MHPs that demonstrated a statistically significant decline in HEDIS MY 2020, as well as a MWA decrease of nearly five percentage points from HEDIS MY 2019. Additionally, the MWA ranked below the 49th percentile for all indicators for the *Childhood Immunization Status* measure.

MDHHS should work with the MHPs and providers to identify potential root causes for the significant decline for the *Lead Screening in Children* measure and work towards possibly increasing the administration of lead blood tests for children 2 years of age. Screening for lead is an easy way to detect an abnormal blood lead level in children. There is no safe blood lead level. If not found early, exposure to lead and high blood levels can lead to irrevocable effects on a child's physical and mental health.¹⁻⁴ If the decline in children receiving these tests is identified as linked to the COVID-19 public health emergency, MDHHS is encouraged to work with other state Medicaid agencies facing similar barriers, to identify safe methods for children to have access to this important test.

Additionally, MDHHS should work with the MHPs and providers to target improving childhood vaccination rates due to the significant decline across multiple indicators for the *Childhood Immunization Status* measure. The ongoing COVID-19 pandemic is a reminder of the importance of vaccination. The identified declines in routine pediatric vaccine ordering and doses administered might indicate that United States children and their communities face increased risks for outbreaks of vaccine-preventable diseases. Reminding parents of the vital need to protect their children against serious vaccine-preventable diseases, even as the COVID-19 pandemic continues, is critical. As social distancing requirements are relaxed, children who are not protected by vaccines will be more vulnerable to diseases such as measles. In response, continued coordinated efforts between health care providers and public health officials at the local, state, and federal levels will be necessary to achieve rapid catch-up vaccination.¹⁻⁵

¹⁻⁴ National Committee for Quality Assurance. Lead Screening in Children. Available at: <u>https://www.ncqa.org/hedis/measures/lead-screening-in-children/</u>. Accessed on: September 17, 2021.

¹⁻⁵ The Centers for Disease Control and Prevention (CDC). Effects of the COVID-19 Pandemic on Routine Pediatric Vaccine Ordering and Administration—United States, 2020. Available at: https://www.cdc.gov/mmwr/volumes/69/wr/mm6919e2.htm/. Accessed on: September 17, 2021.



Women—Adult Care

For the Women—Adult Care domain, the MWA demonstrated a significant decline across all measures and indicators. Total Health Care and Molina demonstrated high performance as the only MHPs to rank above the 50th percentile for all *Chlamydia Screening for Women* measure indicators, and the *Cervical Cancer Screening* measure. No MHP ranked above the HPL for any measure in the Women—Adult Care domain. Additionally, Upper Peninsula fell below the LPL for all *Chlamydia Screening for Women* measure indicators and Aetna fell below the LPL for both the *Cervical Cancer Screening* and *Breast Cancer Screening* measures.

The Chlamydia Screening in Women and Breast Cancer Screening measures had the highest number of MHPs that demonstrated a statistically significant decline in HEDIS MY 2020, as well as a MWA decrease of over five percentage points from HEDIS MY 2019. Further, the Cervical Cancer Screening measure had the most significant MWA decrease of over seven percentage points from HEDIS MY 2019. MDHHS should work with the MHPs and providers to identify barriers that contribute to lower screening rates for cervical cancer and breast cancer and should work towards establishing resources to increase access to routine cancer screenings. Screening can improve outcomes and early detection reduces the risk of dying can lead to a greater range of treatment options and lower health care costs.¹⁻⁶ Prolonged delays in screening related to the COVID-19 pandemic may lead to delayed diagnoses, poor health consequences, and an increase in cancer disparities among women already experiencing health inequities. 1-7 Additionally, MDHHS should work with the MHPs and providers on increasing testing and screening for chlamydia. The CDC has identified several new and innovative ways STD services can meet more people where they are—during the COVID-19 pandemic and in the future—including: STD express clinics, partnerships with pharmacies and retail health clinics, and telehealth.¹⁻⁸ If the decline in women receiving these screenings is identified as linked to the COVID-19 public health emergency, MDHHS is encouraged to work with other state Medicaid agencies facing similar barriers. to identify safe methods for women to have access to these important screening services.

Access to Care

For the Access to Care domain an area of strength was the Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis—Ages 3 Months to 17 Years and Ages 18 to 64 Years measure indicators ranking above the 50th percentile, with the MWA significantly improving by over one percentage point for both indicators. Aetna, Blue Cross, McLaren, Meridian, HAP, Molina, Priority, Total Health and UnitedHealthcare all ranked above the 50th percentile for the Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis—Ages 3 Months to 17 Years and Ages 18 to 64 Years measure indicators.

¹⁻⁶ National Committee for Quality Assurance. Breast Cancer Screening. Available at: <u>https://www.ncqa.org/hedis/measures/breast-cancer-screening/</u>. Accessed on: September 17, 2021.

¹⁻⁷ Centers for Disease Control and Prevention. Sharp Declines in Breast and Cervical Cancer Screening. <u>https://www.cdc.gov/media/releases/2021/p0630-cancer-screenings.html</u>. Accessed on: September 17, 2021.

¹⁻⁸ Centers for Disease Control and Prevention. Reported STDs Reach All-time High for 6th Consecutive Year. <u>https://www.cdc.gov/media/releases/2021/p0413-stds.html</u>. Accessed on: September 17, 2021.



Additionally, the *Appropriate Treatment for Upper Respiratory Infection—18 to 64 Years* indicator ranked above the 50th percentile, with the MWA significantly improving by nearly three percentage points. Priority ranked above the HPL for *Appropriate Treatment for Upper Respiratory Infection—18 to 64 Years*.

Total Health, Aetna, and HAP fell below the LPL for the *Adults' Access to Preventive/Ambulatory Health Services—Ages 20 to 44 years, 45 to 64 Years,* and *Total* indicators, and no MHPs ranked above the 50th percentile for the *Adults' Access to Preventive/Ambulatory Health Services—Ages 20 to 44 years* and 45 to 64 Years indicators. The MWA was below the 50th percentile for all four of the *Adults' Access to Preventive/Ambulatory Health Services* measure indicators and demonstrated a significant decline of over three percentage points from HEDIS MY 2019 for all measure indicators. Blue Cross, UnitedHealthcare, Molina, Aetna, Total Health, and HAP all fell below the LPL for the *Appropriate Testing for Pharyngitis—Total* measure indicator, and the MWA fell below the 50th percentile for the *Appropriate Testing for Pharyngitis—Ages 3 to 17 Years, Ages 18 to 64 Years*, and *Total* measure indicators and demonstrated a significant decline of over one percentage point from HEDIS MY 2019 for these indicators.

MDHHS should continue to monitor the MHPs performance on the four indicators of *Adults' Access to Preventive/Ambulatory Health Services* to ensure the MHPs performance does not continue to decline, in alignment with HSAG's recommendation for *Adults' Access to Preventive/Ambulatory Health Services* in the 2020 Aggregate Report. Additionally, MDHHS should work towards prioritizing preventative and ambulatory health services as part of its quality improvement strategy. Further, MDHHS should conduct a root cause analysis for the decline across multiple indicators for the *Appropriate Testing for Pharyngitis* measure. Proper testing and treatment of pharyngitis prevents the spread of sickness, while reducing unnecessary use of antibiotics. ¹⁻⁹ If the decline in adults accessing these services is identified as related to the COVID-19 public health emergency, MDHHS is encouraged to work with other state Medicaid agencies facing similar barriers, to identify safe methods for ensuring ongoing adults' access to these important services.

Obesity

For the Obesity domain, Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents—Counseling for Physical Activity—Total was an area of strength as the MWA was above the 50th percentile. Additionally, Priority, Upper Peninsula, and UnitedHealthcare demonstrated high performance, ranking above the 50th percentile, but falling below the HPL for all three of the measure indicators within the Obesity domain.

The MWA had significant decreases across all measure indicators and ranked below the 50th percentile for two of the three measures within the Obesity domain (*Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents—Body Mass Index (BMI) Percentile*

¹⁻⁹ National Committee for Quality Assurance. Appropriate Testing for Children with Pharyngitis. Available at: <u>https://www.ncqa.org/hedis/measures/appropriate-testing-for-children-with-pharyngitis/</u>. Accessed on: September 17, 2021.



Documentation—Total and *Counseling for Nutrition—Total*). McLaren ranked below the LPL for all three measure indicators. MDHHS should work with the MHPs and providers to strategize the best way to utilize every office visit or virtual visit to encourage a healthy lifestyle and provide education on healthy habits for children and adolescents. Additionally, MDHHS should monitor McLaren's performance for this measure to ensure the MHP performance does not continue to decline and encourage higher performing MHPs to share and discuss best practices. If the decline in children and adolescents receiving these services is identified to be related to the COVID-19 public health emergency, MDHHS is encouraged to work with other state Medicaid agencies facing similar barriers, to identify safe methods for improved access to these services.

Pregnancy Care

For the Pregnancy Care domain, both measure indicators ranked below the 25th percentile and had a MWA decrease of over three percentage points from HEDIS MY 2019, with the *Prenatal and Postpartum Care—Timeliness of Prenatal Care* indicator demonstrating the most significant MWA decrease of over six percentage points from HEDIS MY 2019. Molina, Meridian, Blue Cross, UnitedHealthcare, McLaren, Aetna, HAP, and Total Health all fell below the LPL for both *Prenatal and Postpartum Care—Timeliness of Prenatal Care* and *Postpartum Care* indicators. The MWA also fell below the LPL for both measure indicators.

Upper Peninsula ranked above the 50th percentile for both measure indicators, and was above the HPL for *Prenatal and Postpartum Care*—*Postpartum Care*. MDHHS should work with the MHPs and providers on the best practices for providing ongoing prenatal and postpartum care. This is especially important during COVID-19, as pregnant and recently pregnant women are at a higher risk for severe illness from COVID-19 than nonpregnant women.¹⁻¹⁰ Additionally, pregnant women with COVID-19 are at a higher risk for preterm birth and might have a higher risk for other adverse pregnancy outcomes. MDHHS is encouraged to work with the higher performing MHPs to identify best practice to ensuring women access to prenatal and postpartum care, which can then be spread to the lower performing MHPs to improve overall access.

Living With Illness

For the Living With Illness domain, Antidepressant Medication Management—Effective Acute Phase Treatment and Adherence to Antipsychotic Medications for Individuals With Schizophrenia were an area of strength. Both measure indicators went from below the 75th percentile in MY 2019 to above the 75th percentile in MY 2020 and demonstrated significant increases, with Antidepressant Medication Management—Effective Acute Phase Treatment increasing by more than four percentage points and Adherence to Antipsychotic Medications for Individuals With Schizophrenia increasing by nearly nine percentage points. Total Health was the only MHP to rank above the HPL and the 50th percentile for all

¹⁻¹⁰ Centers for Disease Control and Prevention. Investigating the Impact of COVID-19 during Pregnancy. Available at: <u>https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/special-populations/pregnancy-data-on-covid-19/what-cdc-is-doing.html</u>. Accessed on: September 17, 2021.

EXECUTIVE SUMMARY



Medical Assistance With Smoking and Tobacco Use Cessation measure indicators. Priority was the only MHP to rank above the 50th percentile for all Comprehensive Diabetes Care measure indicators. Total Health and Meridian ranked above the HPL for Antidepressant Medication Management—Effective Acute Phase Treatment, with Total Health also ranking above the HPL for the Effective Continuation Phase Treatment measure indicator.

For *Medical Assistance With Smoking and Tobacco Use Cessation*, the MWA for all measure indicators demonstrated a significant decline of over one percentage point, with *Advising Smokers and Tobacco Users to Quit* demonstrating the most decline at over three percentage points and ranking below the 50th percentile. McLaren, Molina, Aetna, Blue Cross, HAP, Total Health and the MWA fell below the LPL for *Asthma Medication Ratio—Total*, with the MWA demonstrating a significant decline of over three percentage points from HEDIS MY 2019.

The MWA demonstrated the most significant declines for *Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications, Diabetes Monitoring for People With Diabetes and Schizophrenia,* and all comparable *Comprehensive Diabetes Care* measure indicators. The measures all demonstrated significant declines in the MWA of more than five percentage points from MY 2019 to MY 2020. MDHHS should implement a quality improvement strategy with MHPs and providers that would focus on effective treatment programs for people with diabetes, which should include people with schizophrenia and bipolar disorder. Lack of appropriate care for diabetes and cardiovascular disease for people with schizophrenia or bipolar disorder who use antipsychotic medications can lead to worsening health and death. Addressing these physical health needs is an important way to improve health, quality of life and economic outcomes downstream.¹⁻¹¹ If the decline in receipt of these services is determined to be related to the COVID-19 public health emergency, MDHHS is encouraged to work with other state Medicaid agencies facing similar barriers, to identify safe methods for adults to have access to these important services.

Health Plan Diversity

Although measures under this domain are not performance measures and are not compared to percentiles, changes observed in the results may provide insight into how select member characteristics affect the MHPs' provision of services and care.

Utilization

For the Ambulatory Care—Total (Per 1,000 Member Months)—Emergency Department (ED) Visits— Total measure indicator, the Michigan average decreased by 18.77 visits per 1,000 member months from HEDIS MY 2018 to HEDIS MY 2020. The MWA for the Outpatient Visits—Total measure indicator

¹⁻¹¹ National Committee for Quality Assurance. Dia betes and Cardiovascular Disea se Screening and Monitoring for People With Schizophrenia or Bipolar Disorder. Available at: <u>https://www.ncqa.org/hedis/measures/diabetes-and-cardiovascular-disea se-screening-and-monitoring-for-people-with-schizophrenia-or-bipolar-disorder/</u>. Accessed on: September 17, 2021.



decreased by 28.31 visits per 1,000 member months from HEDIS MY 2018 to HEDIS MY 2020.¹⁻¹² Since the measure of outpatient visits is not linked to performance, the results for this measure are not comparable to percentiles. For the *Plan All-Cause Readmissions* measure, five MHPs had an observed-to-expected (O/E) ratio less than 1.0, indicating that these MHPs had fewer observed readmissions than were expected based on the patient mix. The remaining five MHPs O/E ratio is more than one indicating they had more readmissions.

Limitations and Considerations

Some behavioral health services are carved out and are not provided by the MHPs; therefore, exercise caution when interpreting rates for measures related to behavioral health.

¹⁻¹² For the *ED Visits* indicator, a wareness is a dvised when interpreting results for this indicator as a lower rate is a higher percentile.



2. How to Get the Most From This Report

Introduction

This reader's guide is designed to provide supplemental information to the reader that may aid in the interpretation and use of the results presented in this report.

Michigan Medicaid Health Plan Names

Table 2-1 presents a list of the Michigan MHPs discussed within this report and their corresponding abbreviations.

MHP Name	Short Name	Abbreviation
Aetna Better Health of Michigan	Aetna	AET
Blue Cross Complete of Michigan	Blue Cross	BCC
McLaren Health Plan	McLaren	MCL
Meridian Health Plan of Michigan	Meridian	MER
HAP Empowered	НАР	HAP
Molina Healthcare of Michigan	Molina	MOL
Priority Health Choice, Inc.	Priority	PRI
Total Health Care, Inc.	Total Health	THC
UnitedHealthcare Community Plan	UnitedHealthcare	UNI
Upper Peninsula Health Plan	Upper Peninsula	UPP

Table 2-1—2021 Michigan MHP Names and Abbreviations

Summary of Michigan Medicaid HEDIS MY 2020 Measures

Within this report, HSAG presents the Michigan MWA (i.e., statewide average rates) and MHP-specific performance on HEDIS measures selected by MDHHS for HEDIS MY 2020. These measures were grouped into the following eight domains of care: Child & Adolescent Care, Women—Adult Care, Access to Care, Obesity, Pregnancy Care, Living With Illness, Health Plan Diversity, and Utilization. While performance is reported primarily at the measure indicator level, grouping these measures into domains encourages MHPs and MDHHS to consider the measures as a whole rather than in isolation and to develop the strategic changes required to improve overall performance.



Table 2-2 shows the selected HEDIS MY 2020 measures and measure indicators as well as the corresponding domains of care and the reporting methodologies for each measure. The data collection or calculation method is specified by NCQA in the *HEDIS MY 2020 & MY 2021 and Volume 2 Technical Specifications*. Data collection methodologies are described in detail in the next section.

Performance Measures	HEDIS Data Collection Methodology
Child & Adolescent Care	
Childhood Immunization Status—Combinations 2–10	Hybrid
Well-Child Visits in the First 30 Months of Life—Well-Child Visits in the First 15 Months—Six or More Well-Child Visits and Well-Child Visits for Age 15 Months to 30 Months—Two or More Well-Child Visits	Administrative
Lead Screening in Children	Hybrid
Child and Adolescent Well-Care Visits—Ages 3 to 11 Years, Ages 12 to 17 Years, Ages 18 to 21 Years, and Total	Administrative
Immunizations for Adolescents—Combination 1 and 2	Hybrid
Follow-Up Care for Children Prescribed ADHD Medication—Initiation Phase and Continuation and Maintenance Phase	Administrative
Women—Adult Care	
Chlamydia Screening in Women—Ages 16 to 20 Years, Ages 21 to 24 Years, and Total	Administrative
Cervical Cancer Screening	Hybrid
Breast Cancer Screening	Administrative
Access to Care	
Adults' Access to Preventive/Ambulatory Health Services—Ages 20 to 44 Years, Ages 45 to 64 Years, Ages 65 Years and Older, and Total	Administrative
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis—Ages 3 Months to 17 Years, Ages 18 to 64 Years, Ages 65 Years and Older, and Total	Administrative
Appropriate Testing for Pharyngitis—Ages 3 to 17 Years, Ages 18 to 64 Years, Ages 65 Years and Older, and Total	Administrative
Appropriate Treatment for Upper Respiratory Infection—Ages 3 Months to 17 Years, Ages 18 to 64 Years, Ages 65 Years and Older, and Total	Administrative
Obesity	
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents—BMI Percentile Documentation—Total, Counseling for Nutrition—Total, and Counseling for Physical Activity—Total	Hybrid

Table 2-2—Michigan Medicaid HEDIS MY 2020 Required Measures



Performance Measures	HEDIS Data Collection Methodology
Pregnancy Care	
Prenatal and Postpartum Care—Timeliness of Prenatal Care and Postpartum Care	Hybrid
Living With Illness	·
Comprehensive Diabetes Care—Hemoglobin A1c (HbA1c) Testing, HbA1c Poor Control (>9.0%), HbA1c Control (<8.0%), Eye Exam (Retinal) Performed, and Blood Pressure Control (<140/90 mm Hg)	Hybrid
Kidney Health Evaluation for Patients With Diabetes—Ages 18 to 64 Years, Ages 65 to 74 Years, Ages 75 to 85 Years, and Total	Administrative
Asthma Medication Ratio—Total	Administrative
Controlling High Blood Pressure	Hybrid
Medical Assistance With Smoking and Tobacco Use Cessation—Advising Smokers and Tobacco Users to Quit, Discussing Cessation Medications, and Discussing Cessation Strategies	Administrative
Antidepressant Medication Management—Effective Acute Phase Treatment and Effective Continuation Phase Treatment	Administrative
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications	Administrative
Diabetes Monitoring for People With Diabetes and Schizophrenia	Administrative
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia	Administrative
Adherence to Antipsychotic Medications for Individuals With Schizophrenia	Administrative
Health Plan Diversity	
Race/Ethnicity Diversity of Membership	Administrative
Language Diversity of Membership—Spoken Language Preferred for Health Care, Preferred Language for Written Materials, and Other Language Needs	Administrative
Utilization	
Ambulatory Care—Total (Per 1,000 Member Months)—ED Visits—Total and Outpatient Visits—Total	Administrative
Inpatient Utilization—General Hospital/Acute Care—Total	Administrative
Use of Opioids From Multiple Providers—Multiple Prescribers, Multiple Pharmacies, and Multiple Prescribers and Multiple Pharmacies	Administrative
Use of Opioids at High Dosage	Administrative
Risk of Continued Opioid Use—At Least 15 Days Covered—Total and At Least 31 Days Covered—Total	Administrative
Plan All-Cause Readmissions—Index Total Stays	Administrative



Data Collection Methods

Administrative Method

The administrative method requires that MHPs identify the eligible population (i.e., the denominator) using administrative data, derived from claims and encounters. In addition, the numerator(s), or services provided to the members in the eligible population, are derived solely using administrative data collected during the reporting year. Medical record review data from the prior year may be used as supplemental data. Medical records collected during the current year cannot be used to retrieve information. When using the administrative method, the entire eligible population becomes the denominator, and sampling is not allowed.

Hybrid Method

The hybrid method requires that MHPs identify the eligible population using administrative data and then extract a systematic sample of members from the eligible population, which becomes the denominator. Administrative data are used to identify services provided to those members. Medical records must then be reviewed for those members who do not have evidence of a service being provided using administrative data.

The hybrid method generally produces higher rates because the completeness of documentation in the medical record exceeds what is typically captured in administrative data; however, the medical record review component of the hybrid method is considered more labor intensive. For example, the MHP has 10,000 members who qualify for the *Prenatal and Postpartum Care* measure and chooses to use the hybrid method. After randomly selecting 411 eligible members, the MHP finds that 161 members had evidence of a postpartum visit using administrative data. The MHP then obtains and reviews medical records for the 250 members who did not have evidence of a postpartum visit using administrative data. Of those 250 members, 54 were found to have a postpartum visit recorded in the medical record review. Therefore, the final rate for this measure, using the hybrid method, would be (161 + 54)/411, or 52.3 percent, a 13.1 percentage point increase from the administrative only rate of 39.2 percent.

Understanding Sampling Error


Correct interpretation of results for measures collected using HEDIS hybrid methodology requires an understanding of sampling error. It is rarely possible, logistically or financially, to complete medical record review for the entire eligible population for a given measure. Measures collected using the HEDIS hybrid method include only a sample from the eligible population, and statistical techniques are used to maximize the probability that the sample results reflect the experience of the entire eligible population.

For results to be generalized to the entire eligible population, the process of sample selection must be such that everyone in the eligible population has an equal chance of being selected. The HEDIS hybrid method prescribes a systematic sampling process selecting at least 411 members of the eligible



population. MHP may use a 5 percent, 10 percent, 15 percent, or 20 percent oversample to replace invalid cases (e.g., a male selected for *Postpartum Care*).

Figure 2-1 shows that if 411 members are included in a measure, the margin of error is approximately \pm 4.9 percentage points. Note that the data in this figure are based on the assumption that the size of the eligible population is greater than 2,000. The smaller the sample included in the measure, the larger the sampling error.





As Figure 2-1 shows, sample error decreases as the sample size gets larger. Consequently, when sample sizes are very large and sampling errors are very small, almost any difference is statistically significant. This does not mean that all such differences are important. On the other hand, the difference between two measured rates may not be statistically significant but may, nevertheless, be important. The judgment of the reviewer is always a requisite for meaningful data interpretation.



Data Sources and Measure Audit Results

MHP-specific performance displayed in this report was based on data elements obtained from the IDSS files supplied by the MHPs. Prior to HSAG's receipt of the MHPs' IDSS files, all of the MHPs were required by MDHHS to have their HEDIS MY 2020 results examined and verified through an NCQA HEDIS Compliance Audit.

Through the audit process, each measure indicator rate reported by an MHP was assigned an NCQAdefined audit result. HEDIS MY 2020 measure indicator rates received one of seven predefined audit results: *Reportable (R), Small Denominator (NA), Biased Rate (BR), No Benefit (NB), Not Required (NQ), Un-Audited (UN)*, and *Not Reported (NR)*. The audit results are defined in Section 12.

Rates designated as *NA*, *BR*, *NB*, *NQ*, *UN*, or *NR* are not presented in this report. All measure indicator rates that are presented in this report have been verified as an unbiased estimate of the measure. Please see Section 11 for additional information on NCQA's Information System (IS) standards and the audit findings for the MHPs.

Calculation of Statewide Averages

For all measures, HSAG collected the audited results, numerator, denominator, rate, and eligible population elements reported in the files submitted by MHPs to calculate the MWA rate. Given that the MHPs varied in membership size, the MWA rate was calculated for most of the measures based on MHPs' eligible populations. Weighting the rates by the eligible population sizes ensured that a rate for an MHP with 125,000 members, for example, had a greater impact on the overall MWA rate than a rate for the MHP with only 10,000 members. For MHPs' rates reported as *NA*, the numerators, denominators, and eligible populations were included in the calculations of the MWA rate. MHP rates reported as *BR*, *NB*, *NQ*, *UN*, or *NR* were excluded from the MWA rate calculation. However, traditional unweighted statewide Medicaid average rates were calculated for some utilization-based measures to align with calculations from prior years' deliverables.

Evaluating Measure Results

National Benchmark Comparisons

Benchmark Data

HEDIS MY 2020 MHP and MWA rates were compared to the corresponding national HEDIS benchmarks, which are expressed in percentiles of national performance for different measures. For comparative purposes, HSAG used the most recent data available from NCQA at the time of the publication of this report to evaluate the HEDIS MY 2020 rates: NCQA's Quality Compass national Medicaid HMO percentiles for HEDIS MY 2019 MWA, which are referred to as "percentiles" throughout this report.



Additionally, benchmarking data (i.e., NCQA's Quality Compass and NCQA's Audit Means and Percentiles) are the proprietary intellectual property of NCQA; therefore, this report does not display any actual percentile values. As a result, rate comparisons to benchmarks are illustrated within this report using proxy displays.

Figure Interpretation

For each performance measure indicator presented in Sections 3 through 8 of this report, the horizontal bar graph figure positioned on the right side of the page presents each MHP's performance against the HEDIS MY 2020 MWA (i.e., the bar shaded gray); the HPL (i.e., the green shaded bar), representing the 90th percentile; the P50 bar (i.e., the blue shaded bar), representing the 50th percentile; and the LPL (i.e., the red shaded bar), representing the 25th percentile.

For measures for which lower rates indicate better performance, the 10th percentile (rather than the 90th percentile) and the 75th percentile (rather than the 25th percentile) are considered the HPL and LPL, respectively. An example of the horizontal bar graph figure for measure indicators reported administratively is shown below in Figure 2-2.




Figure 2-2—Sample Horizontal Bar Graph Figure for Administrative Measures



For performance measure rates that were reported using the hybrid method, the "ADMIN%" column presented with each horizontal bar graph figure displays the percentage of the rate derived from administrative data (e.g., claims data and supplemental data). The portion of the bar shaded yellow represents the proportion of the total measure rate attributed to medical record review, while the portion of the bar shaded light blue indicates the proportion of the measure rate that was derived using the administrative method. This percentage describes the level of claims/encounter data completeness of the MHP data for calculating a particular performance measure. A low administrative data percentage suggests that the MHP relied heavily on medical records to report the rate. Conversely, a high administrative data percentage indicates that the MHP's claims/encounter data were relatively complete for use in calculating the performance measure indicator rate. An administrative percentage of 100 percent indicates that the MHP did not report the measure indicator rate using the hybrid method. An example of the horizontal bar graph figure for measure indicators reported using the hybrid method is shown in Figure 2-3.




Figure 2-3—Sample Horizontal Bar Graph Figure for Hybrid Measures



Percentile Rankings and Star Ratings

In addition to illustrating MHP and statewide performance via side-by-side comparisons to national percentiles, benchmark comparisons are denoted within Appendix B of this report using the percentile ranking performance levels and star ratings defined below in Table 2-3.

Star Rating	Performance Level
****	At or above the 90th percentile
****	At or above the 75th percentile but below the 90th percentile
***	At or above the 50th percentile but below the 75th percentile
**	At or above the 25th percentile but below the 50th percentile
*	Below the 25th percentile
NA	NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.
NB	NB indicates that the MHP did not offer the health benefit required by the measure.

Table 2-3—Percentile	Ranking Performance Levels
	Natiking renormance Levels

Measures in the Health Plan Diversity and Utilization measure domains are designed to capture the frequency of services provided and characteristics of the populations served. With the exception of *Ambulatory Care—Total (Per 1,000 Member Months)—ED Visits, Use of Opioids From Multiple Providers, Use of Opioids at High Dosage, Risk of Continued Opioid Use,* and *Plan All-Cause Readmissions,* higher or lower rates in these domains do not necessarily indicate better or worse performance. A lower rate for *Ambulatory Care—Total (Per 1,000 Member Months)—ED Visits* may indicate a more favorable performance since lower rates of ED services may indicate better utilization of services. Further, measures under the Health Plan Diversity measure domain provide insight into how member race/ethnicity or language characteristics are compared to national distributions and are not suggestive of plan performance.

For the Ambulatory Care—Total (Per 1,000 Member Months)—ED Visits and Plan All-Cause Readmissions measure indicators, HSAG inverted the star ratings to be consistently applied to these measures as with the other HEDIS measures. For example, the 10th percentile (a lower rate) was inverted to become the 90th percentile, indicating better performance.

Of note, MHP and statewide average rates were rounded to the second decimal place before performance levels were determined. As HSAG assigned star ratings, an em dash (—) was presented to indicate that the measure indicator was not required and not presented in previous years' HEDIS



deliverables; or that a performance level was not presented in this report either because the measure did not have an applicable benchmark or a comparison to benchmarks was not appropriate.

Performance Trend Analysis

In addition to the star rating results, HSAG also compared HEDIS MY 2020 MWA and MHP rates to the corresponding HEDIS MY 2019 MWA rates. HSAG also evaluated the extent of changes observed in the rates between years. Year-over-year performance comparisons are based on the Chi-square test of statistical significance with a *p* value <0.05 for MHP rate comparisons and a *p* value <0.01 for MWA rate comparisons. Note that statistical testing could not be performed on the utilization-based measures domain given that variances were not available in the IDSS files for HSAG to use for statistical testing. Further statistical testing was not performed on the health plan diversity measures because these measures are for information purposes only.

In general, results from statistical significance testing provide information on whether a change in the rate may suggest improvement or decline in performance. Throughout the report, references to "significant" changes in performance are noted; these instances refer to statistically significant differences between performance from HEDIS MY 2019 MWA to HEDIS MY 2020. At the statewide level, if the number of MHPs reporting *NR* or *BR* differs vastly from year to year, the statewide performance may not represent all of the contracted MHPs, and any changes observed across years may need to take this factor into consideration. Nonetheless, changes (regardless of whether they are significant) could be related to the following factors independent of any effective interventions designed to improve the quality of care:

- Substantial changes in measure specifications. The "Measure Changes Between HEDIS MY 2019 MWA and HEDIS MY 2020" section below lists measures with specification changes made by NCQA.
- Substantial changes in membership composition within the MHP.

Table and Figure Interpretation

Within Sections 3 through 8 and Appendix B of this report, performance measure indicator rates and results of significance testing between HEDIS MY 2019 MWA and HEDIS MY 2020 are presented in tabular format. HEDIS MY 2020 rates shaded green with one cross (+) indicate a significant improvement in performance from the previous year. HEDIS MY 2020 rates shaded red with two crosses (++) indicate a significant decline in performance from the previous year. The colors used are provided below for reference:

+

Indicates that the HEDIS MY 2020 MWA demonstrated a significant improvement from the HEDIS MY 2019 MWA.



Indicates that the HEDIS MY 2020 MWA demonstrated a significant decline from the HEDIS MY 2019 MWA.





Additionally, benchmark comparisons are denoted within Sections 3 through 8. Performance levels are represented using the following percentile rankings:

Percentile Ranking and Shading	Performance Level
≥90th	At or above the 90th percentile
\geq 75th and \leq 89th	At or above the 75th percentile but below the 90th percentile
\geq 50th and \leq 74th	At or above the 50th percentile but below the 75th percentile
\geq 25th and \leq 49th	At or above the 25th percentile but below the 50th percentile
≤25th	Below the 25th percentile

Table 2-4—Percentile Ranking Performance Levels

For each performance measure indicator presented in Sections 3 through 8 of this report, the vertical bar graph figure positioned on the left side of the page presents the HEDIS MY 2018, HEDIS MY 2019 MWA, and HEDIS MY 2020 MWAs with significance testing performed between the HEDIS MY 2019 MWA and HEDIS MY 2020 MWAs. Within these figures, HEDIS MY 2020 rates with one cross (⁺) indicate a significant improvement in performance from HEDIS MY 2019 MWA. HEDIS MY 2020 rates with two crosses (⁺⁺) indicate a significant decline in performance from HEDIS MY 2019 MWA. An example of the vertical bar graph figure for measure indicators reported is included in Figure 2-4.







Interpreting Results Presented in This Report

HEDIS results can differ among MHPs and even across measures for the same MHP.

The following questions should be asked when examining these data:

How accurate are the results?

All Michigan MHPs are required by MDHHS to have their HEDIS results confirmed through an NCQA HEDIS Compliance Audit. As a result, any rate included in this report has been verified as an unbiased estimate of the measure. NCQA's HEDIS protocol is designed so that the hybrid method produces results with a sampling error of ± 5 percent at a 95 percent confidence level.

To show how sampling error affects the accuracy of results, an example was provided in the "Data Collection Methods" section above. When an MHP uses the hybrid method to derive a *Postpartum Care* rate of 52 percent, the true rate is actually within \pm 5 percentage points of this rate, due to sampling error. For a 95 percent confidence level, the rate would be between 47 percent and 57 percent. If the target is a rate of 55 percent, it cannot be said with certainty whether the true rate between 47 percent and 57 percent and 57 percent.

To prevent such ambiguity, this report uses a standardized methodology that requires the reported rate to be at or above the threshold level to be considered as meeting the target. For internal purposes, MHPs should understand and consider the issue of sampling error when evaluating HEDIS results.

How do Michigan Medicaid rates compare to national percentiles?

For each measure, an MHP ranking presents the reported rate in order from highest to lowest, with bars representing the established HPL, LPL, and the national HEDIS MY 2019 MWA Medicaid 50th percentile. In addition, the HEDIS MY 2018, MY 2019, and MY 2020 MWA rates are presented for comparison purposes.

Michigan MHPs with reported rates above the 90th percentile (HPL) rank in the top 10 percent of all MHPs nationally. Similarly, MHPs reporting rates below the 25th percentile (LPL) rank in the bottom 25 percent nationally for that measure.

How are Michigan MHPs performing overall?

For each domain of care, a performance profile analysis compares the MY 2020 MWA for each rate with the MY 2018 and MY 2019 MWA and the 50th percentile.



Measure Changes Between HEDIS MY 2019 MWA and HEDIS MY 2020

The following is a list of measures with technical specification changes that NCQA announced for HEDIS MY 2020.²⁻¹ These changes may have an effect on the HEDIS MY 2020 rates that are presented in this report.

Childhood Immunization Status

• Added a requirement that LAIV (influenza) vaccination must occur on the child's second birthday.

Well-Child Visits in the First 30 Months of Life

- Revised the measure name to Well-Child Visits in the First 30 Months of Life.
- Retired the 0, 1, 2, 3, 4 and 5 well-child visit rates.
- Added Rate 2 for children who turned 30 months old during the measurement year and had two or more well-child visits in the last 15 months.
- Removed the Hybrid Data Collection Method.
- Removed the telehealth exclusion.
- Revised the Data Elements for Reporting table.
- Revised the Ages criteria in the Rules for Allowable Adjustments section to only allow ranges within the specified age range of the measure.

Lead Screening in Children

• Removed the limits to the Ages column in the Rules for Allowable Adjustment of HEDIS section.

Child and Adolescent Well-Care Visits

- This measure is a combination measure that replaces the former "Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life" and "Adolescent Well-Care Visits" HEDIS measures.
- Added members age 7–11 years.
- Removed the Hybrid Data Collection Method.
- Removed the telehealth exclusion.
- Revised the Data Elements for Reporting table.

²⁻¹ National Committee for Quality Assurance. *HEDIS[®] MY 2020 & MY 2021, Volume 2: Technical Specifications for Health Plans*. Washington, DC: NCQA Publication, 2016.



• Revised the Ages criteria in the Rules for Allowable Adjustments section to only allow ranges within the specified age range.

Follow-Up Care for Children Prescribed ADHD Medication

- Clarified in step 4 (of both rates) when the diagnosis must be on the discharge claim.
- Added telehealth and telephone visits to the Rate 1 numerator.
- Added e-visits and virtual check-ins to the Rate 2 numerator and modified the telehealth restrictions.

Cervical Cancer Screening

- Added palliative care as a required exclusion.
- Updated the Hybrid Specification to indicate that sample size reduction is allowed.
- Clarified that documentation of "vaginal hysterectomy" meets criteria for documentation of hysterectomy with no residual cervix (optional exclusion).
- Added the "Number of required exclusions" data element to the Data Elements for Reporting table.
- Added guidance adjusting required exclusions criteria in the Rules for Allowable Adjustments section.

Breast Cancer Screening

- Added palliative care as a required exclusion.
- Added telephone visits, e-visits and virtual check-ins to the advanced illness exclusion.
- Added Donepezil-memantine to the "Dementia combinations" description in the Dementia Medications List.
- Added the "Number of required exclusions" data element to the Data Elements for Reporting table.
- Added guidance adjusting required exclusions criteria in the Rules for Allowable Adjustments section.

Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis

- Updated the instructions for excluding visits that result in an inpatient stay.
- In the Rules for Allowable Adjustments section, clarified that the numerator criteria may be adjusted with limits.



Appropriate Testing for Pharyngitis

- Updated the instructions for excluding visits that result in an inpatient stay.
- Deleted step 8; this step is unnecessary because these members are removed in step 5.

Appropriate Treatment for Upper Respiratory Infection

- Updated the instructions for excluding visits that result in an inpatient stay.
- In the Rules for Allowable Adjustments section, clarified that the numerator criteria may be adjusted with limits.

Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents

- Removed the exclusion of member-reported biometric values (body mass index, height and weight).
- Added a Note to clarify that services rendered during a telephone visit, e-visit or virtual check-in meet criteria for the Counseling for Nutrition and Counseling for Physical Activity indicators.

Prenatal and Postpartum Care

- Revised the definition of last enrollment segment.
- Clarified that visits that occur prior to the enrollment start date (during the pregnancy) meet criteria.
- Added telephone visits (Telephone Visits Value Set) e-visits and virtual check-ins (Online Assessments Value Set) to the Timeliness of Prenatal Care rate (administrative specification) and clarified in the Notes that services provided via telephone, e-visit or virtual check-in are eligible for use in reporting both rates.
- Updated the Hybrid specification to indicate that sample size reduction is allowed using only the current year's administrative rate for MY 2020; for MY 2021, organizations may reduce the sample size using the current year's administrative rate or the prior year's audited, product line-specific rate.
- Added examples of "pregnancy diagnosis" in the Hybrid specification of the Timeliness of Prenatal Care indicator.

Comprehensive Diabetes Care

- Retired the "HbA1c control (<7.0%) for a selected population" indicator.
- Retired the "Medical Attention for Nephropathy" indicator for the commercial and Medicaid product lines.
- Clarified in the measure description that organizations must use the same data collection method for the HbA1c testing and control indicators (this information was previously included in the General Guidelines).



- Removed the restriction that only one of the two visits with a diabetes diagnosis be an outpatient telehealth, telephone visit, e-visit or virtual check-in when identifying the event/diagnosis.
- Added telephone visits, e-visits and virtual check-ins to the advanced illness exclusion.
- Added palliative care as a required exclusion.
- Deleted the HbA1c Level 7.0–9.0 Value Set.
- Updated the Administrative Specification logic and value sets for the Eye Exam indicator.
- Added telephone visits, e-visits and virtual check-ins to the Administrative Specification as appropriate settings for BP readings.
- Added Nebivolol-valsartan to the "Antihypertensive combinations" description in the ACE inhibitor and ARB Medications List.
- Added Donepezil-memantine to the "Dementia combinations" description in the Dementia Medications List.
- Added polycystic ovarian syndrome to the optional exclusions.
- Added a Note to the Denominator-Sample Size Reduction section in the Hybrid Specification.
- Clarified that documentation of "HB1c" meets criteria for the Hybrid Specification of the HbA1c testing indicator.
- Clarified that eye exam results read by a system that provides an artificial intelligence (AI) interpretation meet criteria.
- Removed the requirements for remote monitoring devices to allow BPs taken by any digital device.
- Removed the exclusion of BP readings reported or taken by the member.
- Revised the Data Elements for Reporting tables.
- In the Rules for Allowable Adjustments section, clarified that the required exclusions criteria may be adjusted with limits.

Kidney Health Evaluation for Patients With Diabetes

• First-year measure (MY 2020).

Asthma Medication Ratio

- Removed the restriction that only three of the four visits with an asthma diagnosis be an outpatient telehealth, telephone visit, e-visit or virtual check-in when identifying the event/diagnosis.
- Clarified in step 1 when the diagnosis must be on the discharge claim.
- Added Dupilumab to the "Anti-interleukin-4" description in the Dupilumab Medications List.
- Clarified NDC code mapping requirements in the Notes.



Controlling High Blood Pressure

- Revised the time frame in the event/diagnosis criteria to look for two outpatient visits with a diagnosis of hypertension in the first six months of the measurement year and the year prior to the measurement year.
- Removed the restriction that only one of the two visits with a hypertension diagnosis be an outpatient telehealth, telephone visit, e-visit or virtual check-in when identifying the event/diagnosis.
- Added palliative care as a required exclusion.
- Added telephone visits, e-visits and virtual check-ins to the advanced illness exclusion.
- Added Donepezil-memantine to the "Dementia combinations" description in the Dementia Medications List.
- In the Administrative Specification, added telephone visits, e-visits and virtual check-ins as appropriate settings for BP readings.
- Updated the Hybrid Specification to indicate that sample size reduction is not allowed for MY 2020; sample size reduction is allowed for MY 2021.
- Removed the requirements for remote monitoring devices to allow BPs taken by any digital device.
- Removed the exclusion of BP readings reported or taken by the member.
- Added the "Number of required exclusions" data element to the Data Elements for Reporting table.
- Added guidance for adjusting required exclusions in the Rules for Allowable Adjustments section.

Antidepressant Medication Management

• Added e-visits and virtual check-ins to the event/diagnosis (step 2 required exclusion).

Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications

- Added telephone visits, e-visits and virtual check-ins to step 1 of the event/diagnosis.
- Removed the restriction that only one of the two visits with a diabetes diagnosis be an outpatient telehealth, telephone visit, e-visit or virtual check-in when identifying the event/diagnosis, step 2 required exclusions.

Diabetes Monitoring for People With Diabetes and Schizophrenia

- Added telephone visits, e-visits and virtual check-ins to step 1 of the event/diagnosis.
- Removed the restriction that only one of the two visits with a diabetes diagnosis be an outpatient telehealth, telephone visit, e-visit or virtual check-in when identifying the event/diagnosis.
- Added polycystic ovarian syndrome to the optional exclusions.



Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia

- Clarified in step 2 when the diagnosis must be on the discharge claim.
- Added telephone visits, e-visits and virtual check-ins to step 1 of the event/diagnosis.
- Removed the restriction that only one of the two visits with an IVD diagnosis be an outpatient telehealth, telephone visit, e-visit or virtual check-in when identifying the event/diagnosis.

Adherence to Antipsychotic Medications for Individuals With Schizophrenia

- Relabeled step 2 to "Required exclusions" and moved the exclusions for members with advanced illness, frailty, enrolled in an I-SNP or living long-term in an institutional setting to a new step 3 labeled as "exclusions."
- Added telephone visits, e-visits and virtual check-ins to step 1 of the event/diagnosis.
- Added telephone visits, e-visits and virtual check-ins to the advanced illness exclusion.
- Added Donepezil-memantine to the "Dementia combinations" description in the Dementia Medications List.

Race/Ethnicity Diversity of Membership

- Revised the note referring to total member counts.
- Revised the Data Elements for Reporting tables.

Language Diversity of Membership

• Revised the Data Elements for Reporting tables.

Use of Opioids From Multiple Providers

- Added the Aspirin Codeine Medications List, the Codeine Phosphate Medications List and the Acetaminophen Benzhydrocodone Medications List.
- Clarified the instructions for calculating covered days.
- In the Rules for Allowable Adjustments section, clarified that the event/diagnosis and numerator criteria may be adjusted with limits.

Use of Opioids at High Dosage

- Clarified the instructions for calculating covered days for the numerator.
- Clarified the instructions for treatment period.
- Added palliative care as a required exclusion.



- Added medication lists for acetaminophen benzhydrocodone, aspirin codeine and codeine phosphate.
- In the Rules for Allowable Adjustments section, clarified that the event/diagnosis, required exclusions and numerator criteria may be adjusted with limits.

Risk of Continued Opioid Use

- Added the Aspirin Codeine Medications List, the Codeine Phosphate Medications List and the Acetaminophen Benzhydrocodone Medications List.
- Clarified the instructions for calculating covered days.
- Added palliative care as a required exclusion.
- In the Rules for Allowable Adjustments section clarified that the event/diagnosis, required exclusions and numerator criteria may be adjusted with limits.

Plan All-Cause Readmissions

- Revised the measure description.
- Added a Note to the definition of "plan population" to clarify that it should be used as a denominator for the outlier rate.
- Removed "Risk Adjustment Tables" from the Definitions.
- Replaced references to "Table HCC-Surg" with references to the "Surgery Procedure Value Set" in the Risk Adjustment Determination section.
- Replaced references to "Table PCR-DischCC" with "Table CC_Mapping" in the Risk Adjustment Determination section.
- Updated the Note in the Risk Adjustment Weighting section for IHS that are discharged or transferred to skilled nursing care.
- Removed references to specific risk weight tables in the Risk Adjustment Weighting section.
- Clarified rounding rules in step 8 of the Risk Adjustment Weighting section.
- Revised the data element tables to separate the Medicaid and commercial product lines from the Medicare product line.



3. Child & Adolescent Care

Introduction

The Child & Adolescent Care domain encompasses the following HEDIS measures:

- Childhood Immunization Status—Combinations 2–10
- Well-Child Visits in the First 30 Months of Life—Well-Child Visits in the First 15 Months—Six or More Well-Child Visits and Well-Child Visits for Age 15 Months to 30 Months—Two or More Well-Child Visits
- Lead Screening in Children
- Child and Adolescent Well-Care Visits—Ages 3 to 11 Years, Ages 12 to 17 Years, Ages 18 to 21 Years, and Total
- Immunizations for Adolescents—Combinations 1 and 2
- Follow-Up Care for Children Prescribed ADHD Medication—Initiation Phase and Continuation and Maintenance Phase

Please see the "How to Get the Most From This Report" section for guidance on interpreting the figures presented within this section. For reference, additional analyses for each measure indicator are displayed in Appendices A, B, and C.

Summary of Findings

Table 3-1 presents the Michigan MWA performance for the measure indicators under the Child & Adolescent Care domain. The table lists the HEDIS MY 2020 MWA rates and performance levels, a comparison of the HEDIS MY 2019 MWA to the HEDIS MY 2020 MWA for each measure indicator with trend analysis results, and a summary of the MHPs with rates demonstrating significant changes from HEDIS MY 2019 to HEDIS MY 2020.

Measure	HEDIS MY 2020 MWA and Performance Level ¹	HEDIS MY 2019 MWA– HEDIS MY 2020 MWA Comparison ²	Significant	Number of MHPs With Statistically Significant Decline in HEDIS MY 2020
Childhood Immunization Status				
Combination 2	66.88%	-5.83++	0	6
Combination 3	64.00%	-4.36++	0	3

Table 3-1—HEDIS MY 2020 MWA Performance Levels and Trend Results for Child & Adolescent Care

CHILD & ADOLESCENT CARE



Measure	HEDIS MY 2020 MWA and Performance Level ¹	HEDIS MY 2019 MWA– HEDIS MY 2020 MWA Comparison ²	Significant	Number of MHPs With Statistically Significant Decline in HEDIS MY 2020
Combination 4	63.16%	-4.38 ⁺⁺	0	3
Combination 5	56.31%	-2.75++	0	1
Combination 6	37.33%	-0.53	0	1
Combination 7	55.64%	-2.80 ⁺⁺	0	2
Combination 8	37.17%	-0.52	0	1
Combination 9	33.37%	-0.23	0	1
Combination 10	33.22%	-0.23	0	1
Well-Child Visits in the First 30 Months of Life	55.2270	-0.22	0	1
Well-Child Visits in the First 15 Months—Six or More Well-Child Visits ³	61.88%	NC	NC	NC
Well-Child Visits for Age 15 Months to 30 Months—Two or More Well-Child Visits⁴	67.71%	NC	NC	NC
Lead Screening in Children		·		
Lead Screening in Children	73.44%	-4.83++	0	6
Child and Adolescent Well-Care Visits ³				
Ages 3 to 11 Years	50.92%	NC	NC	NC
Ages 12 to 17 Years	42.35%	NC	NC	NC
Ages 18 to 21 Years	27.36%	NC	NC	NC
Total	44.59%	NC	NC	NC
Immunizations for Adolescents				
Combination 1	82.68%	-2.60++	0	1
Combination 2	37.95%	-2.45++	0	0
Follow-Up Care for Children Prescribed ADHD Medication ⁵				
Initiation Phase	46.03%	+1.59	1	0
Continuation and Maintenance Phase	57.74%	+3.09	2	0

¹ HEDIS MY 2020 performance levels were based on comparisons of the HEDIS MY 2020 MWA rates to national Medicaid Quality Compass HEDIS MY 2019 MWA benchmarks. HEDIS MY 2020 performance levels represent the following percentile comparisons:

$\leq 25th$ $\geq 25th$ and $\leq 49th$	\geq 50th and \leq 74th	\geq 75th and \leq 89th	$\geq 90th$
-----------------------------------------	-----------------------------	-----------------------------	-------------

 2 HEDIS MY 2019 MWA to HEDIS MY 2020 MWA comparisons were based on a Chi-square test of statistical significance with a p-value <0.01 due to large denominators.

³ Due to changes in the technical specifications for this measure, NCQA recommends a break in trending between MY 2020 and prior years; therefore, prior years' rates will not be displayed and comparisons to benchmarks will not be performed for this measure.

⁴ This measure is a first-year measure; therefore, prior years' rates cannot be displayed and comparisons to benchmarks cannot be performed for this measure as benchmarks are not yet available.



⁵ Due to changes in the technical specifications for this measure, NCQA recommends trending between MY 2020 and prior years be considered with caution.

NC indicates that a comparison to HEDIS MY 2019 performance is not appropriate.

Red Shading⁺⁺

Indicates that the HEDIS MY 2020 MWA demonstrated a significant decline from the HEDIS MY 2019 MWA.

Table 3-1 shows that for the Child & Adolescent Care domain, the *Follow-Up Care for Children Prescribed ADHD Medication—Initiation Phase* and *Continuation and Maintenance Phase* measure was an area of strength. Both measure indicators ranked above the 50th percentile and demonstrated improvements. Priority ranked above the 50th percentile for the most measures within the Child & Adolescent Care domain (*Childhood Immunization Status—Combinations 2–10, Lead Screening in Children*, and *Immunizations for Adolescents—Combination 1* and *Combination 2*). Total Health and Blue Cross were the only MHPs to rank above the HPL for one indicator each within the *Follow-Up Care for Children Prescribed ADHD Medication* measure.

The MWA demonstrated a significant decline for the *Childhood Immunization Status—Combinations 2, 3, 4, 5,* and 7, *Lead Screening in Children,* and *Immunizations for Adolescents—Combination 1 and Combination 2* indicators, decreasing by over two percentage points. *Lead Screening in Children* had the highest number of MHPs that demonstrated a statistically significant decline in HEDIS MY 2020, as well as a MWA decrease of nearly five percentage points from HEDIS MY 2019. Additionally, the MWA ranked below the 49th percentile for all indicators for the *Childhood Immunization Status* measure.

MDHHS should work with the MHPs and providers to identify potential root causes for the significant decline for the *Lead Screening in Children* measure and work towards possibly increasing the administration of lead blood tests for children 2 years of age. Screening for lead is an easy way to detect an abnormal blood lead level in children. There is no safe blood lead level. If not found early, exposure to lead and high blood levels can lead to irrevocable effects on a child's physical and mental health.³⁻¹ If the decline in children receiving these tests is identified as linked to the COVID-19 public health emergency, MDHHS is encouraged to work with other state Medicaid agencies facing similar barriers, to identify safe methods for children to have access to this important test.

Additionally, MDHHS should work with the MHPs and providers to target improving childhood vaccination rates due to the significant decline across multiple indicators for the *Childhood Immunization Status* measure. The ongoing COVID-19 pandemic is a reminder of the importance of vaccination. The identified declines in routine pediatric vaccine ordering and doses administered might indicate that United States children and their communities face increased risks for outbreaks of vaccine-preventable diseases. Reminding parents of the vital need to protect their children against serious vaccine-preventable diseases, even as the COVID-19 pandemic continues, is critical. As social distancing requirements are relaxed, children who are not protected by vaccines will be more vulnerable

³⁻¹ National Committee for Quality Assurance. Lead Screening in Children. Available at: <u>https://www.ncqa.org/hedis/measures/lead-screening-in-children/</u>. Accessed on: September 17, 2021.

CHILD & ADOLESCENT CARE



to diseases such as measles. In response, continued coordinated efforts between health care providers and public health officials at the local, state, and federal levels will be necessary to achieve rapid catch-up vaccination.³⁻²


³⁻² The Centers for Disease Control and Prevention. Effects of the COVID-19 Pandemic on Routine Pediatric Vaccine Ordering and Administration — United States, 2020. Available at: <u>https://www.cdc.gov/mmwr/volumes/69/wr/mm6919e2.htm/</u>. Accessed on: September 17, 2021.



Measure-Specific Findings


Childhood Immunization Status—Combination 2

Childhood Immunization Status—Combination 2 assesses the percentage of children 2 years of age who received the following vaccines by their second birthday: four diphtheria, tetanus, and acellular pertussis (DTaP), three polio (IPV), one measles, mumps and rubella (MMR), three haemophilus influenza type B (HiB), three hepatitis B (HepB), and one chicken pox (VZV).



Rates with one cross (++) indicate a significant decline in performance from the previous year.


The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.



One MHP ranked above the 50th percentile but fell below the HPL. Eight MHPs fell below the LPL. MHP performance varied by over 26 percentage points.




Childhood Immunization Status—Combination 3 assesses the percentage of children 2 years of age who received the following vaccines by their second birthday: four DTaP, three IPV, one MMR, three HiB, three HepB, one VZV, and four pneumococcal conjugate (PCV).



Rates with one cross (++) *indicate a significant decline in performance from the previous year.*


The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.



One MHP ranked above the 50th percentile but fell below the HPL. Eight MHPs fell below the LPL. MHP performance varied by over 29 percentage points.




Childhood Immunization Status—Combination 4 assesses the percentage of children 2 years of age who received the following vaccines by their second birthday: four DTaP, three IPV, one MMR, three HiB, three HepB, one VZV, four PCV, and one HepA.



Rates with one cross (++) indicate a significant decline in performance from the previous year.


The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.



One MHP ranked above the 50th percentile but fell below the HPL. Eight MHPs fell below the LPL. MHP performance varied by over 28 percentage points.




Childhood Immunization Status—Combination 5 assesses the percentage of children 2 years of age who received the following vaccines by their second birthday: four DTaP, three IPV, one MMR, three HiB, three HepB, one VZV, four PCV, and two or three rotavirus (RV).



Rates with one cross (++) indicate a significant decline in performance from the previous year.


The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.




One MHP ranked above the 50th percentile but fell below the HPL. Seven MHPs fell below the LPL. MHP performance varied by over 29 percentage points.



Childhood Immunization Status—Combination 6 assesses the percentage of children 2 years of age who received the following vaccines by their second birthday: four DTaP, three IPV, one MMR, three HiB, three HepB, one VZV, four PCV, and two influenza (flu).




The HEDIS MY 2020 MWA rate did not demonstrate a significant change from HEDIS MY 2019.



Two MHPs ranked above the 50th percentile but fell below the HPL. Four MHPs fell below the LPL. MHP performance varied by over 32 percentage points.




Childhood Immunization Status—Combination 7 assesses the percentage of children 2 years of age who received the following vaccines by their second birthday: four DTaP, three IPV, one MMR, three HiB, three HepB, one VZV, four PCV, one HepA, and two or three RV.



Rates with one cross (++) indicate a significant decline in performance from the previous year.


The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.




One MHP ranked above the 50th percentile but fell below the HPL. Seven MHPs fell below the LPL. MHP performance varied by over 28 percentage points.



Childhood Immunization Status—Combination 8 assesses the percentage of children 2 years of age who received the following vaccines by their second birthday: four DTaP, three IPV, one MMR, three HiB, three HepB, one VZV, four PCV, one HepA, and two flu.




The HEDIS MY 2020 MWA rate did not demonstrate a significant change from HEDIS MY 2019.




Two MHPs ranked above the 50th percentile but fell below the HPL. Four MHPs fell below the LPL. MHP performance varied by over 31 percentage points.



Childhood Immunization Status—Combination 9 assesses the percentage of children 2 years of age who received the following vaccines by their second birthday: four DTaP, three IPV, one MMR, three HiB, three HepB, one VZV, four PCV, two or three RV, and two flu.




The HEDIS MY 2020 MWA rate did not demonstrate a significant change from HEDIS MY 2019.




Two MHPs ranked above the 50th percentile but fell below the HPL. Four MHPs fell below the LPL. MHP performance varied by over 30 percentage points.



Childhood Immunization Status—Combination 10 assesses the percentage of children 2 years of age who received the following vaccines by their second birthday: four DTaP, three IPV, one MMR, three HiB, three HepB, one VZV, four PCV, one HepA, two or three RV, and two flu.



The HEDIS MY 2020 MWA rate did not demonstrate a significant change from HEDIS MY 2019.




Two MHPs ranked above the 50th percentile but fell below the HPL. Four MHPs fell below the LPL. MHP performance varied by over 29 percentage points.




Well-Child Visits in the First 15 Months—Six or More Well-Child Visits

Well-Child Visits in the First 15 Months of Life—Six or More Well-Child Visits assesses the percentage of members who turned 15 months old during the MY who received six or more well-child visits with a PCP during their first 15 months of life.



Due to changes in the technical specifications in HEDIS MY 2020 for the *Well-Child Visits in the First 15 Months of Life—Six or More Visits Well-Child Visits* measure, a comparison to prior years' results is not appropriate. The rate in the chart above is presented for informational purposes only.




Due to changes in the technical specifications in HEDIS MY 2020 for the *Well-Child Visits in the First 15 Months of Life—Six or More Well-Child Visits* measure, a comparison to prior years' results is not appropriate. The rates in the chart above are presented for informational purposes only. MHP performance varied by over 28 percentage points.




Well-Child Visits in the First 15 Months to 30 Months—Two or More Well-Child Visits

Well-Child Visits in the First 15 Months to 30 Months—Two or More Well-Child Visits assesses the percentage of members who turned 15 months old during the MY who received six or more well-child visits with a PCP during their first 15 months of life.



The Well-Child Visits in the First 15 Months to 30 Months— Two or More Well-Child Visits measure is a first-year measure for HEDIS MY 2020, and therefore was not included in the prior years' results. Therefore, a comparison to prior years' results is not appropriate. The rate in the chart above is presented for informational purposes only.




For HEDIS MY 2020, *Well-Child Visits in the First 15 Months to 30 Months—Two or More Well-Child Visits* was a first-year measure. Comparison to prior years' results is not appropriate. The rates in the chart above are presented for informational purposes only. MHP performance varied by over 23 percentage points.




Lead Screening in Children

Lead Screening in Children assesses the percentage of children 2 years of age who had one or more capillary or venous lead blood test for lead poisoning by their second birthday.



Rates with two crosses (++) indicate a significant decline in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.




Five MHPs and the MWA ranked above the 50th percentile, and fell below the HPL. Two MHPs fell below the LPL. MHP performance varied by over 15 percentage points.




Child and Adolescent Well-Care Visits—Ages 3 to 11 Years

Child and Adolescent Well-Care Visits assesses the percentage of members who were 3 to 11 years old who had at least one comprehensive well-care visit with a PCP or an OB/GYN practitioner during the MY. Due to changes in the technical specifications for this measure, NCQA recommends a break in trending between MY 2020 and prior years; therefore, prior years' rates will not be displayed and comparisons to benchmarks will not be performed for this measure.



Due to changes in the technical specifications in HEDIS MY 2020 for the *Child and Adolescent Well-Care Visits—Ages 3 to 11 years* measure, a comparison to prior years' results is not appropriate. The rate in the chart above is presented for informational purposes only.




Due to changes in the technical specifications in HEDIS MY 2020 for the *Child and Adolescent Well-Care Visits—Ages 3* to 11 years measure, a comparison to prior years' results is not appropriate. The rates in the chart above are presented for informational purposes only. MHP performance varied by over 21 percentage points.




Child and Adolescent Well-Care Visits—Ages 12 to 17 Years

Child and Adolescent Well-Care Visits assesses the percentage of members who were 12 to 17 years old who had at least one comprehensive well-care visit with a PCP or an OB/GYN practitioner during the MY. Due to changes in the technical specifications for this measure, NCQA recommends a break in trending between MY 2020 and prior years; therefore, prior years' rates will not be displayed and comparisons to benchmarks will not be performed for this measure.



Due to changes in the technical specifications in HEDIS MY 2020 for the *Child and Adolescent Well-Care Visits—Ages* 12 to 17 years measure, a comparison to prior years' results is not appropriate. The rate in the chart above is presented for informational purposes only.




Due to changes in the technical specifications in HEDIS MY 2020 for the *Child and Adolescent Well-Care Visits—Ages 12 to 17 years* measure, a comparison to prior years' results is not appropriate. The rates in the chart above are presented for informational purposes only. MHP performance varied by over 25 percentage points.




Child and Adolescent Well-Care Visits—Ages 18 to 21 Years

Child and Adolescent Well-Care Visits assesses the percentage of members who were 18 to 21 years old who had at least one comprehensive well-care visit with a PCP or an OB/GYN practitioner during the MY. Due to changes in the technical specifications for this measure, NCQA recommends a break in trending between MY 2020 and prior years; therefore, prior years' rates will not be displayed and comparisons to benchmarks will not be performed for this measure.



Due to changes in the technical specifications in HEDIS MY 2020 for the *Child and Adolescent Well-Care Visits—Ages* 18 to 21 years measure, a comparison to prior years' results is not appropriate. The rate in the chart above is presented for informational purposes only.




Due to changes in the technical specifications in HEDIS MY 2020 for the *Child and Adolescent Well-Care Visits—Ages 18 to 21 years* measure, a comparison to prior years' results is not appropriate. The rates in the chart above are presented for informational purposes only. MHP performance varied by over 20 percentage points.




Child and Adolescent Well-Care Visits—Total

Child and Adolescent Well-Care Visits—Total assesses the percentage of members who were 3 to 21 years old who had at least one comprehensive well-care visit with a PCP or an OB/GYN practitioner during the MY. Due to changes in the technical specifications for this measure, NCQA recommends a break in trending between MY 2020 and prior years; therefore, prior years' rates will not be displayed and comparisons to benchmarks will not be performed for this measure.



Due to changes in the technical specifications in HEDIS MY 2020 for the *Child and Adolescent Well-Care Visits—Total* measure, a comparison to prior years' results is not appropriate. The rate in the chart above is presented for informational purposes only.




Due to changes in the technical specifications in HEDIS MY 2020 for the *Child and Adolescent Well-Care Visits—Total* measure, a comparison to prior years' results is not appropriate. The rates in the chart above are presented for informational purposes only. MHP performance varied by over 21 percentage points.




Immunizations for Adolescents—Combination 1

Immunizations for Adolescents—*Combination 1* assesses the percentage of adolescents 13 years of age who had the following by their thirteenth birthday: one dose of meningococcal vaccine; and one Tdap vaccine.



Rates with two crosses (++) indicate a significant decline in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.




Three MHPs and the MWA ranked above the 50th percentile, but fell below the HPL. One MHP fell below the LPL. MHP performance varied by over 16 percentage points.




Immunizations for Adolescents—Combination 2

Immunizations for Adolescents—*Combination 2* assesses the percentage of adolescents 13 years of age who had the following by their thirteenth birthday: one dose of meningococcal vaccine; one Tdap vaccine; and two HP.



Rates with two crosses (++) indicate a significant decline in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.




Five MHPs and the MWA ranked above the 50th percentile but fell below the HPL. Two MHPs fell below the LPL. MHP performance varied by approximately 24 percentage points.




Follow-Up Care for Children Prescribed ADHD Medication—Initiation Phase

Follow-Up Care for Children Prescribed ADHD Medication—Initiation Phase assesses the percentage of children 6 to 12 years of age who were newly prescribed ADHD medication who had one follow-up visit with a practitioner with prescribing authority during the 30-day initiation phase.



The HEDIS MY 2020 MWA rate did not demonstrate a significant change from HEDIS MY 2019.




NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

Six MHPs and the MWA ranked above the 50th percentile with one MHP ranked above the HPL. One MHP fell below the LPL. MHP performance varied by over 18 percentage points.




Follow-Up Care for Children Prescribed ADHD Medication—Continuation and Maintenance Phase

Follow-Up Care for Children Prescribed ADHD Medication—Continuation and Maintenance Phase assesses the percentage of children 6 to 12 years of age newly prescribed ADHD medication who remained on the medication for at least 210 days and who, in addition to the visit in the initiation phase, had at least two follow-up visits with a practitioner within 270 days (nine months) after the initiation phase ended.



The HEDIS MY 2020 MWA rate did not demonstrate a significant change from HEDIS MY 2019.



NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

Six MHPs and the MWA ranked above the 50th percentile with one MHP ranked above the HPL. Two MHPs fell below the LPL. MHP performance varied by approximately 26 percentage points.



Introduction

The Women—Adult Care domain encompasses the following HEDIS measures:

- Chlamydia Screening in Women—Ages 16 to 20 Years, Ages 21 to 24 Years, and Total
- Cervical Cancer Screening
- Breast Cancer Screening

Please see the "How to Get the Most From This Report" section for guidance on interpreting the figures presented within this section. For reference, additional analyses for each measure indicator are displayed in Appendices A, B, and C.

Summary of Findings

Table 4-1 presents the Michigan MWA performance for the measure indicators under the Women— Adult Care domain. The table lists the HEDIS MY 2020 MWA rates and performance levels, a comparison of the HEDIS MY 2019 MWA to the HEDIS MY 2020 MWA for each measure indicator with trend analysis results, and a summary of the MHPs with rates demonstrating significant changes from HEDIS MY 2019 MWA to HEDIS MY 2020 MWA.

Table 4-1—HEDIS MY 2020 MWA Performance Levels and Trend Results for Women—Adult Care

Measure	HEDIS MY 2020 MWA and Performance Level ¹	HEDIS MY 2019 MWA– HEDIS MY 2020 MWA Comparison ²	Significant	Number of MHPs With Statistically Significant Decline in HEDIS MY 2020
Chlamydia Screening in Women				
Ages 16 to 20 Years	57.30%	-5.46++	0	7
Ages 21 to 24 Years	63.68%	-5.22++	0	8
Total	60.20%	-5.22++	0	8
Cervical Cancer Screening ³	•			
Cervical Cancer Screening	60.53%	-7.13++	0	5
Breast Cancer Screening ³				
Breast Cancer Screening	56.31%	-4.52++	0	8

¹ HEDIS MY 2020 performance levels were based on comparisons of the HEDIS MY 2020 MWA rates to national Medicaid Quality Compass HEDIS MY 2019 MWA benchmarks. HEDIS MY 2020 performance levels represent the following percentile comparisons:

|--|

 2 HEDIS MY 2019 MWA to HEDIS MY 2020 MWA comparisons were based on a Chi-square test of statistical significance with a p-value <0.01 due to large denominators.

³ Due to changes in the technical specifications for this measure, NCQA recommends trending between MY 2020 and prior years be considered with caution.

Red Shading⁺⁺ Indicates that the HEDIS MY 2020 MWA demonstrated a significant decline from the HEDIS MY 2019 MWA.

Table 4-1 shows that for the Women—Adult Care domain, the MWA demonstrated a significant decline across all measures and indicators. Total Health Care and Molina demonstrated high performance as the only MHPs to rank above the 50th percentile for all *Chlamydia Screening for Women* measure indicators, and the *Cervical Cancer Screening* measure. No MHP ranked above the HPL for any measure in the Women—Adult Care domain. Additionally, Upper Peninsula fell below the LPL for all *Chlamydia Screening for Women* measure indicators and Aetna fell below the LPL for both the *Cervical Cancer Screening* measures.

The Chlamydia Screening in Women and Breast Cancer Screening measures had the highest number of MHPs that demonstrated a statistically significant decline in HEDIS MY 2020, as well as a MWA decrease of over five percentage points from HEDIS MY 2019. Further, the Cervical Cancer Screening measure had the most significant MWA decrease of over seven percentage points from HEDIS MY 2019. MDHHS should work with the MHPs and providers to identify barriers that contribute to lower screening rates for cervical cancer and breast cancer and should work towards establishing resources to increase access to routine cancer screenings. Screening can improve outcomes and early detection reduces the risk of dving can lead to a greater range of treatment options and lower health care costs.⁴⁻¹ Prolonged delays in screening related to the COVID-19 pandemic may lead to delayed diagnoses, poor health consequences, and an increase in cancer disparities among women already experiencing health inequities.⁴⁻² Additionally, MDHHS should work with the MHPs and providers on increasing testing and screening for chlamydia. The CDC has identified several new and innovative ways STD services can meet more people where they are—during the COVID-19 pandemic and in the future—including: STD express clinics, partnerships with pharmacies and retail health clinics, and telehealth.⁴⁻³ If the decline in women receiving these screenings is identified as linked to the COVID-19 public health emergency, MDHHS is encouraged to work with other state Medicaid agencies facing similar barriers, to identify safe methods for women to have access to these important screening services.

⁴⁻¹ National Committee for Quality Assurance. Breast Cancer Screening. Available at: <u>https://www.ncqa.org/hedis/measures/breast-cancer-screening/</u>. Accessed on: September 17, 2021.

⁴⁻² Centers for Disease Control and Prevention. Sharp Declines in Breast and Cervical Cancer Screening. <u>https://www.cdc.gov/media/releases/2021/p0630-cancer-screenings.html</u>. Accessed on: September 17, 2021.


⁴⁻³ Centers for Disease Control and Prevention. Reported STDs Reach All-time High for 6th Consecutive Year. <u>https://www.cdc.gov/media/releases/2021/p0413-stds.html</u>. Accessed on: September 17, 2021.



Measure-Specific Findings


Chlamydia Screening in Women—Ages 16 to 20 Years

Chlamydia Screening in Women—Ages 16 to 20 Years assesses the percentage of women 16 to 20 years of age who were identified as sexually active and had at least one test for chlamydia during the MY.



Rates with two crosses (++) indicate a significant decline in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.




Seven MHPs and the MWA ranked above the 50th percentile but fell below the HPL. One MHP fell below the LPL. MHP performance varied by over 28 percentage points.




Chlamydia Screening in Women—21 to 24 Years

Chlamydia Screening in Women—21 to 24 Years assesses the percentage of women 21 to 24 years of age who were identified as sexually active and had at least one test for chlamydia during the MY.



Rates with two crosses (++) indicate a significant decline in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.




Two MHPs ranked above the 50th percentile but fell below the HPL. One MHP fell below the LPL. MHP performance varied by over 22 percentage points.




Chlamydia Screening in Women—Total

Chlamydia Screening in Women—Total assesses the percentage of women 16 to 24 years of age who were identified as sexually active and had at least one test for chlamydia during the MY.



Rates with two crosses (++) indicate a significant decline in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.




Seven MHPs and the MWA ranked above the 50th percentile but fell below the HPL. One MHP fell below the LPL. MHP performance varied by over 25 percentage points.



Cervical Cancer Screening


Cervical Cancer Screening assesses the percentage of women 21 to 64 years of age who were screened for cervical cancer using either of the following criteria:

- Women 21 to 64 years of age who had cervical cytology performed every three years.
- Women 30 to 64 years of age who had cervical cytology/human papillomavirus co-testing performed every five years.
- Due to changes in the technical specifications for this measure, exercise caution when trending rates between MY 2020 and prior years.



Rates with two crosses (++) indicate a significant decline in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.




Three MHPs ranked above the 50th percentile, but fell below the HPL. Two MHPs fell below the LPL. MHP performance varied by over 27 percentage points.




Breast Cancer Screening

Breast Cancer Screening assesses the percentage of women 50 to 74 years of age who had a mammogram to screen for breast cancer on or after October 1 two years prior to the MY. Due to changes in the technical specifications for this measure, exercise caution when trending rates between MY 2020 and prior years.



Rates with two crosses (++) indicate a significant decline in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.



Two MHPs ranked above the 50th percentile, but fell below the HPL. Two MHPs fell below the LPL. MHP performance varied by over 14 percentage points.



Introduction

The Access to Care domain encompasses the following HEDIS measures:

- Adults' Access to Preventive/Ambulatory Health Services—Ages 20 to 44 Years, Ages 45 to 64 Years, Ages 65 Years and Older, and Total
- Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis—Ages 3 Months to 17 Years, Ages 18 to 64 Years, Ages 65 Years and Older, and Total
- Appropriate Testing for Pharyngitis—Ages 3 to 17 Years, Ages 18 to 64 Years, Ages 65 Years and Older, and Total
- Appropriate Treatment for Upper Respiratory Infection—Ages 3 Months to 17 Years, Ages 18 to 64 Years, Ages 6 Years and Older, and Total

Please see the "How to Get the Most From This Report" section for guidance on interpreting the figures presented within this section. For reference, additional analyses for each measure indicator are displayed in Appendices A, B, and C.

Summary of Findings

Table 5-1 presents the Michigan MWA performance for the measure indicators under the Access to Care domain. The table lists the HEDIS MY 2020 MWA rates and performance levels, a comparison of the HEDIS MY 2019 MWA to the HEDIS MY 2020 MWA for each measure indicator with trend analysis results, and a summary of the MHPs with rates demonstrating significant changes from HEDIS MY 2019 MWA to HEDIS MY 2020 MWA.

Measure Adults' Access to Preventive/Ambulatory Health	HEDIS MY 2020	HEDIS MY 2019 MWA– HEDIS MY 2020 MWA Comparison ²	Significant	Number of MHPs With Statistically Significant Decline in HEDIS MY 2020
Services Ages 20 to 44 Years	74.60%	-4.42++	0	10
Ages 45 to 64 Years	84.05%	-4.42 -3.26 ⁺⁺	0	10
Ages 65 Years and Older	88.77%	-3.91++	0	9
Total	78.22%	-4.27++	0	10

Table 5-1—HEDIS MY 2020 MWA Performance Levels and Trend Results for Access to Care



Measure	HEDIS MY 2020 MWA and Performance Level ¹	HEDIS MY 2019 MWA– HEDIS MY 2020 MWA Comparison ²	Significant	Number of MHPs With Statistically Significant Decline in HEDIS MY 2020
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis				
Ages 3 Months to 17 Years	61.42%	+1.38+	3	0
Ages 18 to 64 Years	39.69%	+2.04+	1	0
Ages 65 Years and Older	32.87%	-1.84	0	1
Total	50.15%	+1.92+	7	0
Appropriate Testing for Pharyngitis ³		-		
Ages 3 to 17 Years	75.34%	-1.53++	0	4
Ages 18 to 64 Years	57.61%	-2.14++	0	3
Ages 65 Years and Older	25.00%	-9.85	0	0
Total	68.56%	-2.27++	0	6
Appropriate Treatment for Upper Respiratory Infection				
Ages 3 Months to 17 Years	91.30%	+0.69+	5	0
Ages 18 to 64 Years	78.18%	+2.79+	8	0
Ages 65 Years and Older	71.33%	+3.09	2	0
Total	87.28%	+1.02+	7	0

¹ 2020 performance levels were based on comparisons of the HEDIS MY 2020 MWA rates to national Medicaid Quality Compass HEDIS MY 2019 MWA benchmarks. 2020 performance levels represent the following percentile comparisons:

 2 HEDIS MY 2019 MWA to HEDIS MY 2020 MWA comparisons were based on a Chi-square test of statistical significance with a p-value <0.01 due to large denominators.

³ Due to changes in the technical specifications for this measure, NCQA recommends trending between MY 2020 and prior years be considered with caution.

Green Shading⁺ Indicates that the HEDIS MY 2020 MWA demonstrated a significant improvement from the HEDIS MY 2019 MWA.

Red Shading⁺⁺ Indicates that the HEDIS MY 2020 MWA demonstrated a significant decline from the HEDIS MY 2019 MWA.

ACCESS TO CARE



Table 5-1 shows that for the Access to Care domain, an area of strength was the Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis—Ages 3 Months to 17 Years and Ages 18 to 64 Years measure indicators ranking above the 50th percentile, with the MWA significantly improving by over one percentage point for both indicators. Aetna, Blue Cross, McLaren, Meridian, HAP, Molina, Priority, Total Health and UnitedHealthcare all ranked above the 50th percentile for the Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis—Ages 3 Months to 17 Years and Ages 18 to 64 Years measure indicators. Additionally, the Appropriate Treatment for Upper Respiratory Infection—18 to 64 Years indicator ranked above the 50th percentile, with the MWA significantly improving by nearly three percentage points. Priority ranked above the HPL for Appropriate Treatment for Upper Respiratory Infection—18 to 64 Years.

Total Health, Aetna, and HAP fell below the LPL for the *Adults' Access to Preventive/Ambulatory Health Services—Ages 20 to 44 years, 45 to 64 Years,* and *Total* indicators, and no MHPs ranked above the 50th percentile for the *Adults' Access to Preventive/Ambulatory Health Services—Ages 20 to 44 years* and 45 to 64 Years indicators. The MWA was below the 50th percentile for all four of the *Adults' Access to Preventive/Ambulatory Health Services* measure indicators and demonstrated a significant decline of over three percentage points from HEDIS MY 2019 for all measure indicators. Blue Cross, UnitedHealthcare, Molina, Aetna, Total Health, and HAP all fell below the LPL for the *Appropriate Testing for Pharyngitis—Total* measure indicator, and the MWA fell below the 50th percentile for the *Appropriate Testing for Pharyngitis—Ages 3 to 17 Years, Ages 18 to 64 Years,* and *Total* measure indicators and demonstrated a significant decline of over one percentage point from HEDIS MY 2019 for these indicators.

MDHHS should continue to monitor the MHPs performance on the four indicators of *Adults' Access to Preventive/Ambulatory Health Services* to ensure the MHPs performance does not continue to decline, in alignment with HSAG's recommendation for *Adults' Access to Preventive/Ambulatory Health Services* in the 2020 Aggregate Report. Additionally, MDHHS should work towards prioritizing preventative and ambulatory health services as part of its quality improvement strategy. Further, MDHHS should conduct a root cause analysis for the decline across multiple indicators for the *Appropriate Testing for Pharyngitis* measure. Proper testing and treatment of pharyngitis prevents the spread of sickness, while reducing unnecessary use of antibiotics.⁵⁻¹ If the decline in adults accessing these services is identified as related to the COVID-19 public health emergency, MDHHS is encouraged to work with other state Medicaid agencies facing similar barriers, to identify safe methods for ensuring ongoing adults' access to these important services.


⁵⁻¹ National Committee for Quality Assurance. Appropriate Testing for Children with Pharyngitis. Available at: <u>https://www.ncqa.org/hedis/measures/appropriate-testing-for-children-with-pharyngitis/</u>. Accessed on: September 17, 2021.



Measure-Specific Findings


Adults' Access to Preventive/Ambulatory Health Services—Ages 20 to 44 Years

Adults' Access to Preventive/Ambulatory Health Services—Ages 20 to 44 Years assesses the percentage of members 20 to 44 years of age who had an ambulatory or preventive care visit during the MY.



Rates with two crosses (++) indicate a significant decline in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.




Seven MHPs and the MWA ranked above the LPL but fell below the 50th percentile. Three MHPs fell below the LPL. MHP performance varied by over 21 percentage points.




Adults' Access to Preventive/Ambulatory Health Services—Ages 45 to 64 Years

Adults' Access to Preventive/Ambulatory Health Services—Ages 45 to 64 Years assesses the percentage of members 45 to 64 years of age who had an ambulatory or preventive care visit during the MY.



Rates with two crosses (++) indicate a significant decline in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.




Six MHPs and the MWA ranked above the LPL but fell below the 50th percentile and the HPL. Four MHPs fell below the LPL. MHP performance varied by over 10 percentage points.




Adults' Access to Preventive/Ambulatory Health Services—Ages 65 Years and Older

Adults' Access to Preventive/Ambulatory Health Services—Ages 65 Years and Older assesses the percentage of members 65 years of age and older who had an ambulatory or preventive care visit during the MY.



Rates with two crosses (++) indicate a significant decline in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.




Three MHPs ranked above the 50th percentile, but fell below the HPL. Three MHPs fell below the LPL. MHP performance varied by approximately 21 percentage points.




Adults' Access to Preventive/Ambulatory Health Services—Total

Adults' Access to Preventive/Ambulatory Health Services—Total assesses the percentage of members 20 years of age and older who had an ambulatory or preventive care visit during the MY.



Rates with two crosses (++) indicate a significant decline in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.




One MHP ranked above the 50th percentile, but fell below the HPL. Four MHPs fell below the LPL. MHP performance varied by over 12 percentage points.




Avoidance of Antibiotic Treatment in for Acute Bronchitis/Bronchiolitis—Ages 3 Months to 17 Years

Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis—Ages 3 Months to 17 Years assesses the percentage of members 3 months to 17 years of age with a diagnosis of acute bronchitis who were not dispensed an antibiotic prescription.



Rates with one cross (+) indicate a significant improvement in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly improved from HEDIS MY 2019.




Nine MHPs and the MWA ranked above the 50th percentile, but fell below the HPL. All MHPs ranked above the LPL. MHP performance varied by over 17 percentage points.




Avoidance of Antibiotic Treatment in for Acute Bronchitis/Bronchiolitis—Ages 18 to 64 Years

Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis—Ages 18 to 64 Years assesses the percentage of members 18 to 64 years of age with a diagnosis of acute bronchitis who were not dispensed an antibiotic prescription.



Rates with one cross (+) *indicate a significant improvement in performance from the previous year.*

The HEDIS MY 2020 MWA rate significantly improved from HEDIS MY 2019.




Nine MHPs and the MWA ranked above the 50th percentile, but fell below the HPL. All MHPs ranked above the LPL. MHP performance varied by over 12 percentage points.




Avoidance of Antibiotic Treatment in for Acute Bronchitis/Bronchiolitis—Ages 65 Years and Older

Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis—Ages 65 Years and Older assesses the percentage of members 65 years of age and older with a diagnosis of acute bronchitis who were not dispensed an antibiotic prescription.



The HEDIS MY 2020 MWA rate did not demonstrate a significant change from HEDIS MY 2019.



NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.


Four MHPs and the MWA ranked above the LPL, but fell below 50th percentile and the HPL. One MHP fell below the LPL. MHP performance varied by over 8 percentage points.






Avoidance of Antibiotic Treatment in for Acute Bronchitis/Bronchiolitis—Total

Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis—Total assesses the percentage of members 3 months of age or older with a diagnosis of acute bronchitis who were not dispensed an antibiotic prescription.



Rates with one cross (+) indicate a significant improvement in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly improved from HEDIS MY 2019.




One MHP ranked above 50th percentile, but fell below the HPL. Nine MHPs and the MWA fell below the 50th percentile, but ranked above the LPL. MHP performance varied by over 12 percentage points.




Appropriate Testing for Pharyngitis—Ages 3 Months to 17 Years

Appropriate Testing for Pharyngitis—Ages 3 Months to 17 Years assesses the percentage of members 3 months to 17 years of age who were diagnosed with pharyngitis, were dispensed an antibiotic, and received a group A streptococcus test for the episode. Due to changes in the technical specifications for this measure, exercise caution when trending rates between MY 2020 and prior years.



Rates with two crosses (++) indicate a significant decline in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019 MWA.




Four MHPs ranked above the LPL, but fell below the 50th percentile. Six MHPs and the MWA fell below the LPL. MHP performance varied by over 15 percentage points.




Appropriate Testing for Pharyngitis—Ages 18 to 64 Years

Appropriate Testing for Pharyngitis—Ages 18 to 64 Years assesses the percentage of members 18 to 64 years of age who were diagnosed with pharyngitis, were dispensed an antibiotic, and received a group A streptococcus test for the episode. Due to changes in the technical specifications for this measure, exercise caution when trending rates between MY 2020 and prior years.



Rates with two crosses (++) indicate a significant decline in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019 MWA.




Three MHPs ranked above 50th percentile, but fell below the HPL. Six MHPs fell below the LPL. MHP performance varied by over 26 percentage points.




Appropriate Testing for Pharyngitis—Ages 65 Years and Older

Appropriate Testing for Pharyngitis—Ages 65 Years and Older assesses the percentage of members 65 years of age and older who were diagnosed with pharyngitis, were dispensed an antibiotic, and received a group A streptococcus test for the episode. Due to changes in the technical specifications for this measure, exercise caution when trending rates between MY 2020 and prior years.



The HEDIS MY 2020 MWA rate did not demonstrate a significant change from HEDIS MY 2019.




NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

One MHP and the MWA ranked above the 50th percentile and the LPL, but fell below the HPL.




Appropriate Testing for Pharyngitis—Total

Appropriate Testing for Pharyngitis—Total assesses the percentage of members who were diagnosed with pharyngitis, were dispensed an antibiotic, and received a group A streptococcus test for the episode. Due to changes in the technical specifications for this measure, exercise caution when trending rates between MY 2020 and prior years.



Rates with two crosses (++) indicate a significant decline in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.




Four MHPs ranked above the LPL, but fell below the 50th percentile and the HPL. Six MHPs and the MWA fell below the LPL. MHP performance varied by over 23 percentage points.

Access to Care

Appropriate Treatment for Upper Respiratory Infection—Ages 3 Months to 17 Years


Appropriate Treatment for Upper Respiratory Infection—Ages 3 Months to 17 Years assesses the percentage of members 3 months to 17 years of age with a diagnosis of upper respiratory infection that did not result in an antibiotic dispensing event.



Rates with one cross (+) *indicate a significant improvement in performance from the previous year.*

The HEDIS MY 2020 MWA rate significantly improved from HEDIS MY 2019.

Five MHPs ranked above the 50th percentile, but fell below the HPL. Five MHPs and the MWA ranked above the LPL, but fell below the 50th percentile. MHP performance varied by approximately six percentage points.






HSAG HEALTH SERVICES




Appropriate Treatment for Upper Respiratory Infection—Ages 18 to 64 Years

Appropriate Treatment for Upper Respiratory Infection—Ages 18 to 64 Years assesses the percentage of members 18 to 64 years of age with a diagnosis of upper respiratory infection that did not result in an antibiotic dispensing event.



Rates with one cross (+) indicate a significant improvement in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly improved from HEDIS MY 2019.




Nine MHPs and the MWA ranked above the 50th percentile, with one above the HPL. One MHP ranked above the LPL, but fell below the 50th percentile. MHP performance varied by over 12 percentage points.

Page 5-18 MI2021_HEDIS_Aggregate_F1_1021


Access to Care

Appropriate Treatment for Upper Respiratory Infection—Ages 65 Years and Older

Appropriate Treatment for Upper Respiratory Infection—Ages 65 Years and Older assesses the percentage of members 65 years of age and older with a diagnosis of upper respiratory infection that did not result in an antibiotic dispensing event.



The HEDIS MY 2020 MWA rate did not demonstrate a significant change from HEDIS MY 2019.



NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

Three MHPs ranked above the 50th percentile, but fell below the HPL. One MHP fell below the LPL. MHP performance varied by nearly 28 percentage points.





ACCESS TO CARE




Appropriate Treatment for Upper Respiratory Infection—Total

Appropriate Treatment for Upper Respiratory Infection—Total assesses the percentage of members with a diagnosis of upper respiratory infection that did not result in an antibiotic dispensing event.





The HEDIS MY 2020 MWA rate significantly improved from HEDIS MY 2019.



Three MHPs ranked above the 50th percentile, but fell below the HPL. One MHP fell below the LPL. MHP performance varied by over eight percentage points.





Introduction

The Obesity domain encompasses the following HEDIS measures:

• Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents— BMI Percentile Documentation—Total, Counseling for Nutrition—Total, and Counseling for Physical Activity—Total

Please see the "How to Get the Most From This Report" section for guidance on interpreting the figures presented within this section. For reference, additional analyses for each measure indicator are displayed in Appendices A, B, and C.

Summary of Findings

Table 6-1 presents the Michigan MWA performance for the measure indicators under the Obesity domain. The table lists the HEDIS MY 2020 MWA rates and performance levels, a comparison of the HEDIS MY 2019 MWA to the HEDIS MY 2020 MWA for each measure indicator with trend analysis results, and a summary of the MHPs with rates demonstrating significant changes from HEDIS MY 2019 MWA to HEDIS MY 2020 MWA.

Table 6-1—HEDIS MY 2020 MWA Performance Levels and Trend Results for Obesity

Measure	HEDIS MY 2020 MWA and Performance Level ¹		Number of MHPs With Statistically Significant Improvement in HEDIS MY 2020	Number of MHPs With Statistically Significant Decline in HEDIS MY 2020
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents				
BMI Percentile Documentation—Total ³	78.53%	-7.31++	0	6
Counseling for Nutrition—Total	69.51%	-6.17++	0	5
Counseling for Physical Activity—Total	67.60%	-6.16++	0	6

¹ HEDIS MY 2020 performance levels were based on comparisons of the HEDIS MY 2020 MWA rates to national Medicaid Quality Compass HEDIS MY 2019 MWA benchmarks. HEDIS MY 2020 performance levels represent the following percentile comparisons:

$\leq 25th$	\geq 25th and \leq 49th	\geq 50th and \leq 74th	\geq 75th and \leq 89th	$\geq 90th$
-------------	-----------------------------	-----------------------------	-----------------------------	-------------

 2 HEDIS MY 2019 MWA to HEDIS MY 2020 MWA comparisons were based on a Chi-square test of statistical significance with a p-value <0.01 due to large denominators.



³ Due to changes in the technical specifications for this measure, NCQA recommends trending between MY 2020 and prior years be considered with caution.

Red Shading⁺⁺ Indicates that the HEDIS MY 2020 MWA demonstrated a significant decline from the HEDIS MY 2019 MWA.

Table 6-1 shows that for the Obesity domain, *Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents—Counseling for Physical Activity—Total* was an area of strength as the MWA was above the 50th percentile. Additionally, Priority, Upper Peninsula, and UnitedHealthcare demonstrated high performance, ranking above the 50th percentile, but falling below the HPL for all three of the measure indicators within the Obesity domain.


The MWA had significant decreases across all measure indicators and ranked below the 50th percentile for two of the three measures within the Obesity domain (*Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents—BMI Percentile Documentation—Total* and *Counseling for Nutrition—Total*). McLaren ranked below the LPL for all three measure indicators. MDHHS should work with the MHPs and providers to strategize the best way to utilize every office visit or virtual visit to encourage a healthy lifestyle and provide education on healthy habits for children and adolescents. Additionally, MDHHS should monitor McLaren's performance for this measure to ensure the MHP performance does not continue to decline and encourage higher performing MHPs to share and discuss best practices. If the decline in children and adolescents receiving these services is identified to be related to the COVID-19 public health emergency, MDHHS is encouraged to work with other state Medicaid agencies facing similar barriers, to identify safe methods for improved access to these services.



Measure-Specific Findings


Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents— BMI Percentile Documentation—Total

Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents—BMI Percentile Documentation—Total assesses the percentage of members 3 to 17 years of age who had an outpatient visit with a PCP or OB/GYN and had evidence of BMI percentile documentation during the MY. Due to changes in the technical specifications for this measure, exercise caution when trending rates between MY 2020 and prior years.



Rates with two crosses (++) indicate a significant decline in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.




Four MHPs ranked above the 50th percentile, but fell below the HPL. One MHP fell below the LPL. MHP performance varied by over 24 percentage points.




Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents— Counseling for Nutrition—Total

Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents—Counseling for Nutrition— Total assesses the percentage of members 3 to 17 years of age who had an outpatient visit with a PCP or OB/GYN and had evidence of counseling for nutrition during the MY.



Rates with two crosses (++) indicate a significant decline in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.




Four MHPs ranked above the 50th percentile, but fell below the HPL. One MHP fell below the LPL. MHP performance varied by over 28 percentage points.




Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents— Counseling for Physical Activity—Total

Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents—Counseling for Physical Activity—Total assesses the percentage of members 3 to 17 years of age who had an outpatient visit with a PCP or OB/GYN and had evidence of counseling for physical activity during the MY.



Rates with two crosses (++) indicate a significant decline in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.



Eight MHPs and the MWA ranked above the 50th percentile, but fell below the HPL. One MHP fell below the LPL. MHP performance varied by over 26 percentage points.



Introduction

The Pregnancy Care domain encompasses the following HEDIS measure:

• Prenatal and Postpartum Care—Timeliness of Prenatal Care and Postpartum Care

Please see the "How to Get the Most From This Report" section for guidance on interpreting the figures presented within this section. For reference, additional analyses for each measure indicator are displayed in Appendices A, B, and C.

Summary of Findings

Table 7-1 presents the Michigan MWA performance for the measure indicators under the Pregnancy Care domain.

			Number of	Number of
			MHPs With	MHPs With
		HEDIS MY 2019	Statistically	Statistically
	HEDIS MY 2020		Significant	Significant
		HEDIS MY 2020		Decline in
	Performance	MWA	in HEDIS	HEDIS
Measure	Level ¹	Comparison ²	MY 2020	MY 2020
Prenatal and Postpartum Care ³				
Timeliness of Prenatal Care	79.54%	-6.63++	0	6
Postpartum Care	70.13%	-3.63++	0	4

Table 7-1—HEDIS MY 2020 MWA Performance Levels and Trend Results for Pregnancy Care

¹ HEDIS MY 2020 performance levels were based on comparisons of the HEDIS MY 2020 MWA rates to national Medicaid Quality Compass HEDIS MY 2019 MWA benchmarks. HEDIS MY 2020 performance levels represent the following percentile comparisons:

	<i>≤25th</i>	th ≥ 25 th and ≤ 49 th	\geq 50th and \leq 74th	\geq 75th and \leq 89th	$\geq 90th$
--	--------------	----------------------------------	-----------------------------	-----------------------------	-------------

 2 HEDIS MY 2019 MWA to HEDIS MY 2020 MWA comparisons were based on a Chi-square test of statistical significance with a p-value <0.01 due to large denominators.

³ Due to changes in the technical specifications for this measure, NCQA recommends trending between MY 2020 and prior years be considered with caution.

Red Shading⁺⁺ Indicates that the HEDIS MY 2020 MWA demonstrated a significant decline from the HEDIS MY 2019 MWA.



Table 7-1 shows that for the Pregnancy Care domain, both measure indicators ranked below the 25th percentile and had a MWA decrease of over three percentage points from HEDIS MY 2019, with the *Prenatal and Postpartum Care—Timeliness of Prenatal Care* indicator demonstrating the most significant MWA decrease of over six percentage points from HEDIS MY 2019. Molina, Meridian, Blue Cross, UnitedHealthcare, McLaren, Aetna, HAP, and Total Health all fell below the LPL for both *Prenatal and Postpartum Care—Timeliness of Prenatal Care* and *Postpartum Care* indicators. The MWA also fell below the LPL for both measure indicators.

Upper Peninsula ranked above the 50th percentile for both measure indicators, and was above the HPL for *Prenatal and Postpartum Care*—*Postpartum Care*. MDHHS should work with the MHPs and providers on the best practices for providing ongoing prenatal and postpartum care. This is especially important during COVID-19, as pregnant and recently pregnant women are at a higher risk for severe illness from COVID-19 than nonpregnant women. Additionally, pregnant women with COVID-19 are at a higher risk for preterm birth and might have a higher risk for other adverse pregnancy outcomes.⁷⁻¹ MDHHS is encouraged to work with the higher performing MHPs to identify best practice to ensuring women access to prenatal and postpartum care, which can then be spread to the lower performing MHPs to improve overall access.


⁷⁻¹ Centers for Disease Control and Prevention. Investigating the Impact of COVID-19 during Pregnancy. Available at: <u>https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/special-populations/pregnancy-data-on-covid-19/what-cdc-is-doing.html</u>. Accessed on: September 17, 2021.



Measure-Specific Findings


Prenatal and Postpartum Care—Timeliness of Prenatal Care

Prenatal and Postpartum Care—Timeliness of Prenatal Care assesses the percentage of deliveries of live births that received a prenatal care visit as a member of the MHP in the first trimester or within 42 days of enrollment in the MHP. Due to changes in the technical specifications for this measure, exercise caution when trending rates between MY 2020 and prior years.



Rates with two crosses (++) indicate a significant decline in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.




One MHP ranked above the 50th percentile, but fell below the HPL. Eight MHPs and the MWA fell below the LPL. MHP performance varied by over 26 percentage points.




Prenatal and Postpartum Care—Postpartum Care

Prenatal and Postpartum Care—Postpartum Care assesses the percentage of deliveries of live births that had a postpartum visit on or between 21 and 56 days after delivery. Due to changes in the technical specifications for this measure, exercise caution when trending rates between MY 2020 and prior years.



Rates with two crosses (++) indicate a significant decline in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.



Two MHPs ranked above the 50th percentile, with one MHP above the HPL. Seven MHPs and the MWA fell below the LPL. MHP performance varied by over 34 percentage points.



Introduction

The Living With Illness domain encompasses the following HEDIS measures:

- Comprehensive Diabetes Care—HbA1c Testing, HbA1c Poor Control (>9.0%), HbA1c Control (<8.0%), Eye Exam (Retinal) Performed, and Blood Pressure Control (<140/90 mm Hg)
- Kidney Health Evaluation for Patients With Diabetes—Ages 18 to 64 Years, Ages 65 to 74 Years, Ages 75 to 85 Years, and Total
- Asthma Medication Ratio—Total
- Controlling High Blood Pressure
- Medical Assistance With Smoking and Tobacco Use Cessation—Advising Smokers and Tobacco Users to Quit, Discussing Cessation Medications, and Discussing Cessations Strategies
- Antidepressant Medication Management—Effective Acute Phase Treatment and Effective Continuation Phase Treatment
- Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications
- Diabetes Monitoring for People With Diabetes and Schizophrenia
- Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia
- Adherence to Antipsychotic Medications for Individuals With Schizophrenia

Please see the "How to Get the Most From This Report" section for guidance on interpreting the figures presented within this section. For reference, additional analyses for each measure indicator are displayed in Appendices A, B, and C.

Summary of Findings

Table 8-1 presents the Michigan MWA performance for the measure indicators under the Living With Illness domain. The table lists the HEDIS MY 2020 MWA rates and performance levels, a comparison of the HEDIS MY 2019 MWA to the HEDIS MY 2020 MWA for each measure indicator with trend analysis results, and a summary of the MHPs with rates demonstrating significant changes from HEDIS MY 2019 MWA to HEDIS MY 2020 MWA.



Measure	HEDIS MY 2020 MWA and Performance Level	HEDIS MY 2019 MWA– HEDIS MY 2020 MWA Comparison	Number of MHPs With Statistically Significant Improvement in HEDIS MY 2020	Number of MHPs With Statistically Significant Decline in HEDIS MY 2020
Comprehensive Diabetes Care				
Hemoglobin A1C (HbA1c) Testing ⁴	83.13%	-6.07++	0	6
HbA1c Poor Control (>9.0%)*4	43.03%	+5.82++	0	4
HbA1c Control (<8.0%) ⁴	47.46%	-5.26++	0	5
Eye Exam (Retinal) Performed⁴	53.65%	-8.95 ⁺⁺	0	6
Blood Pressure Control (<140/90 mm Hg) ⁵	58.38%	NC	NC	NC
Kidney Health Evaluation for Patients With Diabetes ⁶	·			
Ages 18 to 64 Years	30.63%	NC	NC	NC
Ages 65 to 74 Years	32.03%	NC	NC	NC
Ages 75 to 85 Years	29.97%	NC	NC	NC
Total	30.68%	NC	NC	NC
Asthma Medication Ratio				
Total	56.83%	-3.03++	0	5
Controlling High Blood Pressure ⁵	·			
Controlling High Blood Pressure	54.48%	NC	NC	NC
Medical Assistance With Smoking and Tobacco Use Cessation ³				
Advising Smokers and Tobacco Users to Quit	76.98%	-3.66++	0	0
Discussing Cessation Medications	56.97%	-2.21++	0	1
Discussing Cessation Strategies	50.01%	-1.55++	0	0
Antidepressant Medication Management				
Effective Acute Phase Treatment	59.28%	+4.31+	3	2
Effective Continuation Phase Treatment	42.98%	+4.21+	1	2
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications				
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications	78.01%	-6.37++	0	6
Diabetes Monitoring for People With Diabetes and Schizophrenia				
Diabetes Monitoring for People With Diabetes and Schizophrenia	61.98%	-6.33++	0	3

Table 8-1—HEDIS MY 2020 MWA Performance Levels and Trend Results for Living With Illness



Measure	HEDIS MY 2020	HEDIS MY 2019 MWA– HEDIS MY 2020 MWA Comparison	Significant	Number of MHPs With Statistically Significant Decline in HEDIS MY 2020
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia				
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia	64.95%	-8.21	0	1
Adherence to Antipsychotic Medications for Individuals With Schizophrenia				
Adherence to Antipsychotic Medications for Individuals With Schizophrenia	68.17%	+8.91+	2	0

¹ HEDIS MY 2020 performance levels were based on comparisons of the HEDIS MY 2019 MWA rates to national Medicaid Quality Compass HEDIS MY 2019 MWA benchmarks. HEDIS MY 2020 performance levels represent the following percentile comparisons:

$\leq 25 th and \leq 49 th \geq 50 th and \leq 74 th \geq 75 th and \leq 89 th \geq 90 th$

 2 HEDIS MY 2019 MWA to HEDIS MY 2020 MWA comparisons were based on a Chi-square test of statistical significance with a p-value <0.01 due to large denominators.

³ To align with calculations from prior years, the weighted average for this measure used the eligible population for the survey rather than the number of people who responded as being smokers.

⁴ Due to changes in the technical specifications for this measure, NCQA recommends trending between MY 2020 and prior years be considered with caution.

⁵ Due to changes in the technical specifications for this measure, NCQA recommends a break in trending between MY 2020 and prior years; therefore, prior years' rates will not be displayed and comparisons to benchmarks will not be performed for this measure.

⁶ This measure is a first-year measure; therefore, prior years' rates cannot be displayed and comparisons to benchmarks cannot be performed for this measure as benchmarks are not yet available.

NC indicates that a comparison to 2019 performance is not appropriate.

* For this indicator, a lower rate indicates better performance.

Green Shading^{*} Indicates that the HEDIS MY 2020 MWA demonstrated a significant improvement from the HEDIS MY 2019 MWA.

Red Shading⁺⁺ Indicates that the HEDIS MY 2020 MWA demonstrated a significant decline from the HEDIS MY 2019 MWA.

LIVING WITH ILLNESS



Table 8-1 shows that for the Living With Illness domain, *Antidepressant Medication Management— Effective Acute Phase Treatment* and *Adherence to Antipsychotic Medications for Individuals With Schizophrenia* were an area of strength. Both measure indicators went from below the 75th percentile in MY 2019 to above the 75th percentile in MY 2020 and demonstrated significant increases, with *Antidepressant Medication Management—Effective Acute Phase Treatment* increasing by more than four percentage points and *Adherence to Antipsychotic Medications for Individuals With Schizophrenia* increasing by nearly nine percentage points. Total Health was the only MHP to rank above the HPL and the 50th percentile for all *Medical Assistance With Smoking and Tobacco Use Cessation* measure indicators. Priority was the only MHP to rank above the 50th percentile for all *Comprehensive Diabetes Care* measure indicators. Total Health and Meridian ranked above the HPL for *Antidepressant Medication Management—Effective Acute Phase Treatment*, with Total Health also ranking above the HPL for the *Effective Continuation Phase Treatment* measure indicator.

For *Medical Assistance With Smoking and Tobacco Use Cessation*, the MWA for all measure indicators demonstrated a significant decline of over one percentage point, with *Advising Smokers and Tobacco Users to Quit* demonstrating the most decline at over three percentage points and ranking below the 50th percentile. McLaren, Molina, Aetna, Blue Cross, HAP, Total Health and the MWA fell below the LPL for *Asthma Medication Ratio—Total*, with the MWA demonstrating a significant decline of over three percentage points from HEDIS MY 2019.

The MWA demonstrated the most significant declines for *Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications, Diabetes Monitoring for People With Diabetes and Schizophrenia,* and all comparable *Comprehensive Diabetes Care* measure indicators. The measures all demonstrated significant declines in the MWA of more than five percentage points from MY 2019 to MY 2020. MDHHS should implement a quality improvement strategy with MHPs and providers that would focus on effective treatment programs for people with diabetes, which should include people with schizophrenia and bipolar disorder. Lack of appropriate care for diabetes and cardiovascular disease for people with schizophrenia or bipolar disorder who use antipsychotic medications can lead to worsening health and death. Addressing these physical health needs is an important way to improve health, quality of life and economic outcomes downstream.⁸⁻¹ If the decline in receipt of these services is determined to be related to the COVID-19 public health emergency, MDHHS is encouraged to work with other state Medicaid agencies facing similar barriers, to identify safe methods for adults to have access to these important services.


⁸⁻¹ National Committee for Quality Assurance. Diabetes and Cardiovascular Disease Screening and Monitoring for People With Schizophrenia or Bipolar Disorder. Available at: <u>https://www.ncqa.org/hedis/measures/diabetes-and-cardiovascular-disease-screening-and-monitoring-for-people-with-schizophrenia-or-bipolar-disorder/</u> Accessed on: September 17, 2021.



Measure-Specific Findings


Comprehensive Diabetes Care—HbA1c Testing

Comprehensive Diabetes Care—HbA1c Testing assesses the percentage of members 18 to 75 years of age with diabetes (type 1 and type 2) who had HbA1c testing. Due to changes in the technical specifications for this measure, exercise caution when trending rates between MY 2020 and prior years.



Rates with two crosses (++) indicate a significant decline in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.



One MHP ranked above the 50th percentile, but fell below the HPL. Eight MHPs and the MWA fell below the LPL. MHP performance varied by over 12 percentage points. HSAG HEALTH SERVICES

Comprehensive Diabetes Care—HbA1c Poor Control (>9.0%)

Comprehensive Diabetes Care—HbA1c Poor Control (>9.0%) assesses the percentage of members 18 to 75 years of age with diabetes (type 1 and type 2) whose most recently documented HbA1c level was greater than 9.0 percent. For this measure, a lower rate indicates better performance. Due to changes in the technical specifications for this measure, exercise caution when trending rates between MY 2020 and prior years.





Figure 8–3—Comprehensive Diabetes Care—HbA1c Poor Control (>9.0%)

Michigan MWAs

Rates with two crosses (++) indicate a significant decline in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.




Three MHPs ranked above the 50th percentile, but fell below the HPL. Four MHPs fell below the LPL. MHP performance varied by approximately 28 percentage points.




Comprehensive Diabetes Care—HbA1c Control (<8.0%)

Comprehensive Diabetes Care—HbA1c Control (<8.0%) assesses the percentage of members 18 to 75 years of age with diabetes (type 1 and type 2) whose most recently documented HbA1c level was less than 8.0 percent. Due to changes in the technical specifications for this measure, exercise caution when trending rates between MY 2020 and prior years.



Rates with two crosses (++) indicate a significant decline in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.




Three MHPs ranked above the 50th percentile, but fell below the HPL. Four MHPs fell below the LPL. MHP performance varied by over 22 percentage points.




Comprehensive Diabetes Care—Eye Exam (Retinal) Performed

Comprehensive Diabetes Care—Eye Exam (Retinal) Performed assesses the percentage of members 18 to 75 years of age with diabetes (type 1 and type 2) who had screening or monitoring for diabetic retinal disease. Due to changes in the technical specifications for this measure, exercise caution when trending rates between MY 2020 and prior years.



Rates with two crosses (++) indicate a significant decline in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.




Three MHPs ranked above the 50th percentile, but fell below the HPL. Four MHPs fell below the LPL. MHP performance varied by approximately 21 percentage points.




Comprehensive Diabetes Care—Blood Pressure Control (<140/90 mm Hg)

Comprehensive Diabetes Care—Blood Pressure Control (<140/90 mm Hg) assesses the percentage of members 18 to 75 years of age with diabetes (type 1 and type 2) whose most recent blood pressure reading was less than 140/90 mm Hg. Due to changes in the technical specifications for this measure, NCQA recommends a break in trending between MY 2020 and prior years; therefore, prior years' rates will not be displayed and comparisons to benchmarks will not be performed for this measure.



Due to changes in the technical specifications in HEDIS MY 2020 for the *Comprehensive Diabetes Care—Blood Pressure Control (<140/90 mm Hg)* measure, a comparison to prior years' results is not appropriate. The rate in the chart above is presented for informational purposes only.




Due to changes in the technical specifications in HEDIS MY 2020 for the *Comprehensive Diabetes Care—Blood Pressure Control (<140/90 mm Hg)* measure, a comparison to prior years' results is not appropriate. The rates in the chart above are presented for informational purposes only. MHP performance varied by approximately 31 percentage points.




Kidney Health Evaluation for People With Diabetes—Ages 18 to 64 Years

Kidney Health Evaluation for Patients With Diabetes assesses the percentage of members 18 to 64 years of age with diabetes (type 1 and type 2) who received a kidney health evaluation, defined by an estimated glomerular filtration rate (eGFR) and a urine albumin-creatinine ratio (uACR), during the MY.



The Kidney Health Evaluation for Patients With Diabetes— Ages 18 to 64 Years measure is a first-year measure for HEDIS MY 2020, and therefore was not included in the prior years' results. Therefore, a comparison to prior years' results is not appropriate. The rate in the chart above is presented for informational purposes only.




NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

For HEDIS MY 2020, *Kidney Health Evaluation for Patients With Diabetes—Ages 18 to 64 Years* was a first-year measure. Comparison to prior years' results is not appropriate. The rates in the chart above are presented for informational purposes only. MHP performance varied by approximately 23 percentage points.




Kidney Health Evaluation for People With Diabetes—Ages 65 to 74 Years

Kidney Health Evaluation for Patients With Diabetes assesses the percentage of members 65 to 74 years of age with diabetes (type 1 and type 2) who received a kidney health evaluation, defined by an eGFR and an uACR, during the MY.



The Kidney Health Evaluation for Patients With Diabetes— Ages 65 to 74 Years measure is a first-year measure for HEDIS MY 2020, and therefore was not included in the prior years' results. Therefore, a comparison to prior years' results is not appropriate. The rate in the chart above is presented for informational purposes only.




For HEDIS MY 2020, *Kidney Health Evaluation for Patients With Diabetes—Ages 65 to 74 Years* was a first-year measure. Comparison to prior years' results is not appropriate. The rates in the chart above are presented for informational purposes only. MHP performance varied by over 19 percentage points.




Kidney Health Evaluation for People With Diabetes—Ages 75 to 85 Years

Kidney Health Evaluation for Patients With Diabetes assesses the percentage of members 75 to 85 years of age with diabetes (type 1 and type 2) who received a kidney health evaluation, defined by an estimated glomerular filtration rate (eGFR) and a urine albumin-creatinine ratio (uACR), during the MY.



The Kidney Health Evaluation for Patients With Diabetes— Ages 75 to 85 Years measure is a first-year measure for HEDIS MY 2020, and therefore was not included in the prior years' results. Therefore, a comparison to prior years' results is not appropriate. The rate in the chart above is presented for informational purposes only.




For HEDIS MY 2020, *Kidney Health Evaluation for Patients With Diabetes—Ages 75 to 85 Years* was a first-year measure. Comparison to prior years' results is not appropriate. The rates in the chart above are presented for informational purposes only. MHP performance varied by over 38 percentage points.




Kidney Health Evaluation for People With Diabetes—Total

Kidney Health Evaluation for Patients With Diabetes—Total assesses the percentage of members 18 to 85 years of age with diabetes (type 1 and type 2) who received a kidney health evaluation, defined by an estimated glomerular filtration rate (eGFR) and a urine albumin-creatinine ratio (uACR), during the MY.



The Kidney Health Evaluation for Patients With Diabetes— Total measure is a first-year measure for HEDIS MY 2020, and therefore was not included in the prior years' results. Therefore, a comparison to prior years' results is not appropriate. The rate in the chart above is presented for informational purposes only.




For HEDIS MY 2020, *Kidney Health Evaluation for Patients With Diabetes—Total* was a first-year measure. Comparison to prior years' results is not appropriate. The rates in the chart above are presented for informational purposes only. MHP performance varied by approximately 22 percentage points.




Asthma Medication Ratio—Total

Asthma Medication Ratio—Total assesses the percentage of members 5 to 64 years of age who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater during the MY.



Rates with two crosses (++) indicate a significant decline in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.




One MHP ranked above the 50th percentile, but fell below the HPL. Six MHPs and the MWA fell below the LPL. MHP performance varied by over 27 percentage points.




Controlling High Blood Pressure

Controlling High Blood Pressure assesses the percentage of members 18 to 85 years of age who had a diagnosis of hypertension and whose blood pressure was adequately controlled during the MY. Due to changes in the technical specifications for this measure, NCQA recommends a break in trending between MY 2020 and prior years; therefore, prior years' rates will not be displayed and comparisons to benchmarks will not be performed for this measure.



Due to changes in the technical specifications in HEDIS MY 2020 for the *Controlling High Blood Pressure* measure, a comparison to prior years' results is not appropriate. The rate in the chart above is presented for informational purposes only.




Due to changes in the technical specifications in HEDIS MY 2020 for the *Controlling High Blood Pressure* measure, a comparison to prior years' results is not appropriate. The rates in the chart above are presented for informational purposes only. MHP performance varied by over 29 percentage points.




Medical Assistance With Smoking and Tobacco Use Cessation—Advising Smokers and Tobacco Users to Quit

Medical Assistance With Smoking and Tobacco Use Cessation—Advising Smokers and Tobacco Users to Quit assesses the percentage of members 18 years of age and older who are current smokers or tobacco users and received cessation advice during the MY.



Rates with two crosses (++) indicate a significant decline in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.




Six MHPs ranked above the 50th percentile, with one MHP ranking above the HPL. Two MHPs fell below the LPL. MHP performance varied by approximately 16 percentage points.




Medical Assistance With Smoking and Tobacco Use Cessation—Discussing Cessation Medications

Medical Assistance With Smoking and Tobacco Use Cessation—Discussing Cessation Medications assesses the percentage of members 18 years of age and older who are current smokers or tobacco users and discussed or were recommended cessation medications during the MY.



Rates with two crosses (++) indicate a significant decline in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.




Nine MHPs ranked above the 50th percentile, with one MHP ranking above the HPL. One MHPs ranked below the 50th percentile, but was above the LPL. MHP performance varied by over 17 percentage points.




Medical Assistance With Smoking and Tobacco Use Cessation—Discussing Cessation Strategies

Medical Assistance With Smoking and Tobacco Use Cessation—Discussing Cessation Strategies assesses the percentage of members 18 years of age or older who are current smokers or tobacco users and discussed or were provided cessation methods or strategies during the MY.



Rates with two crosses (++) indicate a significant decline in performance from the previous year.


The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.



Eight MHPs and the MWA ranked above the 50th percentile, with one MHP ranking above the HPL. Two MHPs ranked below the 50th percentile, but was above the LPL. MHP performance varied by over 13 percentage points.


Antidepressant Medication Management—Effective Acute Phase Treatment

Antidepressant Medication Management—Effective Acute Phase Treatment assesses the percentage of members 18 years of age and older who were treated with antidepressant medication, had a diagnosis of major depression, and remained on an antidepressant medication treatment for at least 84 days (12 weeks).



Rates with one cross (+) *indicate a significant improvement in performance from the previous year.*

The HEDIS MY 2020 MWA rate significantly improved from HEDIS MY 2019.




Eight MHPs and the MWA ranked above the 50th percentile, with two MHPs ranking above the HPL. Two MHPs ranked below the 50th percentile, but were above the LPL. MHP performance varied by approximately 20 percentage points.






Antidepressant Medication Management—Effective Continuation Phase Treatment

Antidepressant Medication Management—Effective Continuation Phase Treatment assesses the percentage of members 18 years of age and older who were treated with antidepressant medication, had a diagnosis of major depression, and remained on an antidepressant medication treatment for at least 180 days (6 months).



Rates with one cross (+) indicate a significant improvement in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly improved from HEDIS MY 2019




Eight MHPs and the MWA ranked above the 50th percentile, with one MHPs ranking above the HPL. Two MHPs ranked below the 50th percentile, with one falling below the LPL. MHP performance varied by over 23 percentage points.




Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications

Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications assesses the percentage of members 18 to 64 years of age with schizophrenia, schizoaffective disorder, or bipolar disorder, who were dispensed an antipsychotic medication and had a diabetes screening test during the MY.



Rates with two crosses (++) indicate a significant decline in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.




Two MHPs ranked above the 50th percentile, but fell below the HPL. Four MHPs and the MWA fell below the LPL. MHP performance varied by approximately 22 percentage points.




Diabetes Monitoring for People With Diabetes and Schizophrenia

Diabetes Monitoring for People With Diabetes and Schizophrenia assesses the percentage of members 18 to 64 years of age with schizophrenia or schizoaffective disorder and diabetes, who had both a low-density lipoprotein cholesterol (LDL-C) test and an HbA1c test during the MY.



Rates with two crosses (++) indicate a significant decline in performance from the previous year.

The HEDIS MY 2020 MWA rate significantly declined from HEDIS MY 2019.




One MHPs ranked above the 50th percentile and the HPL. The remainder of MHPs fell below the LPL, along with the MWA. MHP performance varied by over 29 percentage points.




Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia

Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia assesses the percentage of members 18 to 64 years of age with schizophrenia or schizoaffective disorder and cardiovascular disease who had an LDL-C test during the MY.



The HEDIS MY 2020 MWA rate did not demonstrate a significant change from HEDIS MY 2019.




NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

All MHPs and the MWA fell below the 50th percentile, HPL and the LPL. MHP performance varied by over 16 percentage points.


Adherence to Antipsychotic Medications for Individuals With Schizophrenia

Adherence to Antipsychotic Medications for Individuals With Schizophrenia assesses the percentage of members 19 to 64 years of age with schizophrenia or schizoaffective disorder who were dispensed and remained on an antipsychotic medication for at least 80 percent of their treatment period.



Rates with one cross (+) *indicate a significant improvement in performance from the previous year.*

The HEDIS MY 2020 MWA rate significantly improved from HEDIS MY 2019.



Eight MHPs and the MWA ranked above the 50th percentile, with one MHP ranking above the HPL. One MHP fell below the LPL. MHP performance varied by over 31 percentage points.





Introduction

The Health Plan Diversity domain encompasses the following HEDIS measures:

- Race/Ethnicity Diversity of Membership
- Language Diversity of Membership—Spoken Language Preferred for Health Care, Preferred Language for Written Materials, and Other Language Needs

Summary of Findings

Although measures under this domain are not performance measures and are not compared to percentiles, changes observed in the results may provide insight into how select member characteristics affect the MHPs' provision of services and care. The *Race/Ethnicity Diversity of Membership* measure shows that the HEDIS MY 2020 MWA rates for different racial/ethnic groups were fairly stable across years, with less than three percentage points difference between MY 2019 and MY 2020 for all racial/ethnic groups.

For the *Language Diversity of Membership* measure, MY 2020 rates remained similar to prior years, with Michigan members reporting English as the preferred spoken language for healthcare and preferred language for written materials, with nearly two percentage points difference between MY 2019 and MY 2020.



Race/Ethnicity Diversity of Membership

Measure Definition

Race/Ethnicity Diversity of Membership is an unduplicated count and percentage of members enrolled at any time during the MY, by race and ethnicity.

Results

Table 9-1a and b show that the statewide rates for reported racial/ethnic groups remained similar to prior years.

МНР	Eligible Population	White	Black or African American	American Indian or Alaska Native	Asian	Native Hawaiian and Other Pacific Islander
AET	64,191	32.58%	53.80%	0.19%	1.16%	0.08%
BCC	308,376	46.98%	34.60%	1.01%	1.77%	3.26%
HAP	30,185	39.22%	46.62%	0.15%	1.74%	0.04%
MCL	260,190	64.38%	20.63%	0.55%	0.80%	0.09%
MER	560,437	59.95%	22.36%	0.48%	2.43%	0.08%
MOL	419,718	45.74%	34.04%	0.27%	0.30%	<0.01%
PRI	173,634	59.62%	15.20%	0.55%	0.97%	0.08%
THC	70,651	29.57%	50.92%	0.22%	0.00%	0.08%
UNI	319,061	50.57%	29.76%	0.30%	3.38%	0.08%
UPP	60,478	87.12%	1.66%	2.67%	0.44%	0.13%
HEDIS MY 2020 MWA		53.44%	28.03%	0.54%	1.61%	0.50%
HEDIS MY 2019 MWA		53.27%	27.45%	0.49%	1.87%	0.44%
HEDIS MY 2018 MWA		52.40%	26.89%	0.45%	0.88%	0.39%

Table 9-1a—MHP and MWA Results for Race/Ethnicity Diversity of Membership



МНР	Eligible Population	Some Other Race	Two or More Races	Unknown	Declined	Hispanic or Latino*
AET	64,191	0.00%	0.00%	6.03%	6.16%	3.62%
BCC	308,376	<0.01%	0.04%	12.35%	<0.01%	3.11%
НАР	30,185	3.98%	0.00%	8.24%	<0.01%	3.72%
MCL	260,190	6.06%	0.00%	7.48%	0.00%	6.06%
MER	560,437	0.00%	0.00%	14.70%	0.00%	0.00%
MOL	419,718	0.00%	0.00%	19.64%	0.00%	6.92%
PRI	173,634	0.00%	0.00%	23.58%	0.00%	11.27%
THC	70,651	0.00%	0.00%	6.28%	12.94%	3.41%
UNI	319,061	0.00%	0.00%	15.90%	0.00%	6.34%
UPP	60,478	2.08%	0.00%	0.00%	5.90%	2.08%
HEDIS MY 2020 MWA		0.80%	0.00%	14.33%	0.74%	4.47%
HEDIS MY 2019 MWA		0.69%	0.00%	12.90%	2.89%	6.02%
HEDIS MY 2018 MWA		0.85%	0.00%	12.15%	5.99%	5.53%

Table 9-1b—MHP and MWA Results for Race/Ethnicity Diversity of Membership (Continued)

* Starting from HEDIS 2011, the rates associated with members of Hispanic origin were not based on the total number of members in the health plan. Therefore, the rates presented here were calculated by HSAG using the total number of members reported from the Hispanic or Latino column divided by the total number of members in the health plan reported in the MHP IDSS files.



Language Diversity of Membership

Measure Definition

Language Diversity of Membership is an unduplicated count and percentage of members enrolled at any time during the MY by spoken language preferred for healthcare, the preferred language for written materials, and the preferred language for other language needs.

Results

Table 9-2 shows that the percentage of Michigan members using English as the preferred spoken language for healthcare decreased slightly (nearly two percentage points) when compared to MY 2019 but remains the preferred spoken language for healthcare at the statewide level.

МНР	Eligible Population	Declined	English	Non-English	Unknown
AET	64,191	0.00%	0.00%	0.00%	100.00%
BCC	308,376	0.00%	98.39%	1.61%	0.01%
НАР	30,185	0.00%	90.36%	0.74%	8.91%
MCL	260,190	0.00%	52.87%	0.40%	46.73%
MER	560,437	0.00%	98.48%	0.67%	0.84%
MOL	419,718	0.00%	98.51%	1.47%	0.02%
PRI	173,634	0.00%	0.00%	0.00%	100.00%
THC	70,651	0.00%	57.53%	0.11%	42.36%
UNI	319,061	0.00%	96.13%	3.86%	0.01%
UPP	60,478	0.00%	99.90%	0.07%	0.03%
HEDIS MY 2020 MWA		0.00%	81.23%	1.26%	17.51%
HEDIS MY 2019 MWA		0.00%	83.19%	1.48%	15.33%
HEDIS MY 2018 MWA		0.00%	86.29%	1.58%	12.12%

Table 9-2—MHP and MWA Results for Language Diversity of Membership—Spoken Language Preferred for Healthcare



Table 9-3 shows that for each MHP, over 57 percent of Michigan members who reported a language reported English as the language preferred for written materials. At the statewide level, English remained the preferred language for written materials for most (over 75 percent) Michigan members from MY 2018 to MY 2020.

МНР	Eligible Population	English	Non-English	Unknown	Declined
AET	64,191	0.00%	0.00%	100.00%	0.00%
BCC	308,376	98.38%	1.62%	0.01%	0.00%
НАР	30,185	90.36%	0.74%	8.91%	0.00%
MCL	260,190	0.00%	0.00%	100.00%	0.00%
MER	560,437	98.48%	0.67%	0.84%	0.00%
MOL	419,718	98.51%	1.47%	0.02%	0.00%
PRI	173,634	0.00%	0.00%	100.00%	0.00%
THC	70,651	57.53%	0.11%	42.36%	0.00%
UNI	319,061	96.13%	3.86%	0.01%	0.00%
UPP	60,478	99.90%	0.07%	0.03%	0.00%
HEDIS MY 2020 MWA		75.16%	1.22%	23.62%	0.00%
HEDIS MY 2019 MWA		76.52%	1.44%	22.04%	0.00%
HEDIS MY 2018 MWA		77.07%	1.51%	21.41%	0.00%

Table 9-3—MHP and MWA Results for Language Diversity of Membership—
Preferred Language for Written Materials



Table 9-4 shows that at the statewide level, over 57 percent of Michigan members reported English as their preferred language for other language needs, and the Michigan members that listed Unknown as their preferred language for other language needs remained fairly constant from the prior year. Please note that *Language Diversity of Membership—Other Language Needs* captures data collected from questions that cannot be mapped to any other category (e.g., What is the primary language spoken at home?).

МНР	Eligible Population	English	Non-English	Unknown	Declined
AET	64,191	97.73%	0.99%	1.28%	0.00%
BCC	308,376	98.80%	1.19%	0.01%	0.00%
НАР	30,185	90.36%	0.74%	8.91%	0.00%
MCL	260,190	0.00%	0.00%	100.00%	0.00%
MER	560,437	98.48%	0.67%	0.84%	0.00%
MOL	419,718	98.51%	1.47%	0.02%	0.00%
PRI	173,634	0.00%	0.00%	100.00%	0.00%
THC	70,651	57.53%	0.11%	42.36%	0.00%
UNI	319,061	96.13%	3.86%	0.01%	0.00%
UPP	60,478	0.00%	0.00%	100.00%	0.00%
HEDIS MY 2020 MWA		75.32%	1.19%	23.50%	0.00%
HEDIS MY 2019 MWA		76.58%	1.41%	22.01%	0.00%
HEDIS MY 2018 MWA		76.55%	1.48%	21.98%	0.00%

Table 9-4—MHP and MWA Results for Language Diversity of Membership—Other Language Needs



Introduction

The Utilization domain encompasses the following HEDIS measures:

- Ambulatory Care—Total (Per 1,000 Member Months)—ED Visits—Total and Outpatient Visits— Total
- Inpatient Utilization—General Hospital/Acute Care—Total; Inpatient—Discharges per 1,000 Member Months—Total and Average Length of Stay—Total; Maternity—Discharges per 1,000 Member Months—Total and Average Length of Stay—Total; Surgery—Discharges per 1,000 Member Months—Total and Average Length of Stay—Total; and Medicine—Discharges per 1,000 Member Months—Total and Average Length of Stay—Total; and Medicine—Discharges per 1,000
- Use of Opioids From Multiple Providers—Multiple Prescribers, Multiple Pharmacies, and Multiple Prescribers and Multiple Pharmacies
- Use of Opioids at High Dosage
- Risk of Continued Opioid Use—At Least 15 Days Covered—Total and At Least 31 Days Covered—Total
- Plan All-Cause Readmissions—Index Admissions—Total, Observed Readmissions Rate—Total, Expected Readmissions Rate—Total, and O/E Ratio—Total

The following tables present the HEDIS MY 2020 MHP-specific rates as well as the MWA or Michigan Medicaid Average (MA) for HEDIS MY 2020, HEDIS MY 2019, and HEDIS MY 2018, where applicable. To align with calculations from prior years, HSAG calculated traditional averages for the *Ambulatory Care*—*Total (Per 1,000 Member Months)* and *Inpatient Utilization*—*General Hospital/Acute Care*—*Total* measure indicators in the Utilization domain; therefore, the MA is presented for those two measures rather than the MWA, which was calculated and presented for all other measures. The *Ambulatory Care* and *Inpatient Utilization* measures are designed to describe the frequency of specific services provided by the MHPs and are not risk adjusted. Therefore, it is important to assess utilization supplemented by information on the characteristics of each MHP's population.

Summary of Findings

Reported rates for the MHPs and MWA rates for the *Ambulatory Care* and *Inpatient Utilization* measures do not take into account the characteristics of the population; therefore, HSAG could not draw conclusions on performance based on these measures. Due to changes in the technical specifications for the opioid measures, NCQA recommends trending between MY 2020 and prior years be considered with caution. For the *Plan All-Cause Readmissions* measure, five MHPs had an O/E ratio less than 1.0, indicating that these MHPs had fewer observed readmissions than were expected based on patient mix. The remaining five MHPs O/E ratio is more than one indicating they had more readmissions.



Measure-Specific Findings

Ambulatory Care—Total (Per 1,000 Member Months)

The Ambulatory Care—Total (Per 1,000 Member Months) measure summarizes use of ambulatory care for ED Visits—Total and Outpatient Visits—Total. In this section, the results for the total age group are presented.

Results

Table 10-1 shows *ED Visits—Total* and *Outpatient Visits—Total* per 1,000 member months for ambulatory care for the total age group.

МНР	Member Months	Emergency Department Visits—Total*	Outpatient Visits—Total
AET	591,544	55.97	550.95
BCC	2,833,707	44.38	334.57
НАР	258,272	50.14	329.12
MCL	2,570,812	51.72	447.82
MER	5,775,940	45.54	397.73
MOL	4,072,877	47.07	340.07
PRI	1,670,934	49.54	294.42
THC	661,627	47.79	287.21
UNI	3,147,239	46.01	315.19
UPP	602,457	42.87	317.54
HEDIS MY 2020 MWA		48.10	361.46
HEDIS MY 2019 MWA		66.05	433.13
HEDIS MY 2018 MWA		66.87	389.77

Table 10-1—Ambulatory Care—Total (Per 1,000 Member Months) for Total Age Group

* Awareness is advised when interpreting results for this indicator as a lower rate is a higher percentile.

For the *ED Visits—Total* measure indicator, the MWA decreased by 18.77 visits per 1,000 member months from HEDIS MY 2018 to HEDIS MY 2020. The MWA for the *Outpatient Visits—Total* measure indicator decreased from HEDIS MY 2018 to HEDIS MY 2020 by 28.31 visits per 1,000 member months.



Inpatient Utilization—General Hospital/Acute Care—Total

The Inpatient Utilization—General Hospital/Acute Care—Total measure summarizes use of acute inpatient care and services in four categories: Total Inpatient, Maternity, Surgery, and Medicine.

Results

Table 10-2 shows the member months for all ages and the *Total Discharges per 1,000 Member Months* for the total age group. The values in the table below are presented for informational purposes only.

Table 10-2—Inpatient Utilization—General Hospital/Acute Care: Total Discharges per 1,000 Member Months for Total Age Group

МНР	Member Months	Total Inpatient	Maternity*	Surgery	Medicine
AET	591,544	10.53	2.32	2.50	6.34
BCC	2,833,707	6.18	2.53	1.20	3.03
НАР	258,272	10.20	1.85	2.44	6.42
MCL	2,570,812	8.31	2.61	2.07	4.28
MER	5,775,940	6.67	2.63	1.52	3.25
MOL	4,072,877	5.99	2.44	1.35	2.86
PRI	1,670,934	5.35	2.72	1.30	2.13
THC	661,627	8.36	2.16	1.78	4.89
UNI	3,147,239	5.29	2.27	1.19	2.41
UPP	602,457	6.20	2.01	1.83	2.88
HEDIS MY 2020 MWA		7.31	2.35	1.72	3.85
HEDIS MY 2019 MWA		8.63	2.53	2.18	4.62
HEDIS MY 2018 MWA		7.93	2.36	1.92	4.29

* The Maternity measure indicators were calculated using member months for members 10 to 64 years of age.



Table 10-3 displays the *Total Average Length of Stay* for all ages and are presented for informational purposes only.

		IUI IUIAIAgeo	noup		
МНР	Member Months	Total Inpatient	Maternity	Surgery	Medicine
AET	591,544	5.60	2.58	9.05	5.05
BCC	2,833,707	4.40	2.41	7.67	4.38
HAP	258,272	5.95	2.57	9.44	5.33
MCL	2,570,812	3.87	1.69	6.00	3.86
MER	5,775,940	4.30	2.67	7.18	3.91
MOL	4,072,877	5.13	2.83	9.18	4.65
PRI	1,670,934	4.27	3.01	6.23	4.21
THC	661,627	3.85	1.91	7.01	3.36
UNI	3,147,239	4.70	2.46	8.02	4.61
UPP	602,457	4.41	2.75	6.46	3.96
HEDIS MY 2020 MWA		4.65	2.49	7.62	4.33
HEDIS MY 2019 MWA		4.43	2.54	7.00	4.00
HEDIS MY 2018 MWA		4.33	2.66	6.89	3.87

Table 10-3—Inpatient Utilization—General Hospital/Acute Care: Total Average Length of Stay for Total Age Group



Use of Opioids From Multiple Providers

The Use of Opioids From Multiple Providers summarizes use of prescription opioids for at least 15 days received from four or more providers. Three rates are reported: Multiple Prescribers, Multiple Pharmacies, and Multiple Prescribers and Multiple Pharmacies. Due to changes in the technical specifications for this measure, NCQA recommends trending between MY 2020 and prior years be considered with caution.

Results

Table 10-4 shows the HEDIS MY 2020 rates for receiving prescription opioids. The values in the table below are presented for informational purposes only.

МНР	Use of Opioids From Multiple Providers— Eligible Population	Use of Opioids From Multiple Providers— Multiple Prescribers		Use of Opioids From Multiple Providers— Multiple Prescribers and Multiple Pharmacies
AET	2,510	14.94%	3.43%	2.23%
BCC	7,737	14.62%	3.00%	1.84%
HAP	1,166	12.95%	3.34%	1.63%
MCL	8,604	14.77%	2.60%	1.21%
MER	17,806	14.84%	3.78%	2.59%
MOL	14,554	13.36%	2.75%	1.70%
PRI	4,300	18.70%	2.23%	1.21%
THC	3,107	12.71%	2.48%	1.29%
UNI	8,888	14.38%	2.00%	1.17%
UPP	2,263	16.04%	6.41%	4.77%
HEDIS MY 2020 MWA		14.60%	3.03%	1.88%
HEDIS MY 2019 MWA		15.48%	4.21%	2.13%
HEDIS MY 2018 MWA		18.67%	6.16%	3.30%

Table 10-4—Use of Opioids From Multiple Providers*,1

*For this measure, a lower rate indicates better performance.

¹ Due to changes in the technical specifications for this measure, NCQA recommends trending between MY 2020 and prior years be considered with caution.



Use of Opioids at High Dosage

The Use of Opioids at High Dosage summarizes use of prescription opioids received at a high dosage for at least 15 days. Due to changes in the technical specifications for this measure, NCQA recommends trending between MY 2020 and prior years be considered with caution.

Results

Table 10-5 shows the HEDIS MY 2020 rates for members receiving prescription opioids at a high dosage. The values in the table below are presented for informational purposes only.

МНР	Eligible Population	Rate
AET	2,135	2.53%
BCC	6,798	1.69%
HAP	971	2.16%
MCL	6,613	2.65%
MER	16,048	2.65%
MOL	13,001	2.15%
PRI	3,820	3.04%
THC	2,819	10.57%
UNI	7,888	2.90%
UPP	2,040	3.33%
HEDIS MY 2020 MWA		2.86%
HEDIS MY 2019 MWA		3.36%
HEDIS MY 2018 MWA		

Table 10-5—Use of Opi	oids at High Dosage ^{*,1}
-----------------------	------------------------------------

* For this measure, a lower rate indicates better performance.

¹ Due to changes in the technical specifications for this measure, NCQA

recommends trending between MY 2020 and prior years be considered with caution. — indicates that NCQA recommended a break in trending; therefore, prior year rates are not displayed.



Risk of Continued Opioid Use

The *Risk of Continued Opioid Use* summarizes new episodes of opioid use that puts members at risk for continued opioid use. Due to changes in the technical specifications for this measure, NCQA recommends trending between MY 2020 and prior years be considered with caution.

Results

Table 10-6 shows the HEDIS MY 2020 rates for members whose new episode lasted at least 15 days in a 30-day period and at least 31 days in a 62-day period. The values in the table below are presented for informational purposes only.

•						
МНР	Eligible Population	At Least 15 Days Covered — Total	At Least 31 Days Covered—Total			
AET	2,459	16.92%	9.03%			
BCC	12,146	8.40%	5.69%			
HAP	858	14.45%	9.91%			
MCL	11,890	12.40%	6.36%			
MER	25,944	9.38%	5.91%			
MOL	17,906	9.82%	6.95%			
PRI	6,228	10.85%	5.88%			
THC	2,710	28.78%	19.19%			
UNI	12,653	9.87%	6.80%			
UPP	3,095	9.27%	5.43%			
HEDIS MY 2020 MWA		10.66%	6.72%			
HEDIS MY 2019 MWA		14.41%	7.54%			
HEDIS MY 2018 MWA		17.31%	7.43%			

Table 10-6—Risk of Continued Opioid Use^{*,1}

* For this measure, a lower rate indicates better performance.

¹ Due to changes in the technical specifications for this measure, NCQA recommends trending between MY 2020 and prior years be considered with caution.



Plan All-Cause Readmissions

The *Plan All-Cause Readmissions* measure summarizes the percentage of inpatient hospital admissions that result in an unplanned readmission for any diagnosis within 30 days. This measure is risk-adjusted, so an O/E ratio is also calculated that indicates whether an MHP had more readmissions (O/E ratio greater than 1.0) or fewer readmissions (O/E ratio less than 1.0) than expected based on population mix.

Results

Table 10-7 shows the HEDIS MY 2020 observed rates, expected rates, and the O/E ratio for inpatient hospital admissions that were followed by an unplanned readmission for any diagnosis within 30 days.

МНР	Index Admissions	Observed Readmissions —Total	Expected Readmissions —Total	O/E Ratio —Total			
AET	2,162	11.42%	9.91%	1.15			
BCC	5,963	11.00%	10.23%	1.08			
HAP	157	13.38%	9.81%	1.36			
MCL	9,049	9.63%	9.76%	0.99			
MER	17,606	8.60%	9.60%	0.90			
MOL	12,933	9.43%	9.90%	0.95			
PRI	3,366	7.75%	9.61%	0.81			
THC	2,480	10.48%	10.01%	1.05			
UNI	5,724	12.05%	10.77%	1.12			
UPP	1,173	9.38%	9.97%	0.94			
HEDIS MY 2020 MWA		9.65%	9.90%	0.98			
HEDIS MY 2019 MWA		9.09%	9.90%	0.92			
HEDIS MY 2018 MWA							

Table 10-7—Plan		Readmissions*
rable 10-7-Plan	All-Cause	Redumissions

* For this measure, a lower rate indicates better performance.

— indicates that NCQA recommended a break in trending; therefore, prior year rates are not displayed.

The rates of observed readmissions ranged from 7.75 percent for Priority to 13.38 percent for HAP; however, five of the 10 MHPs had an O/E ratio greater than 1.0 indicating these MHPs had more readmissions. The remaining five MHPs had an O/E ratio less than 1.0, indicating that these MHPs had fewer observed readmissions than were expected based on patient mix.



11. HEDIS Reporting Capabilities—Information Systems Findings

HEDIS Reporting Capabilities—Information Systems Findings

NCQA's IS standards are the guidelines used by certified HEDIS compliance auditors to assess an MHP's ability to report HEDIS data accurately and reliably.¹¹⁻¹ Compliance with the guidelines also helps an auditor to understand an MHP's HEDIS reporting capabilities. For HEDIS MY 2020, MHPs were assessed on six IS standards. To assess an MHP's adherence to the IS standards, HSAG reviewed several documents for the MHPs. These included the MHPs' final audit reports (FARs), IS compliance tools, and the IDSS files approved by their respective NCQA-licensed audit organization (LO).

All 10 of the Michigan MHPs that underwent NCQA HEDIS Compliance AuditsTM in Michigan in 2020 contracted with the same LOs in 2021.¹¹⁻² The MHPs were able to select the LO of their choice. Overall, the Michigan MHPs consistently maintain the same LOs across reporting years.

For HEDIS MY 2020, all but two MHPs contracted with external software vendors for HEDIS measure production and rate calculation. HSAG reviewed the MHPs' FARs and ensured that these software vendors participated in and passed the NCQA's Measure Certification process. MHPs could purchase the software with certified measures and generate HEDIS measure results internally or provide all data to the software vendor to generate HEDIS measures for them. Either way, using software with NCQA-certified measures may reduce the MHPs' burden for reporting and help ensure rate validity. For the MHP that calculated its rate using internally developed source code, the auditor selected a core set of measures and manually reviewed the programming codes to verify accuracy and compliance with HEDIS MY 2020 technical specifications.

HSAG found that, in general, all MHPs' IS and processes were compliant with the applicable IS standards and the HEDIS determination reporting requirements related to the measures for HEDIS MY 2020. The following sections present NCQA's IS standards and summarize the audit findings related to each IS standard for the MHPs.

¹¹⁻¹ National Committee for Quality Assurance. *HEDIS*[®] *MY2020, Volume 5: HEDIS Compliance Audit*TM: *Standards, Policies and Procedures.* Washington D.C.

¹¹⁻² NCQA HEDIS Compliance AuditTM is a trademark of the National Committee for Quality Assurance (NCQA).



IS 1.0—Medical Service Data—Sound Coding Methods and Data Capture, Transfer, and Entry

This standard assesses whether:

- Industry standard codes are used and all characters are captured.
- Principal codes are identified and secondary codes are captured.
- Nonstandard coding schemes are fully documented and mapped back to industry standard codes.
- Standard submission forms are used and capture all fields relevant to measure reporting; all proprietary forms capture equivalent data; and electronic transmission procedures conform to industry standards.
- Data entry and file processing procedures are timely and accurate and include sufficient edit checks to ensure the accurate entry and processing of submitted data in transaction files for measure reporting.
- The organization continually assesses data completeness and takes steps to improve performance.
- The organization regularly monitors vendor performance against expected performance standards.

All MHPs were fully compliant with *IS 1.0, Medical Service Data—Sound Coding Methods and Data Capture, Transfer, and Entry.* The auditors confirmed that the MHPs captured all necessary data elements appropriately for HEDIS reporting. A majority of the MHPs accepted industry standard codes on industry standard forms. Any nonstandard code that was used for measure reporting was mapped to industry standard code appropriately. Adequate validation processes such as built-in edit checks, data monitoring, and quality control audits were in place to ensure that only complete and accurate claims and encounter data were used for HEDIS reporting.

IS 2.0—Enrollment Data—Data Capture, Transfer, and Entry

This standard assesses whether:

- The organization has procedures for submitting measure-relevant information for data entry, and whether electronic transmissions of membership data have necessary procedures to ensure accuracy.
- Data entry processes are timely and accurate and include sufficient edit checks to ensure accurate entry of submitted data in transaction files.
- The organization continually assesses data completeness and takes steps to improve performance.
- The organization regularly monitors vendor performance against expected performance standards.

All MHPs were fully compliant with *IS 2.0, Enrollment Data—Data Capture, Transfer, and Entry*. Data fields required for HEDIS measure reporting were captured appropriately. Based on the auditors' review, all MHPs processed eligibility files in a timely manner. Enrollment information housed in the MHPs' systems was reconciled against the enrollment files provided by the State. Sufficient data validations were in place to ensure that only accurate data were used for HEDIS reporting.



IS 3.0—Practitioner Data—Data Capture, Transfer, and Entry

This standard assesses whether:

- Provider specialties are fully documented and mapped to HEDIS provider specialties necessary for measure reporting.
- The organization has effective procedures for submitting measure-relevant information for data entry, and whether electronic transmissions of practitioner data are checked to ensure accuracy.
- Data entry processes are timely and accurate and include edit checks to ensure accurate entry of submitted data in transaction files.
- The organization continually assesses data completeness and takes steps to improve performance.
- The organization regularly monitors vendor performance against expected performance standards.

All MHPs were fully compliant with *IS 3.0, Practitioner Data—Data Capture, Transfer, and Entry.* MHPs had sufficient processes in place to capture all data elements required for HEDIS reporting. Primary care practitioners and specialists were appropriately identified by all MHPs. Provider specialties were fully and accurately mapped to HEDIS-specified provider types. Adequate validation processes were in place to ensure that only accurate provider data were used for HEDIS reporting.

IS 4.0—Medical Record Review Processes—Training, Sampling, Abstraction, and Oversight

This standard assesses whether:

- Forms capture all fields relevant to measure reporting and whether electronic transmission procedures conform to industry standards and have necessary checking procedures to ensure data accuracy (logs, counts, receipts, hand-off, and sign-off).
- Retrieval and abstraction of data from medical records are reliably and accurately performed.
- Data entry processes are timely and accurate and include sufficient edit checks to ensure accurate entry of submitted data in the files for measure reporting.
- The organization continually assesses data completeness and takes steps to improve performance.
- The organization regularly monitors vendor performance against expected performance standards.

All MHPs were fully compliant with *IS 4.0, Medical Record Review Processes—Training, Sampling, Abstraction, and Oversight.* Medical record data were used by all MHPs to report HEDIS hybrid measures. Medical record abstraction tools were reviewed and approved by the MHPs' auditors for HEDIS reporting. Contracted vendor staff or internal staff used by the MHPs had sufficient qualification and training in the current year's HEDIS technical specifications and the use of MHP-specific abstraction tools to accurately conduct medical record reviews. Sufficient validation processes and edit checks were in place to ensure data completeness and data accuracy.



IS 5.0—Supplemental Data—Capture, Transfer, and Entry

This standard assesses whether:

- Nonstandard coding schemes are fully documented and mapped to industry standard codes.
- The organization has effective procedures for submitting measure-relevant information for data entry and whether electronic transmissions of data have validation procedures to ensure accuracy.
- Data entry processes are timely and accurate and include edit checks to ensure accurate entry of submitted data in transaction files.
- The organization continually assesses data completeness and takes steps to improve performance.
- The organization regularly monitors vendor performance against expected performance standards.
- Data approved for electronic clinical data system (ECDS) reporting met reporting requirements.

All MHPs were fully compliant with *IS 5.0, Supplemental Data—Capture, Transfer, and Entry.* Supplemental data sources used by the MHPs were verified and approved by the auditors. The auditors performed primary source verification of a sample of records selected from each nonstandard supplemental database used by the MHPs. In addition, the auditors reviewed the supplemental data impact reports provided by the MHPs for reasonability. Validation processes such as reconciliation between original data sources and MHP-specific data systems, edit checks, and system validations ensured data completeness and data accuracy. There were no issues noted regarding how the MHPs managed the collection, validation, and integration of the various supplemental data sources. The auditors continued to encourage the MHPs to explore ways to maximize the use of supplemental data.

IS 6.0—Data Production Processing—Transfer, Consolidation, Control Procedures That Support Measure Reporting Integrity

This standard assesses whether:

- Nonstandard coding schemes are fully documented and mapped to industry standard codes. Organization-to-vendor mapping is fully documented.
- Data transfers to HEDIS repository from transaction files are accurate.
- File consolidations, extracts, and derivations are accurate.
- Repository structure and formatting is suitable for measures and enable required programming efforts.
- Report production is managed effectively and operators perform appropriately.
- The organization regularly monitors vendor performance against expected performance standards.

All MHPs were fully compliant with IS 6.0—Data Production Processing—Transfer, Consolidation, Control Procedures That Support Measure Reporting Integrity.



All but two MHPs contracted with external software vendors for HEDIS measure production and rate calculation. Measures were benchmarked to assess potential for bias. Cross measure checks were performed to determine appropriate relationships exist. Confirmed data logic for code mapping was applied consistently. When non-standard coding schemes were used, mapping documents showed that code systems were identified and mapped according to the requirements in the specifications. Data source identifiers were clear and documented.

IS 7.0—Data Integration and Reporting—Accurate HEDIS Reporting, Control Procedures That Support HEDIS Reporting Integrity

This standard assesses whether:

- Data transfers to the HEDIS measure vendor from the HEDIS repository are accurate.
- Report production is managed effectively and operators perform appropriately.
- Measure reporting software is managed properly with regard to development, methodology, documentation, revision control, and testing.
- The organization regularly monitors vendor performance against expected performance standards.

All MHPs were fully compliant with *IS 7.0, Data Integration and Reporting—Accurate HEDIS Reporting, Control Procedures That Support HEDIS Reporting Integrity.* For the MHP that did not use a software vendor, the auditor requested, reviewed, and approved source code for a selected core set of HEDIS measures. For all MHPs, the auditors determined that data mapping, data transfers, and file consolidations were sufficient. Adequate validation processes were in place for all MHPs to ensure that only accurate and complete data were used for HEDIS reporting. The auditors did not document any issues with the MHPs' data integration and report production processes. Sufficient vendor oversight was in place for each MHP using a software vendor.



Glossary

Table 12-1 provides definitions of terms and acronyms used throughout this report.

Term	Description
ADHD	Attention-deficit/hyperactivity disorder.
Audit Result	The HEDIS auditor's final determination, based on audit findings, of the appropriateness of the MHP to publicly report its HEDIS measure rates. Each measure indicator rate included in the HEDIS audit receives an audit result of <i>Reportable (R), Small Denominator (NA), Biased Rate (BR), No Benefit (NB), Not Required (NQ), Not Reported (NR),</i> and <i>Un-Audited (UN).</i>
ADMIN%	Percentage of the rate derived using administrative data (e.g., claims data and immunization registry).
BMI	Body mass index.
BR	Biased Rate; indicates that the MHP's reported rate was invalid, therefore, the rate was not presented.
CDC	Centers for Disease Control and Prevention.
COVID-19	Coronavirus disease 2019.
Data Completeness	The degree to which occurring services/diagnoses appear in the MHP's administrative data systems.
Denominator	The number of members who meet all criteria specified in a measure for inclusion in the eligible population. When using the administrative method, the entire eligible population becomes the denominator. When using the hybrid method, a sample of the eligible population becomes the denominator.
DTaP	Diphtheria, tetanus, and acellular pertussis vaccine.
ECDS	Electronic clinical data system. A structured, electronic version of a patient's comprehensive medical experiences maintained over time that may include some or all key administrative clinical data relevant to care (e.g., demographics, progress notes, problems, medications, vital signs, past medical history, social history, immunizations, laboratory data, radiology reports).
ED	Emergency department.
EDI	Electronic data interchange; the direct computer-to-computer transfer of data.
eGFR	Estimated Glomerular Filtration Rate.
Encounter Data	Billing data received from a capitated provider. (Although the MHP does not reimburse the provider for each encounter, submission of encounter data allows the MHP to collect the data for future HEDIS reporting.)

Table 12-1—Definition of Terms



Term	Description
FAR	Following the MHP's completion of any corrective actions, an auditor completes the final audit report (FAR), documenting all final findings and results of the HEDIS audit. The FAR includes a summary report, IS capabilities assessment, medical record review validation findings, measure results, and the auditor's audit opinion (the final audit statement).
HEDIS	The Healthcare Effectiveness Data and Information Set (HEDIS), developed and maintained by NCQA, is a set of performance measures used to assess the quality of care provided by managed health care organizations.
HEDIS Repository	The data warehouse where all data used for HEDIS reporting are stored.
Hep B	Hepatitis B vaccine.
HiB Vaccine	Haemophilus influenza type B vaccine.
НМО	Health maintenance organization.
HPL	High performance level. (For most performance measures, MDHHS defined the HPL as the most recent national Medicaid 90th percentile. For measures such as <i>Comprehensive Diabetes Care—HbA1c Poor Control [>9.0%]</i> , in which lower rates indicate better performance, the 10th percentile [rather than the 90th percentile] is considered the HPL.)
HPV	Human papillomavirus vaccine.
HSAG	Health Services Advisory Group, Inc., the State's external quality review organization.
Hybrid Measures	Measures that can be reported using the hybrid method.
IDSS	The Interactive Data Submission System, a tool used to submit data to NCQA.
IPV	Inactivated polio virus vaccine.
IS	Information system: an automated system for collecting, processing, and transmitting data.
IS Standards	Information System (IS) standards: an NCQA-defined set of standards that measure how an organization collects, stores, analyzes, and reports medical, customer service, member, practitioner, and vendor data. ¹²⁻¹
LPL	Low performance level. (For most performance measures, MDHHS defined the LPL as the most recent national Medicaid 25th percentile. For measures such as <i>Comprehensive Diabetes Care—HbA1c Poor Control</i> [>9.0%], in which lower rates in indicate better performance, the 75th percentile [rather than the 25th percentile] is considered the LPL).

¹²⁻¹ National Committee for Quality Assurance. *HEDIS Compliance Audit Standards, Policies and Procedures, Volume 5.* Washington D.C.



Term	Description			
Material Bias	For most measures reported as a rate, any error that causes $a \pm 5$ percent difference in the reported rate is considered materially biased. For non-rate measures, any error that causes $a \pm 10$ percent difference in the reported rate or calculation is considered materially biased.			
Medical Record Validation	The process that the MHP's medical record abstraction staff uses to identify numerator positive cases.			
Medicaid Percentiles	The NCQA national percentiles for each HEDIS measure for the Medicaid product line used to compare the MHP's performance and assess the reliability of the MHP's HEDIS rates.			
MDHHS	Michigan Department of Health and Human Services.			
MHP	Medicaid health plan.			
MMR	Measles, mumps, and rubella vaccine.			
MRR	Medical record review.			
MY	Measurement year.			
NA	Small Denominator: indicates that the MHP followed the specifications but the denominator was too small (<30) to report a valid rate, resulting in an NA designation.			
NB	No Benefit: indicates that the required benefit to calculate the measure was not offered.			
NCQA	The National Committee for Quality Assurance (NCQA) is a not-for-profit organization that assesses, through accreditation reviews and standardized measures, the quality of care provided by managed healthcare delivery systems; reports results of those assessments to employers, consumers, public purchasers, and regulators; and ultimately seeks to improve the health care provided within the managed care industry.			
NR	Not Reported: indicates that the MHP chose not to report the required HEDIS 2018 measure indicator rate. This designation was assigned to rates during previous reporting years to indicate one of the following designations: The MHP chose not to report the required measure indicator rate, or the MHP's reported rate was invalid.			
Numerator	The number of members in the denominator who received all the services as specified in the measure.			
NQ	Not Required: indicates that the MHP was not required to report this measure.			
OB/GYN	Obstetrician/Gynecologist.			
РСР	Primary care practitioner.			
PCV	Pneumococcal conjugate vaccine.			
РОР	Eligible population.			
Provider Data	Electronic files containing information about physicians such as type of physician, specialty, reimbursement arrangement, and office location.			



Term	Description				
RV	Rotavirus vaccine.				
Software Vendor	A third party, with source code certified by NCQA, that contracts with the MHP to write source code for HEDIS measures. (For the measures to be certified, the vendor must submit programming codes associated with the measure to NCQA for automated testing of program logic, and a minimum percentage of the measures must receive a "Pass" or "Pass With Qualifications" designation.)				
Tdap	Tetanus, diphtheria toxoids, and acellular pertussis vaccine.				
uACR	Urine albumin-creatinine ratio.				
UN	Unaudited: indicates that the organization chose to report a measure that is not required to be audited. This result applies only to a limited set of measures.				
URI	Upper respiratory infection.				
Quality Compass	NCQA Quality Compass benchmark.				
VZV	Varicella zoster virus (chicken pox) vaccine.				



Appendix A. Tabular Results

Appendix A presents tabular results for each measure indicator. Where applicable, the results provided include the eligible population and rate as well as the Michigan MWA for HEDIS MY 2018, HEDIS MY 2019, and HEDIS MY 2020. Yellow shading with one cross (⁺) indicates that the HEDIS MY 2020 rate was at or above the Quality Compass HEDIS MY 2019 MWA national Medicaid 50th percentile.



Child & Adolescent Care Performance Measure Results

	Eligible	Combo 2	Combo 3	Combo 4	Combo 5	Combo 6	Combo 7	Combo 8	Combo 9	Combo 10
Plan	Population		Rate							
AET	640	52.66%	49.38%	48.75%	41.25%	21.41%	40.63%	21.41%	18.13%	18.13%
BCC	4,437	64.96%	62.53%	61.80%	53.04%	37.71%	52.55%	37.71%	31.39%	31.39%
НАР	109	49.54%	44.95%	44.95%	37.61%	23.85%	37.61%	23.85%	20.18%	20.18%
MCL	4,324	65.94%	63.26%	61.56%	52.55%	37.23%	51.34%	36.74%	31.87%	31.39%
MER	10,921	64.72%	62.53%	62.04%	56.69%	35.77%	56.20%	35.77%	32.85%	32.85%
MOL	7,127	71.29%	67.15%	66.18%	59.37%	37.23%	58.64%	36.98%	34.06%	33.82%
PRI	3,230	75.91%+	74.70%+	73.72%+	66.67%+	53.53%+	65.94%+	53.04%+	48.42%+	47.93%+
THC	972	60.34%	53.04%	53.04%	44.53%	28.47%	44.53%	28.47%	24.57%	24.57%
UNI	5,117	65.21%	61.80%	61.07%	55.47%	32.85%	54.74%	32.85%	29.68%	29.68%
UPP	964	68.36%	66.08%	64.52%	55.08%	45.02%+	53.94%	44.40%+	39.83%+	39.21%+
HEDIS MY 2020 MWA		66.88%	64.00%	63.16%	56.31%	37.33%	55.64%	37.17%	33.37%	33.22%
HEDIS MY 2019 MWA		72.71%	68.36%	67.54%	59.06%	37.86%	58.44%	37.69%	33.60%	33.44%
HEDIS MY 2018 MWA		72.51%	67.93%	67.00%	57.79%	38.40%	57.07%	38.20%	33.40%	33.24%

Table A-1—MHP and MWA Results for Childhood Immunization Status

Yellow shading with one cross (+) indicates the HEDIS MY 2020 MHP or MWA rate was at or above the Quality Compass HEDIS MY 2019 MWA national Medicaid 50th percentile.



Plan	Well-Child Visits in the First 15 Months— Six or More Well- Child Visits— Eligible Population	Well-Child Visits in the First 15 Months—Six or More Well-Child Visits—Rate ¹	Well-Child Visits for Age 15 Months to 30 Months— Two or More Well-Child Visits— Eligible Population	Well-Child Visits for Age 15 Months to 30 Months—Two or More Well-Child Visits—Rate ²
AET	526	41.63%	574	52.61%
BCC	3,668	64.39%	3,959	66.84%
НАР	41	51.22%	56	55.36%
MCL	3,484	61.22%	3,851	67.44%
MER	8,907	63.12%	10,152	68.93%
MOL	5,822	59.93%	6,711	67.01%
PRI	2,571	65.77%	2,799	75.71%
THC	721	48.82%	813	57.20%
UNI	4,059	61.25%	4,782	65.10%
UPP	777	70.27%	897	73.13%
HEDIS MY 2020 MWA		61.88%		67.71%
HEDIS MY 2019 MWA				
HEDIS MY 2018 MWA				

Table A-2—MHP and MWA Results for Well-Child Visits in the First 30 Months of Life

¹Due to changes in the technical specifications for this measure, NCQA recommends a break in trending between MY 2020 and prior years; therefore, prior years' rates will not be displayed and comparisons to benchmarks will not be performed for this measure.

 2 This measure is a first-year measure; therefore, prior years' rates cannot be displayed and comparisons to benchmarks cannot be performed for this measure as benchmarks are not yet available.



Plan	Eligible Population	Rate
AET	643	62.83%
BCC	4,437	71.53%
HAP	109	62.39%
MCL	4,337	74.21%+
MER	10,921	73.87%+
MOL	7,142	72.14%
PRI	3,231	78.35%+
THC	972	67.64%
UNI	5,117	74.70%+
UPP	964	74.48%+
HEDIS MY 2020 MWA		73.44% ⁺
HEDIS MY 2019 MWA		78.27%
HEDIS MY 2018 MWA		78.40%

Table A-3—MHP and MWA Results for Lead Screening in Children

Yellow shading with one cross (+) indicates the HEDIS MY 2020 MHP or MWA rate was at or above the Quality Compass HEDIS MY 2019 MWA national Medicaid 50th percentile.



	Ages 3 to 11 Years—Eligible	Ages 3 to 11	Ages 12 to 17 Years—Eligible	Ages 12 to 17	Ages 18 to 21 Years—Eligible	Ages 18 to 21	Total—Eligible	
Plan	Population	Years—Rate	Population	Years—Rate	Population	Years—Rate	Population	Total—Rate
AET	7,415	41.17%	4,573	32.25%	2,738	21.59%	14,726	34.76%
BCC	35,840	50.56%	20,379	40.79%	11,410	27.43%	67,629	43.71%
HAP	2,064	34.54%	876	20.66%	755	18.28%	3,695	27.93%
MCL	39,295	48.09%	23,240	37.63%	12,281	21.68%	74,816	40.50%
MER	106,684	52.28%	59,665	42.30%	26,302	26.22%	192,651	45.63%
MOL	71,354	51.03%	46,993	45.06%	21,650	29.85%	139,997	45.75%
PRI	29,375	55.86%	17,156	46.32%	7,341	28.87%	53,872	49.14%
THC	8,709	48.36%	5,989	43.70%	3,365	38.72%	18,063	45.02%
UNI	54,690	50.09%	35,269	42.31%	16,695	29.19%	106,654	44.24%
UPP	8,759	50.87%	5,159	43.87%	2,539	22.41%	16,457	44.29%
HEDIS MY 2020 MWA		50.92%		42.35%		27.36%		44.59%
HEDIS MY 2019 MWA								
HEDIS MY 2018 MWA						_		

${\sf Table}\,{\sf A-4-MHP}\,{\sf and}\,\,{\sf MWA}\,{\sf Results}\,{\sf for}\,{\sf Child}\,\,{\sf and}\,{\sf Adolescents}\,{\sf Well-Care}\,{\sf Visits}^1$

¹Due to changes in the technical specifications for this measure, NCQA recommends a break in trending between MY 2020 and prior years; therefore, prior years' rates will not be displayed and comparisons to benchmarks will not be performed for this measure.



Plan	Eligible Population	Combination 1 Rate	Combination 2 Rate
AET	718	79.56%	37.23%+
BCC	3,162	82.00%	34.06%
НАР	41	70.73%	21.95%
MCL	3,666	81.75%	30.90%
MER	9,776	82.73%+	36.50%
MOL	7,640	83.70%+	42.34%+
PRI	2,767	87.59%+	45.99%+
THC	974	81.75%	36.98%+
UNI	5,725	80.78%	38.20%+
UPP	856	80.72%	34.93%
HEDIS MY 2020 MWA		82.68%+	37.95%+
HEDIS MY 2019 MWA		85.28%	40.40%
HEDIS MY 2018 MWA		85.66%	

Table A-5—MHP and MWA Results for Immunizations for Adolescents

Yellow shading with one cross (+) indicates the HEDIS MY 2020 MHP or MWA rate was at or above the Quality Compass HEDIS MY 2019 MWA national Medicaid 50th percentile. ¹The Immunizations for Adolescents—Combination 2 measure was not included in the MY 2018 results. Therefore, the MY 2018 results are not included here.



Plan	Initiation Phase— Eligible Population	Initiation Phase— Rate	Continuation and Maintenance Phase—Eligible Population	Continuation and Maintenance Phase—Rate
AET	167	36.53%	37	45.95%
BCC	807	48.33%+	188	68.62%+
HAP	4	NA	1	NA
MCL	1,142	49.12%+	371	59.30%+
MER	2,577	44.59%+	714	55.18%+
MOL	1,796	51.67%+	455	65.49%+
PRI	669	37.07%	216	42.59%
THC	200	55.50%+	48	62.50%+
UNI	1,461	41.20%	318	54.09%
UPP	236	50.42%+	82	62.20%+
HEDIS MY 2020 MWA		46.03%+		57.74% ⁺
HEDIS MY 2019 MWA		44.44%		54.65%
HEDIS MY 2018 MWA		46.59%		58.80%

Table A-6—MHP and MWA Results for Follow-Up Care for Children Prescribed ADHD Medication— Initiation Phase and Continuation and Maintenance Phase¹

Yellow shading with one cross (+) indicates the HEDIS MY 2020 MHP or MWA rate was at or above the Quality Compass HEDIS MY 2019 MWA national Medicaid 50th percentile.

NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate. ¹Due to changes in the technical specifications for this measure, NCQA recommends trending between MY 2020 and prior years be considered with caution.



Women—Adult Care Performance Measure Results

Plan	Ages 16 to 20 Years—Eligible Population	Ages 16 to 20 Years—Rate	Ages 21 to 24 Years—Eligible Population	Ages 21 to 24 Years—Rate	Total—Eligible Population	Total—Rate	
AET	935	57.01%+	861	63.88%	1,796	60.30%+	
BCC	3,921	58.99%+	4,086	64.86%	8,007	61.98%+	
НАР	177	51.98%	236	59.75%	413	56.42%	
MCL	4,704	53.49%	4,281	61.32%	8,985	57.22%	
MER	10,496	55.53%+	8,720	62.83%	19,216	58.84%+	
MOL	8,117	59.09%+	6,083	65.40%+	14,200	61.79%+	
PRI	3,120	58.78%+	2,438	63.95%	5,558	61.05%+	
THC	1,198	69.37%+	930	72.69%+	2,128	$70.82\%^{+}$	
UNI	5,820	59.85%+	4,476	64.95%	10,296	62.06%+	
UPP	1,068	41.01%	841	49.82%	1,909	44.89%	
HEDIS MY 2020 MWA		57.30% ⁺		63.68%		60.20% ⁺	
HEDIS MY 2019 MWA		62.76%		68.90%		65.42%	
HEDIS MY 2018 MWA		63.98%		69.17%		66.28%	

Table A-7—MHP and MWA Results for Chlamydia Screening in Women



	Cervical Cancer Screening— Eligible	Cervical Cancer
Plan	Population	Screening—Rate
AET	10,169	54.01%
BCC	52,196	60.73%
HAP	3,496	40.00%
MCL	46,037	59.85%
MER	109,120	59.41%
MOL	72,741	63.99%+
PRI	28,213	67.88%+
THC	11,549	61.56%+
UNI	56,011	57.66%
UPP	11,886	58.15%
HEDIS MY 2020 MWA		60.53%
HEDIS MY 2019 MWA		67.66%
HEDIS MY 2018 MWA		65.76%

Table A-8—MHP and MWA Results for Cervical Cancer Screening in Women¹

Yellow shading with one cross (+) indicates the HEDIS MY 2020 MHP or MWA rate was at or above the Quality Compass HEDIS MY 2019 MWA national Medicaid 50th percentile.

¹Due to changes in the technical specifications for this measure, NCQA recommends trending between MY 2020 and prior years be considered with caution.



Plan	Breast Cancer Screening— Eligible Population	Breast Cancer Screening—Rate
AET	2,600	50.35%
BCC	7,916	55.48%
НАР	1,019	57.02%
MCL	8,564	56.20%
MER	19,213	56.65%
MOL	16,053	55.52%
PRI	5,731	64.51%+
THC	2,503	50.62%
UNI	10,056	54.30%
UPP	2,914	61.87%+
HEDIS MY 2020 MWA		56.31%
HEDIS MY 2019 MWA		60.83%
HEDIS MY 2018 MWA		61.37%

Table A-9—MHP and MWA Results for Breast Cancer Screening in Women¹

Yellow shading with one cross (+) indicates the HEDIS MY 2020 MHP or MWA rate was at or above the Quality Compass HEDIS MY 2019 MWA national Medicaid 50th percentile.

¹Due to changes in the technical specifications for this measure, NCQA recommends trending between MY 2020 and prior years be considered with caution.



Access to Care Performance Measure Results

Plan	Ages 20 to 44 Years—Eligible Population	Ages 20 to 44 Years—Rate	Ages 45 to 64 Years—Eligible Population	Ages 45 to 64 Years—Rate	Ages 65+ Years—Eligible Population	Ages 65+ Years—Rate	Total—Eligible Population	Total—Rate
AET	13,447	65.40%	8,274	79.70%	3,004	87.72%	24,725	72.90%
BCC	68,653	74.84%	38,286	82.29%	604	71.52%	107,543	77.48%
НАР	5,566	57.06%	3,465	74.49%	2,364	88.16%	11,395	68.81%
MCL	64,707	73.17%	34,458	83.28%	311	72.67%	99,476	76.67%
MER	140,954	76.20%	72,173	84.67%	2,399	88.91%	215,526	79.18%
MOL	91,905	75.54%	53,132	85.30%	6,110	90.28%+	151,147	79.57%
PRI	35,690	76.55%	18,209	85.47%	2,271	91.77%+	56,170	80.06%
THC	15,029	69.67%	9,697	82.94%	331	81.87%	25,057	74.97%
UNI	70,785	73.73%	38,981	84.72%	1,574	88.25%	111,340	77.79%
UPP	14,323	78.29%	8,860	85.12%	1,734	92.68%+	24,917	81.72%+
HEDIS MY 2020 MWA		74.60%		84.05%		88.77%		78.22%
HEDIS MY 2019 MWA		79.02%		87.31%		92.68%		82.49%
HEDIS MY 2018 MWA		78.26%		87.05%		92.99%		81.95%

Table A-10—MHP and MWA Results for Adults' Access to Preventive/Ambulatory Health Services



Plan	Ages 3 Months to 17 Years— Eligible Population	Ages 3 Months to 17 Years— Rate	Ages 18 to 64 Years—Eligible Population	Ages 18 to 64 Years—Rate	Ages 65+ Years—Eligible Population	Ages 65+ Years—Rate	Total—Eligible Population	Total—Rate
AET	369	61.25%+	567	43.03%+	67	28.36%	1,003	48.75%
BCC	2,189	62.81%+	2,658	38.45%+	7	NA	4,854	49.46%
НАР	54	75.93%+	116	40.52%+	44	29.55%	214	47.20%
MCL	2,269	61.39%+	2,560	39.96%+	2	NA	4,831	50.05%
MER	6,095	60.82%+	5,826	39.00%+	48	31.25%	11,969	50.08%
MOL	4,458	58.59%	4,047	38.65%+	110	22.73%	8,615	48.76%
PRI	1,266	71.56%+	1,467	48.74%+	28	NA	2,761	59.51%+
THC	514	64.79%+	734	39.51%+	6	NA	1,254	49.92%
UNI	3,279	60.54%+	3,414	38.84%+	32	31.25%	6,725	49.38%
UPP	280	64.64%+	414	36.47%	15	NA	709	47.53%
HEDIS MY 2020 MWA		61.42% ⁺		39.69% ⁺		32.87%		50.15%
HEDIS MY 2019 MWA		60.04%		37.65%		34.71%		48.23%
HEDIS MY 2018 MWA								

Table A-11—MHP and MWA Results for Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis

Yellow shading with one cross (+) indicates the HEDIS MY 2020 MHP or MWA rate was at or above the Quality Compass HEDIS MY 2019 MWA national Medicaid 50th percentile. NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.



Plan	Ages 3 to 17 Years—Eligible Population	Ages 3 to 17 Years—Rate	Ages 18 to 64 Years—Eligible Population	Ages 18 to 64 Years—Rate	Ages 65+ Years—Eligible Population	Ages 65+ Years—Rate	Total—Eligible Population	Total—Rate
AET	627	68.58%	526	49.81%	22	NA	1,175	59.23%
BCC	4,110	75.69%	3,732	54.39%	2	NA	7,844	65.57%
НАР	97	65.98%	138	47.10%	19	NA	254	52.76%
MCL	6,022	81.62%	3,600	67.58%+	1	NA	9,623	76.36%
MER	14,387	77.32%	8,072	60.88%	12	NA	22,471	71.39%
MOL	10,897	70.08%	5,839	52.12%	50	24.00%+	16,786	63.70%
PRI	2,658	81.08%	1,534	68.19%+	2	NA	4,194	76.32%
THC	869	65.71%	733	45.57%	0	NA	1,602	56.49%
UNI	7,898	73.31%	4,743	51.63%	25	NA	12,666	65.10%
UPP	980	79.18%	593	71.84%+	3	NA	1,576	76.40%
HEDIS MY 2020 MWA		75.34%		57.61%		25.00% ⁺		68.56%
HEDIS MY 2019 MWA		76.87%		59.75%		34.85%		70.83%
HEDIS MY 2018 MWA								_

Table A-12—MHP and MWA Results for Appropriate Testing for Pharyngitis¹

Yellow shading with one cross (+) indicates the HEDIS MY 2020 MHP or MWA rate was at or above the Quality Compass HEDIS MY 2019 MWA national Medicaid 50th percentile. ¹Due to changes in the technical specifications for this measure, NCQA recommends trending between MY 2020 and prior years be considered with caution. NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.



Plan	Ages 3 Months to 17 Years— Eligible Population	Ages 3 Months to 17 Years— Rate	Ages 18 to 64 Years—Eligible Population	Ages 18 to 64 Years—Rate	Ages 65+ Years—Eligible Population	Ages 65+ Years—Rate	Total—Eligible Population	Total—Rate
AET	2,384	91.28%	1,293	80.28%+	80	70.00%	3,757	87.04%
BCC	13,455	91.91%+	7,607	76.51%+	21	NA	21,083	86.34%
НАР	302	91.72%+	319	79.94%+	80	73.75%+	701	84.31%
MCL	11,246	90.52%	5,851	79.90%+	2	NA	17,099	86.88%
MER	36,486	91.71%+	14,751	78.27%+	60	88.33%+	51,297	87.84%+
MOL	27,509	89.18%	10,681	76.95%+	199	61.31%	38,389	85.63%
PRI	9,809	95.18%+	3,822	87.57%+	39	89.74%+	13,670	93.04%+
THC	2,972	91.99%+	1,519	75.58%+	9	NA	4,500	86.44%
UNI	21,746	91.43%	8,571	75.01%	59	67.80%	30,376	86.75%
UPP	2,673	91.43%	1,257	83.13%+	23	NA	3,953	88.72%+
HEDIS MY 2020 MWA		91.30%		78.18% ⁺		71.33%		87.28%
HEDIS MY 2019 MWA		90.61%		75.39%		68.24%		86.26%
HEDIS MY 2018 MWA								

Table A-13—MHP and MWA Results for Appropriate Treatment for Upper Respiratory Infection

Yellow shading with one cross (+) indicates the HEDIS MY 2020 MHP or MWA rate was at or above the Quality Compass HEDIS MY 2019 MWA national Medicaid 50th percentile. NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.



Obesity Performance Measure Results

Plan	Eligible Population	BMI Percentile Documentation— Total—Rate ¹	Counseling for Nutrition— Total—Rate	Counseling for Physical Activity— Total—Rate
AET	6,602	80.29%	72.02%+	68.61%+
BCC	36,963	78.14%	64.87%	63.80%
НАР	1,190	80.67%+	69.85%	67.27%+
MCL	41,812	65.21%	53.53%	53.77%
MER	116,879	78.59%	69.83%	68.13%+
MOL	82,031	76.89%	70.80%	67.64%+
PRI	32,694	90.02%+	81.75%+	80.29%+
THC	8,486	75.91%	69.10%	66.91%+
UNI	58,693	82.48%+	73.72%+	71.29%+
UPP	10,329	88.08%+	72.99%+	69.59%+
HEDIS MY 2020 MWA		78.53%	69.51%	67.60% ⁺
HEDIS MY 2019 MWA		85.84%	75.68%	73.76%
HEDIS MY 2018 MWA		84.18%	75.19%	72.04%

Table A-14—MHP and MWA Results for Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents

Yellow shading with one cross (+) indicates the HEDIS MY 2020 MHP or MWA rate was at or above the Quality Compass HEDIS MY 2019 MWA national Medicaid 50th percentile.

¹Due to changes in the technical specifications for this measure, NCQA recommends trending between MY 2020 and prior years be considered with caution.



Pregnancy Care Performance Measure Results

Plan	Eligible Population	Timeliness of Prenatal Care— Rate	Postpartum Care—Rate
AET	820	68.86%	54.01%
BCC	4,540	78.91%	71.09%
HAP	228	68.30%	52.68%
MCL	4,026	78.59%	70.32%
MER	9,815	79.08%	67.88%
MOL	6,438	81.27%	70.32%
PRI	2,742	86.37%	79.56%+
THC	880	64.72%	53.53%
UNI	4,775	78.83%	71.78%
UPP	794	91.24%+	87.59%+
HEDIS MY 2020 MWA		79.54%	70.13%
HEDIS MY 2019 MWA		86.17%	73.76%
HEDIS MY 2018 MWA		_	_

Table A-15—MHP and MWA Results for Prenatal and Postpartum Care¹

Yellow shading with one cross (+) indicates the HEDIS MY 2020 MHP or MWA rate was at or above the Quality Compass HEDIS MY 2019 MWA national Medicaid 50th percentile. ¹ Due to changes in the technical specifications for this measure, NCQA recommends trending

between MY 2020 and prior years be considered with caution.



Living With Illness Performance Measure Results

Plan	Eligible Population	HbA1c Testing—Rate ¹	HbA1c Poor Control (>9.0%)— Rate ^{*,1}	HbA1c Control (<8.0%)—Rate ¹	Eye Exam (Retinal) Performed— Rate ¹	Blood Pressure Control (<140 90 mm Hg)— Rate ²
AET	3,200	80.05%	48.91%	44.04%	45.74%	52.07%
BCC	10,433	80.29%	41.61%	49.15%	58.64%+	56.93%
НАР	1,478	84.18%	46.96%	46.47%	44.77%	53.28%
MCL	9,605	77.86%	56.45%	37.71%	54.74%	50.85%
MER	21,459	85.89%	44.04%	47.45%	50.17%	56.45%
MOL	18,200	82.73%	44.77%	43.31%	53.28%	56.93%
PRI	5,607	90.51%+	28.47%+	60.58%+	63.02%+	75.91%
THC	2,877	77.62%	52.31%	40.39%	41.85%	47.45%
UNI	12,831	83.21%	34.79%+	54.26%+	55.23%	63.75%
UPP	2,373	87.59%	29.93%+	57.42%+	61.07%+	78.35%
HEDIS MY 2020 MWA		83.13%	43.03%	47.46%	53.65%	58.38%
HEDIS MY 2019 MWA		89.20%	37.21%	52.72%	62.60%	
HEDIS MY 2018 MWA		88.35%	38.37%	51.41%	62.24%	—

Table A-16—MHP and MWA Results for Comprehensive Diabetes Care

Yellow shading with one cross (+) indicates the HEDIS MY 2020 MHP or MWA rate was at or above the Quality Compass HEDIS MY 2019 MWA national Medicaid 50th percentile.

 1 Due to changes in the technical specifications for this measure, NCQA recommends trending between MY 2020 and prior years be considered with caution. 2 Due to changes in the technical specifications for this measure, NCQA recommends a break in trending between MY 2020 and prior years; therefore, prior years' rates will not be displayed and comparisons to benchmarks will not be performed for this measure.



	Ages 18 to 64 Years—Eligible		Ages 65 to 74 Years—Eligible		Ages 75 to 85 Years—Eligible		Total—Eligible	
Plan	Population	Years—Rate	Population	Years—Rate	Population	Years—Rate	Population	Total—Rate
AET	2,404	15.43%	582	19.24%	165	15.76%	3,151	16.15%
BCC	9,938	26.81%	107	32.71%	36	2.78%	10,081	26.78%
HAP	917	30.86%	444	34.23%	147	30.61%	1,508	31.83%
MCL	9,382	26.56%	61	27.87%	12	NA	9,455	26.57%
MER	20,205	31.06%	488	36.07%	127	35.43%	20,820	31.21%
MOL	16,193	30.64%	1,319	33.74%	312	34.29%	17,824	30.94%
PRI	5,031	38.84%	430	31.63%	110	36.36%	5,571	38.23%
THC	2,690	28.22%	61	22.95%	7	NA	2,758	28.03%
UNI	11,922	35.65%	423	35.70%	83	40.96%	12,428	35.69%
UPP	2,046	34.80%	238	38.66%	72	27.78%	2,356	34.97%
HEDIS MY 2020 MWA		30.63%		32.03%		29.97%		30.68%
HEDIS MY 2019 MWA								_
HEDIS MY 2018 MWA								

Table A-17—MHP and MWA Results for Kidney Health Evaluation for People With Diabetes¹

NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

¹ This measure is a first-year measure; therefore, prior years' rates cannot be displayed and comparisons to benchmarks cannot be performed for this measure as benchmarks are not yet available.



Plan	Eligible Population	Total—Rate
AET	647	50.39%
BCC	3,014	50.13%
HAP	67	46.27%
MCL	3,938	53.48%
MER	6,399	60.15%
MOL	5,491	52.96%
PRI	2,023	73.36%+
THC	996	45.68%
UNI	3,453	61.08%
UPP	885	58.42%
HEDIS MY 2020 MWA		56.83%
HEDIS MY 2019 MWA		59.86%
HEDIS MY 2018 MWA		62.57%

Table A-18—MHP and MWA Results for Asthma Medication Ratio



Plan	Eligible Population	Rate
AET	5,551	46.23%
BCC	17,114	54.99%
HAP	2,354	52.55%
MCL	15,694	47.20%
MER	35,068	51.82%
MOL	29,787	50.85%
PRI	8,735	74.94%
THC	5,141	45.26%
UNI	19,372	62.53%
UPP	3,699	73.24%
HEDIS MY 2020 MWA		54.48%
HEDIS MY 2019 MWA		
HEDIS MY 2018 MWA		

Table A-19—MHP and MWA Results for Controlling High Blood Pressure¹

¹Due to changes in the technical specifications for this measure, NCQA recommends a break in trending between MY 2020 and prior years; therefore, prior years' rates will not be displayed and comparisons to benchmarks will not be performed for this measure.



Plan	Eligible Population	Advising Smokers and Tobacco Users to Quit— Rate	Discussing Cessation Medications— Rate	Discussing Cessation Strategies— Rate
AET	57,807	78.68%+	57.87%+	53.72%+
BCC	255,790	79.29%+	54.31%+	49.74%+
НАР	22,988	76.13%	59.35%+	53.80%+
MCL	225,327	72.51%	51.79%	47.31%
MER	498,053	75.72%	56.12%+	46.81%
MOL	335,910	73.80%	58.38%+	51.35%+
PRI	128,044	79.39%+	56.29%+	51.22%+
THC	50,976	88.84%+	69.51%+	60.09%+
UNI	257,152	80.79%+	60.12%+	52.02%+
UPP	55,499	79.50%+	63.00%+	56.03%+
HEDIS MY 2020 MWA		76.98%	56.97%+	50.01%+
HEDIS MY 2019 MWA		80.64%	59.18%	51.56%
HEDIS MY 2018 MWA		81.34%	58.38%	48.98%



Plan	Eligible Population	Effective Acute Phase Treatment—Rate	Effective Continuation Phase Treatment—Rate
AET	795	51.32%	37.48%
BCC	4,364	62.35%+	47.14%+
HAP	153	70.59%+	47.06%+
MCL	5,196	63.95%+	48.85%+
MER	4,582	50.48%	33.33%
MOL	6,238	61.61%+	43.83%+
PRI	1,203	62.76%+	45.30%+
THC	841	69.08%+	56.84%+
UNI	4,475	54.48%+	38.21%+
UPP	573	62.13%+	44.50%+
HEDIS MY 2020 MWA		59.28% ⁺	42.98%+
HEDIS MY 2019 MWA		54.97%	38.77%
HEDIS MY 2018 MWA		55.75%	39.46%

Table A-21—MHP and MWA Results for Antidepressant Medication Management



	Eligible	
Plan	Population	Rate
AET	1,066	62.95%
BCC	2,199	80.17%
НАР	309	71.52%
MCL	4,297	74.61%
MER	3,074	81.52%
MOL	4,336	78.55%
PRI	692	80.64%
THC	498	82.53%+
UNI	2,419	80.12%
UPP	783	85.06%+
HEDIS MY 2020 MWA		78.01%
HEDIS MY 2019 MWA		84.38%
HEDIS MY 2018 MWA		84.22%

Table A-22—MHP and MWA Results for Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications



Plan	Eligible Population	Rate
AET	181	52.49%
BCC	195	66.67%
HAP	63	66.67%
MCL	323	60.37%
MER	443	61.17%
MOL	706	62.18%
PRI	100	61.00%
THC	72	58.33%
UNI	323	61.61%
UPP	85	82.35%+
HEDIS MY 2020 MWA		61.98%
HEDIS MY 2019 MWA		68.31%
HEDIS MY 2018 MWA		70.56%

Table A-23—MHP and MWA Results for Diabetes Monitoring for People With Diabetes and Schizophrenia



Plan	Eligible Population	Rate				
AET	25	NA				
BCC	20	NA				
HAP	9	NA				
MCL	45	51.11%				
MER	63	61.90%				
MOL	110	67.27%				
PRI	9	NA				
THC	19	NA				
UNI	56	67.86%				
UPP	12	NA				
HEDIS MY 2020 MWA		64.95%				
HEDIS MY 2019 MWA		73.16%				
HEDIS MY 2018 MWA		76.26%				

Table A-24—MHP and MWA Results for Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia

NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.



Plan	Eligible Population	Rate
AET	831	63.54%+
BCC	837	58.66%
НАР	246	65.04%+
MCL	1,611	71.26%+
MER	992	68.04%+
MOL	2,405	71.35%+
PRI	256	72.27%+
THC	294	53.40%
UNI	1,087	65.78%+
UPP	360	84.72%+
HEDIS MY 2020 MWA		68.17% ⁺
HEDIS MY 2019 MWA		59.26%
HEDIS MY 2018 MWA		64.91%

Table A-25—MHP and MWA Results for Adherence to Antipsychotic Medications for Individuals With Schizophrenia

APPENDIX A. TABULAR RESULTS



Health Plan Diversity and Utilization Measure Results

The Health Plan Diversity and Utilization measures' MHP and MWA results are presented in tabular format in Section 9 and Section 10 of this report.



Appendix B. Trend Tables

Appendix B includes trend tables for the MHPs. Where applicable, each measure's HEDIS MY 2018, HEDIS MY 2019, and HEDIS MY 2020 rates are presented as well as the HEDIS MY 2019 to HEDIS MY 2020 rate comparison and the HEDIS MY 2020 Performance Level. HEDIS MY 2019 and HEDIS MY 2020 rates were compared based on a Chi-square test of statistical significance with a *p* value <0.05. Values in the MY 2019–MY 2020 Comparison column that are shaded green with one cross (⁺) indicate significant improvement from the previous year. Values in the MY 2019–MY 2020 Comparison column shaded red with two crosses (⁺⁺) indicate a significant decline in performance from the previous year.

Details regarding the trend analysis and performance ratings are found in Section 2.



Table B-1—AET Trend Table

Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Child & Adolescent Care					
Childhood Immunization St	atus				
Combination 2	63.02%	63.02%	52.66%	-10.36++	*
Combination 3	58.64%	58.64%	49.38%	-9.26**	*
Combination 4	58.39%	58.39%	48.75%	-9.64 ⁺⁺	*
Combination 5	46.47%	46.47%	41.25%	-5.22	*
Combination 6	29.68%	29.68%	21.41%	-8.27**	*
Combination 7	46.47%	46.47%	40.63%	-5.84	*
Combination 8	29.68%	29.68%	21.41%	-8.27**	*
Combination 9	23.84%	23.84%	18.13%	-5.71++	*
Combination 10	23.84%	23.84%	18.13%	-5.71++	*
Well-Child Visits in the Firs	t 30 Months of	Life	•		
Well-Child Visits in the First 15 Months—Six or More Well-Child Visits⁴	_	_	41.63%	NC	NC
Well-Child Visits for Age 15 Months to 30 Months—Two or More Well-Child Visits ⁵	_	_	52.61%	NC	NC
Lead Screening in Children					
Lead Screening in Children	76.40%	76.40%	62.83%	-13.57**	*
Child and Adolescent Well-C	Care Visits⁴				
Ages 3 to 11 Years	_	_	41.17%	NC	NC
Ages 12 to 17 Years	_	_	32.25%	NC	NC
Ages 18 to 21 Years	_	_	21.59%	NC	NC
Total	_		34.76%	NC	NC
Immunizations for Adolesce	nts				
Combination 1 (Meningococcal, Tdap)	88.56%	88.56%	79.56%	-9.00++	**
Combination 2 (Meningococcal, Tdap, HPV)	_	37.96%	37.23%	-0.73	***
Follow-Up Care for Children	n Prescribed Al	DHD Medication	n^3	•	•
Initiation Phase	25.11%	27.78%	36.53%	+8.75	*

Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Continuation and Maintenance Phase	44.74%	52.63%	45.95%	-6.68	*
Women—Adult Care					
Chlamydia Screening in Wo	men				
Ages 16 to 20 Years	67.86%	60.39%	57.01%	-3.38	***
Ages 21 to 24 Years	69.88%	69.84%	63.88%	-5.96++	**
Total	68.65%	64.27%	60.30%	-3.97++	***
Cervical Cancer Screening ³					
Cervical Cancer Screening	60.51%	60.51%	54.01%	-6.50	*
Breast Cancer Screening ³					
Breast Cancer Screening	54.55%	54.38%	50.35%	-4.03++	*
Access to Care					
Adults' Access to Preventive/	Ambulatory H	ealth Services			
Ages 20 to 44 Years	69.67%	72.86%	65.40%	-7.46**	*
Ages 45 to 64 Years	83.50%	84.44%	79.70%	-4.74++	*
65 Years and Older	89.86%	89.72%	87.72%	-2.00++	**
Total	77.52%	79.50%	72.90%	-6.60**	*
Avoidance of Antibiotic Trea	utment for Acut	e Bronchitis/Bi	ronchiolitis		
Ages 3 Months to 17 Years	_	54.25%	61.25%	$+7.00^{+}$	***
Ages 18 to 64 Years	_	35.34%	43.03%	$+7.69^{+}$	****
Ages 65 Years And Older	_	25.93%	28.36%	+2.43	**
Total		42.53%	48.75%	$+6.22^{+}$	**
Appropriate Testing for Pha	ryngitis ³				
Ages 3 to 17 Years	_	67.21%	68.58%	+1.37	*
Ages 18 to 64 Years		51.61%	49.81%	-1.80	*
Ages 65 Years And Older	_	NA	NA	NC	NC
Total		60.09%	59.23%	-0.86	*
Appropriate Treatment for U	pper Respirato	ry Infection			
Ages 3 Months to 17 Years		91.36%	91.28%	-0.08	**
Ages 18 to 64 Years	_	74.70%	80.28%	$+5.58^{+}$	***
Ages 65 Years And Older	_	61.90%	70.00%	+8.10	**
Total		85.73%	87.04%	+1.31	**



Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²	M
Obesity						Discuss
Weight Assessment and Cou	nseling for Nut	trition and Phys	ical Activity for	Children/Adolesc	cents	Medica
Body Mass index (BMI) Percentile—Total ³	87.23%	87.23%	80.29%	-6.94++	**	Discuss Strateg
Counseling for Nutrition—Total	81.65%	81.65%	72.02%	-9.63++	***	Antidepres Effectiv
Counseling for Physical Activity—Total	78.72%	78.72%	68.61%	-10.11**	***	Treatm Effectiv
Pregnancy Care		•				Phase 2
Prenatal and Postpartum Co	ure ³					Diabetes S
Timeliness of Prenatal Care	_	70.07%	68.86%	-1.21	*	Medication Diabete
Postpartum Care	_	63.02%	54.01%	-9.01++	*	People Schizop
Living With Illness		•				Disord
Comprehensive Diabetes Ca	re					Antipsy
Hemoglobin A1c (HbA1c) Testing ³	84.43%	84.43%	80.05%	-4.38	*	Diabetes M Diabete
HbA1c Poor Control (>9.0%)* ³	38.93%	38.93%	48.91%	+9.98++	*	People and Sch
HbA1c Control ($< 8.0\%$) ³	52.31%	52.31%	44.04%	-8.27**	*	Cardiovas
Eye Exam (Retinal) Performed ³	54.50%	54.50%	45.74%	-8.76++	*	Cardio Monito
Blood Pressure Control (<140/90 mm Hg) ⁴	_	_	52.07%	NC	NC	With Co Disease
Kidney Health Evaluation for	or Patients With	Diabetes ⁵		-		Schizop
Ages 18 to 64 Years			15.43%	NC	NC	Adherence
Ages 65 to 74 Years	_		19.24%	NC	NC	Adherer Antipsy
Ages 75 to 85 Years	_		15.76%	NC	NC	Medica
Total	_		16.15%	NC	NC	Individ
Asthma Medication Ratio				-		Schizop
Total	52.42%	50.22%	50.39%	+0.17	*	Health Pla
Controlling High Blood Pre	ssure ⁴	•		•		Race/Ethr
Controlling High Blood Pressure	_	_	46.23%	NC	NC	Total— Total—
Medical Assistance With Sm	oking and Tob	acco Use Cessat	ion	•	·	America
Advising Smokers and Tobacco Users to Quit	85.14%	85.78%	78.68%	-7.10	***	Total— and Ald

Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Discussing Cessation Medications	63.71%	60.00%	57.87%	-2.13	***
Discussing Cessation Strategies	56.10%	54.05%	53.72%	-0.33	***
Antidepressant Medication M	<i>Management</i>				
Effective Acute Phase Treatment	53.29%	49.93%	51.32%	+1.39	**
Effective Continuation Phase Treatment	35.48%	36.45%	37.48%	+1.03	**
Diabetes Screening for Peop Medications	le With Schizo	phrenia or Bipo	lar Disorder W	ho Are Using Ant	ipsychotic
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication	78.64%	74.64%	62.95%	-11.69**	*
Diabetes Monitoring for Peo	ple With Diabe	etes and Schizop	hrenia		
Diabetes Monitoring for People With Diabetes and Schizophrenia	67.48%	48.80%	52.49%	+3.69	*
Cardiovascular Monitoring	for People With	h Cardiovascula	r Disease and S	Schizophrenia	
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia	NA	NA	NA	NC	NC
Adherence to Antipsychotic	Medications fo	r Individuals W	ith Schizophre	nia	-
Adherence to Antipsychotic Medications for Individuals With Schizophrenia	60.61%	60.36%	63.54%	+3.18	***
Health Plan Diversity ⁵					
Race/Ethnicity Diversity of M	1embership				
Total—White	25.44%	30.77%	32.58%	+1.81	NC
Total—Black or African American	63.29%	55.54%	53.80%	-1.74	NC
Total—American–Indian and Alaska Native	0.20%	0.26%	0.19%	-0.07	NC
Total—Asian	0.69%	1.82%	1.16%	-0.66	NC

APPENDIX B. TREND TABLES

2021 HEDIS Aggregate Report for Michigan Medicaid State of Michigan



Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²	Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Total—Native Hawaiian and Other Pacific Islander	0.05%	0.08%	0.08%	0.00	NC	Other Language Needs— Declined	0.00%	0.00%	0.00%	0.00	NC
Total—Some Other Race	0.00%	0.00%	0.00%	0.00	NC	Utilization ⁶	1 000 16 1	14 d \			
Total—Two or More Races	0.00%	0.00%	0.00%	0.00	NC	Ambulatory Care—Total (Pe	er 1,000 Membe	er Months)			1
Total—Unknown ³	4.19%	4.78%	6.03%	+1.25	NC	Emergency Department Visits—Total*	80.69	75.36	55.97	-19.39	***
Total—Declined ³	6.13%	6.76%	6.16%	-0.60	NC	Outpatient Visits—Total	388.39	590.74	550.95	-39.79	NC
Total—Hispanic or						Inpatient Utilization—Gene				0,11,7	110
Latino ³	3.05%	3.40%	3.62%	+0.22	NC	Discharges per 1,000					
Language Diversity of Memb	bership					Member Months—Total	10.02	11.95	10.53	-1.42	NC
Spoken Language						Inpatient—Total All Ages					
Preferred for Health Care—English	0.00%	0.00%	0.00%	0.00	NC	Average Length of Stay— Total Inpatient—Total All Ages	4.89	5.41	5.60	+0.19	NC
Spoken Language Preferred for Health Care—Non-English	0.00%	0.00%	0.00%	0.00	NC	Discharges per 1,000 Member Months—	2.19	2.39	2.32	-0.07	NC
Spoken Language Preferred for Health Care—Unknown	100.00%	100.00%	100.00%	0.00	NC	Maternity—Total All Ages Average Length of Stay— Maternity—Total All	2.66	2.72	2.58	-0.14	NC
Spoken Language						Ages	2.00	2.72	2.00	0.11	110
Preferred for Health Care—Declined	0.00%	0.00%	0.00%	0.00	NC	Discharges per 1,000 Member Months— Surgery—Total All Ages	2.52	2.91	2.50	-0.41	NC
Language Preferred for Written Materials— English	0.00%	0.00%	0.00%	0.00	NC	Average Length of Stay— Surgery—Total All Ages	7.48	7.91	9.05	+1.14	NC
Language Preferred for Written Materials—Non- English	0.00%	0.00%	0.00%	0.00	NC	Discharges per 1,000 Member Months— Medicine—Total All	5.93	7.33	6.34	-0.99	NC
Language Preferred for Written Materials— Unknown	100.00%	100.00%	100.00%	0.00	NC	Ages Average Length of Stay— Medicine—Total All Ages	4.38	5.05	5.05	0.00	NC
Language Preferred for						Use of Opioids From Multip	le Providers *3				
Written Materials—	0.00%	0.00%	0.00%	0.00	NC	Multiple Prescribers	15.90%	15.69%	14.94%	-0.75	****
Declined			ļ	L	<u> </u>]	Multiple Pharmacies	12.05%	16.15%	3.43%	-12.72 ⁺	***
Other Language Needs— English	99.06%	98.26%	97.73%	-0.53	NC	Multiple Prescribers and Multiple Pharmacies	4.34%	4.60%	2.23%	-2.37+	***
Other Language Needs— Non-English	0.67%	0.97%	0.99%	+0.02	NC	Use of Opioids at High Dosa	ge* ³				
Other Language Needs— Unknown	0.28%	0.78%	1.28%	+0.50	NC	Use of Opioids at High Dosage*	_	3.30%	2.53%	-0.77	****



Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²			
Risk of Continued Opioid Use ^{**,3}								
At Least 15 Days Covered—Total	23.40%	18.46%	16.92%	-1.54	*			
At Least 31 Days Covered—Total	9.32%	9.21%	9.03%	-0.18	*			
Plan All-Cause Readmission	ns							
Observed Readmissions—Total*		10.10%	11.42%	+1.32	*			
Expected Readmissions—Total*		9.36%	9.91%	+0.55	**			
O/E Ratio—Total*	_	1.08	1.15	+0.07++	*			

¹HEDIS MY 2019 to HEDIS MY 2020 comparisons were based on a Chi-square test of statistical significance with a p value of < 0.05. MY 2019–MY 2020 Comparisons shaded green with one cross (+) indicate significant improvement from the previous year. MY 2019–MY 2020 Comparisons shaded red with two crosses (++) indicate a significant decline in performance from the previous year.

²HEDIS MY 2020 Performance Levels were based on comparisons of the HEDIS MY 2020 measure indicator rates to national Medicaid Quality Compass HEDIS MY 2019 benchmarks, with the exception of the Plan All-Cause Readmissions measure indicator rates, which were compared to the national Medicaid NCQA Audit Means and Percentiles HEDIS MY 2019 benchmark.

³Due to changes in the technical specifications for this measure, NCQA recommends trending between MY 2020 and prior years be considered with caution.

⁴Due to changes in the technical specifications for this measure, NCQA recommends a break in trending between MY 2020 and prior years; therefore, prior years' rates are not displayed and comparisons to benchmarks are not performed for this measure.

⁵This measure is a first-year measure; therefore, the prior year's rates cannot be displayed and comparisons to benchmarks cannot be performed for this measure as benchmarks are not yet available. ⁶Significance testing was not performed for utilization-based or health plan description measure indicator rates and any Performance Levels for MY 2020 or MY 2019–MY 2020 Comparisons provided for these measures are for information purposes only.

* For this indicator, a lower rate indicates better performance.

— indicates that the rate is not presented in this report as the measure is a first-year measure; therefore, no trending information is available. This symbol may also indicate that NCQA recommended a break in trending; therefore, no prior year rates are displayed.

NC indicates that a comparison is not appropriate, or the measure did not have an applicable benchmark. *NA* indicates that the *MHP* followed the specifications, but the denominator was too small (<30) to report a valid rate.

HEDIS MY 2020 Performance Levels represent the following percentile comparisons:

 $\star \star \star \star \star = 90$ th percentile and above

 $\star \star \star \star = 75$ th to 89th percentile

- $\star \star \star = 50$ th to 74th percentile
- $\star\star$ = 25th to 49th percentile
- \star = Below 25th percentile

2021 HEDIS Aggregate Report for Michigan Medicaid State of Michigan



Table B-2—BCC Trend Table MY 2019-MY 2020 HEDIS MY MY 2020 HEDIS MY **HEDIS MY** Performance Measure 2018 2019 2020 **Comparison**¹ Level² Child & Adolescent Care **Childhood Immunization Status** 70.32% 72.02% Combination 2 64.96% -7.06+ \star Combination 3 66.67% 67.15% 62.53% -4.62 * Combination 4 66.18% 66.42% 61.80% -4.62 * Combination 5 53.04% 59.61% 53.04% -6.57 * Combination 6 36.01% 36.50% 37.71% +1.21** Combination 7 52.80% 59.37% 52.55% -6.82+ \star Combination 8 36.01% 36.50% 37.71% +1.21** ** 30.17% 34.55% 31.39% -3.16 Combination 9 Combination 10 30.17% 34.55% 31.39% -3.16 ** Well-Child Visits in the First 30 Months of Life Well-Child Visits in the First 15 Months—Six or More 64.39% NC NC Well-Child Visits⁴ Well-Child Visits for Age 15 Months to 30 Months—Two 66.84% NC NC ____ or More Well-Child Visits⁵ Lead Screening in Children Lead Screening in Children 76.16% 74.94% 71.53% -3.41 ** Child and Adolescent Well-Care Visits⁴ Ages 3 to 11 Years 50.56% NC NC ____ ____ Ages 12 to 17 Years 40.79% NC NC Ages 18 to 21 Years 27.43% NC NC _ ____ Total 43.71% NC NC Immunizations for Adolescents Combination 1 82.24% 80.05% 82.00% +1.95** (Meningococcal, Tdap) Combination 2 ** 39.42% 34.06% -5.36 (Meningococcal, Tdap, HPV) Follow-Up Care for Children Prescribed ADHD Medication³ Initiation Phase 44.44% 45.45% 48.33% +2.88**** Continuation and 58.26% 68.62% 55.26% $+10.36^{+}$ ***** Maintenance Phase

Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Women—Adult Care					
Chlamydia Screening in Wom	en				
Ages 16 to 20 Years	65.45%	65.99%	58.99%	-7.00++	***
Ages 21 to 24 Years	69.62%	69.35%	64.86%	-4.49++	**
Total	67.58%	67.67%	61.98%	-5.69**	***
Cervical Cancer Screening ³					
Cervical Cancer Screening	69.10%	69.10%	60.73%	-8.37**	**
Breast Cancer Screening ³					
Breast Cancer Screening	58.63%	59.22%	55.48%	-3.74++	**
Access to Care	-				
Adults' Access to Preventive/A	nbulatory Hea	lth Services			
Ages 20 to 44 Years	75.71%	77.99%	74.84%	-3.15**	**
Ages 45 to 64 Years	83.78%	84.70%	82.29%	-2.41++	*
65 Years and Older	84.21%	82.23%	71.52%	-10.71 ⁺⁺	*
Total	78.84%	80.57%	77.48%	-3.09++	**
Avoidance of Antibiotic Treatment	nent for Acute	Bronchitis/B	ronchiolitis⁴		
Ages 3 Months to 17 Years	_	61.98%	62.81%	+0.83	***
Ages 18 to 64 Years	_	36.29%	38.45%	+2.16	***
Ages 65 Years And Older	—	NA	NA	NC	NC
Total	_	47.17%	49.46%	$+2.29^{+}$	**
Appropriate Testing for Phary	ngitis ³	-			
Ages 3 to 17 Years	_	76.04%	75.69%	-0.35	*
Ages 18 to 64 Years	_	55.99%	54.39%	-1.60	*
Ages 65 Years And Older	_	NA	NA	NC	NC
Total	_	67.07%	65.57%	-1.50++	*
Appropriate Treatment for Upp	per Respiratory	v Infection ⁴			
Ages 3 Months to 17 Years	—	91.40%	91.91%	+0.51	***
Ages 18 to 64 Years		73.71%	76.51%	$+2.80^{+}$	***
Ages 65 Years And Older		NA	NA	NC	NC
Total	_	85.65%	86.34%	$+0.69^{+}$	**
Obesity					
Weight Assessment and Couns	eling for Nutr	ition and Phy	sical Activity f	or Children/Ado	lescents
Body Mass index (BMI) Percentile—Total ³	86.62%	87.21%	78.14%	-9.07**	**
Counseling for Nutrition— Total	78.35%	80.00%	64.87%	-15.13**	**

APPENDIX B. TREND TABLES

2021 HEDIS Aggregate Report for Michigan Medicaid State of Michigan



Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Counseling for Physical Activity—Total	76.16%	79.02%	63.80%	-15.22**	**
regnancy Care					
renatal and Postpartum Care	3				
Timeliness of Prenatal Care	—	78.83%	78.91%	+0.08	*
Postpartum Care	_	71.78%	71.09%	-0.69	*
iving With Illness					
Comprehensive Diabetes Care					
Hemoglobin A1c (HbA1c) Testing ³	85.16%	88.32%	80.29%	-8.03++	*
HbA1c Poor Control (>9.0%)* ³	44.77%	42.34%	41.61%	-0.73	**
<i>HbA1c Control</i> (<8.0%) ³	43.80%	48.18%	49.15%	+0.97	**
Eye Exam (Retinal) Performed ³	57.42%	59.85%	58.64%	-1.21	***
Blood Pressure Control (<140/90 mm Hg) ⁴	_		56.93%	NC	NC
idney Health Evaluation for I	Patients With I	Diabetes ⁵			
Ages 18 to 64 Years	_		26.81%	NC	NC
Ages 65 to 74 Years	_	_	32.71%	NC	NC
Ages 75 to 85 Years	_		2.78%	NC	NC
Total	_		26.78%	NC	NC
sthma Medication Ratio					
Total	64.02%	57.31%	50.13%	-7.18++	*
ontrolling High Blood Pressu	ire ⁴				
Controlling High Blood Pressure		_	54.99%	NC	NC
ledical Assistance With Smok	ing and Toba	cco Use Cessat	tion		
Advising Smokers and Tobacco Users to Quit	82.89%	85.23%	79.29%	-5.94	***
Discussing Cessation Medications	60.35%	65.14%	54.31%	-10.83**	***
Discussing Cessation Strategies	51.54%	56.07%	49.74%	-6.33	***
ntidepressant Medication Ma	nagement				
55.52%	62.04%	62.35%	+0.31	****	55.52%
55.5270					

Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Diabetes Screening for People V	Vith Schizoph	renia or Bipa	olar Disorder)	Who Are Using A	ntipsychotic
Medications Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications	86.23%	85.24%	80.17%	-5.07**	**
Diabetes Monitoring for People	With Diabete	s and Schizop	ohrenia		
Diabetes Monitoring for People With Diabetes and Schizophrenia	60.80%	72.16%	66.67%	-5.49	*
Cardiovascular Monitoring for	People With	Cardiovascula	ır Disease and	Schizophrenia	
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia	NA	NA	NA	NC	NC
Adherence to Antipsychotic Me	lications for 1	Individuals W	ith Schizophi	enia	
Adherence to Antipsychotic Medications for Individuals With Schizophrenia	55.33%	56.98%	58.66%	+1.68	**
Health Plan Diversity ⁵					
Race/Ethnicity Diversity of Men	nbership				
Total—White	45.97%	46.23%	46.98%	+0.75	NC
Total—Black or African American	35.95%	35.41%	34.60%	-0.81	NC
Total—American–Indian and Alaska Native	0.67%	0.75%	1.01%	+0.26	NC
Total—Asian	1.64%	2.01%	1.77%	-0.24	NC
Total—Native Hawaiian and Other Pacific Islander	2.85%	3.22%	3.26%	+0.04	NC
Total—Some Other Race	0.00%	0.00%	0.00%	0.00	NC
Total—Two or More Races	0.03%	0.04%	0.04%	0.00	NC
Total—Unknown ³	12.88%	12.34%	12.35%	+0.01	NC
Total—Declined ³	0.00%	0.00%	0.00%	0.00	NC
Total—Hispanic or Latino ³	3.16%	3.32%	3.11%	-0.21	NC
Language Diversity of Members	hip				
Spoken Language Preferred for Health Care—English	98.40%	98.35%	98.39%	+0.04	NC



Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²	Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2 Perfor Lev
en Language Preferred Iealth Care—Non-	1.59%	1.65%	1.61%	-0.04	NC	Average Length of Stay— Maternity—Total All Ages	2.63	2.58	2.41	-0.17	N
Language Preferred lth Care—Unknown	0.01%	0.00%	0.01%	+0.01	NC	Discharges per 1,000 Member Months—Surgery— Total All Ages	1.52	1.65	1.20	-0.45	١
ken Language Preferred Health Care—Declined	0.00%	0.00%	0.00%	0.00	NC	Average Length of Stay— Surgery—Total All Ages	5.94	6.57	7.67	+1.10	ſ
nguage Preferred for itten Materials—English	98.39%	98.32%	98.38%	+0.06	NC	Discharges per 1,000 Member Months—Medicine—	3.66	3.48	3.03	-0.45	
anguage Preferred for ′ritten Materials—Non- nglish	1.60%	1.68%	1.62%	-0.06	NC	Total All Ages Average Length of Stay— Medicine—Total All Ages	3.96	3.83	4.38	+0.55	
Language Preferred for	0.01%	0.00%	0.01%	+0.01	NC	Use of Opioids From Multiple	Providers* ³				
Written Materials—Unknown	0.0170	0.0070	0.0170	0.01	inc.	Multiple Prescribers	18.34%	16.58%	14.62%	-1.96+	*
Language Preferred for Written Materials—Declined	0.00%	0.00%	0.00%	0.00	NC	Multiple Pharmacies	8.45%	4.51%	3.00%	-1.51+	*
Other Language Needs— English	98.78%	98.75%	98.80%	+0.05	NC	Multiple Prescribers and Multiple Pharmacies	4.08%	2.57%	1.84%	-0.73+	*
Other Language Needs—						Use of Opioids at High Dosage	*3				
Non-English	1.20%	1.24%	1.19%	-0.05	NC	Use of Opioids at High Dosage*	_	2.23%	1.69%	-0.54+	*
Other Language Needs— Unknown	0.01%	0.01%	0.01%	0.00	NC	Risk of Continued Opioid Use*	,3				
Other Language Needs— Declined	0.00%	0.00%	0.00%	0.00	NC	At Least 15 Days Covered— Total	16.69%	13.52%	8.40%	-5.12+	7
Utilization ⁶	l		l			At Least 31 Days Covered—	7.21%	6.42%	5.69%	-0.73 ⁺	
Ambulatory Care—Total (Per 1	,000 Member	Months)				Total Plan All-Cause Readmissions	,				
Emergency Department Visits—Total*	62.97	62.86	44.38	-18.48	****	Observed Readmissions— Total*		10.60%	11.00%	+0.40	
Outpatient Visits—Total	388.15	393.07	334.57	-58.50	NC	Expected Readmissions—					
npatient Utilization—General	Hospital/Acu	te Care—Toto	ıl			Total*	—	9.80%	10.23%	+0.43	
Discharges per 1,000 Member Months—Total	7.24	7.23	6.18	-1.05	NC	O/E Ratio—Total*	—	1.08	1.08	0.00	
Inpatient—Total All Ages Average Length of Stay— Total Inpatient—Total All Ages	4.00	4.09	4.40	+0.31	NC	¹ HEDIS MY 2019 to HEDIS MY significance with a p value of < indicate significant improvemen crosses (++) indicate a signific ² HEDIS MY 2020 Performance	0.05. MY 2019 t from the pre ant decline in j	–MY 2020 Co vious year. 20 performance f	omparisons sha 19–2020 Com From the previo	aded green with o parisons shaded i pus year.	ne cross red with
Discharges per 1,000 Member Months— Maternity—Total All Ages	2.68	2.73	2.53	-0.20	NC	⁻ HEDIS MY 2020 Performance indicator rates to national Media the Plan All-Cause Readmission NCQA Audit Means and Percent	caid Quality C is measure ind	Compass HED icator rates, w	IS MY 2019 be which were con	enchmarks, with t	he excep

APPENDIX B. TREND TABLES



³Due to changes in the technical specifications for this measure, NCQA recommends trending between MY 2020 and prior years be considered with caution.

⁴Due to changes in the technical specifications for this measure, NCQA recommends a break in trending between MY 2020 and prior years; therefore, prior years' rates are not displayed and comparisons to benchmarks are not performed for this measure.

⁵This measure is a first-year measure; therefore, the prior year's rates cannot be displayed and comparisons to benchmarks cannot be performed for this measure as benchmarks are not yet available. ⁶Significance testing was not performed for utilization-based or health plan description measure indicator rates and any Performance Levels for MY 2020 or MY 2019–MY 2020 Comparisons provided for these measures are for information purposes only.

* For this indicator, a lower rate indicates better performance.

— indicates that the rate is not presented in this report as the measure is a first-year measure; therefore, no trending information is available. This symbol may also indicate that NCQA recommended a break in trending; therefore, no prior year rates are displayed.

NC indicates that a comparison is not appropriate, or the measure did not have an applicable benchmark. NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

HEDIS MY 2020 Performance Levels represent the following percentile comparisons:

 $\star \star \star \star \star = 90$ th percentile and above

 $\star \star \star \star = 75$ th to 89th percentile

- $\star \star \star = 50$ th to 74th percentile
- $\star \star = 25$ th to 49th percentile
- \star = Below 25th percentile



Table B-3—HAP Trend Table

Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Child & Adolescent Care					
Childhood Immunization Star	tus				
Combination 2	55.32%	70.21%	49.54%	-20.67**	*
Combination 3	55.32%	68.09%	44.95%	-23.14++	*
Combination 4	53.19%	68.09%	44.95%	-23.14++	*
Combination 5	38.30%	55.32%	37.61%	-17.71**	*
Combination 6	27.66%	25.53%	23.85%	-1.68	*
Combination 7	38.30%	55.32%	37.61%	-17.71**	*
Combination 8	27.66%	25.53%	23.85%	-1.68	*
Combination 9	17.02%	21.28%	20.18%	-1.10	*
Combination 10	17.02%	21.28%	20.18%	-1.10	*
Well-Child Visits in the First .	30 Months of	Life			
Well-Child Visits in the First 15 Months—Six or More Well-Child Visits⁴	_	_	51.22%	NC	NC
Well-Child Visits for Age 15 Months to 30 Months—Two or More Well-Child Visits ⁵	_	_	55.36%	NC	NC
Lead Screening in Children					
Lead Screening in Children	63.83%	80.85%	62.39%	-18.46++	*
Child and Adolescent Well-Ca	re Visits ^₄				
Ages 3 to 11 Years		_	34.54%	NC	NC
Ages 12 to 17 Years		_	20.66%	NC	NC
Ages 18 to 21 Years	_	_	18.28%	NC	NC
Total	_		27.93%	NC	NC
Immunizations for Adolescent	ts				
Combination 1 (Meningococcal, Tdap)	NA	NA	70.73%	NC	*
Combination 2 (Meningococcal, Tdap, HPV)	_	NA	21.95%	NC	*
Follow-Up Care for Children	Prescribed Al	DHD Medicati	on ³		
Initiation Phase	NA	NA	NA	NC	NC
Continuation and Maintenance Phase	NA	NA	NA	NC	NC

Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Women—Adult Care					
Chlamydia Screening in Wom	en				
Ages 16 to 20 Years	NA	61.29%	51.98%	-9.31	**
Ages 21 to 24 Years	45.95%	57.63%	59.75%	+2.12	**
Total	39.34%	58.89%	56.42%	-2.47	**
Cervical Cancer Screening ³					
Cervical Cancer Screening	56.34%	56.34%	40.00%	-16.34++	*
Breast Cancer Screening ³					
Breast Cancer Screening	57.25%	55.94%	57.02%	+1.08	**
Access to Care					
Adults' Access to Preventive/A	mbulatory H	ealth Services			
Ages 20 to 44 Years	71.98%	70.22%	57.06%	-13.16++	*
Ages 45 to 64 Years	88.33%	88.65%	74.49%	-14.16++	*
65 Years and Older	88.19%	89.20%	88.16%	-1.04	**
Total	83.99%	83.10%	68.81%	-14.29++	*
Avoidance of Antibiotic Treat	ment for Acut	te Bronchitis/	Bronchiolitis		
Ages 3 Months to 17 Years		NA	75.93%	NC	****
Ages 18 to 64 Years	_	33.65%	40.52%	+6.87	***
Ages 65 Years And Older	_	32.69%	29.55%	-3.14	**
Total	_	37.84%	47.20%	+9.36	**
Appropriate Testing for Phary	vngitis ³				
Ages 3 to 17 Years		83.33%	65.98%	-17.35++	*
Ages 18 to 64 Years	_	50.00%	47.10%	-2.90	*
Ages 65 Years And Older		NA	NA	NC	NC
Total		59.31%	52.76%	-6.55	*
Appropriate Treatment for Up	per Respirato		-	· · · · ·	
Ages 3 Months to 17 Years		89.68%	91.72%	+2.04	***
Ages 18 to 64 Years	_	70.80%	79.94%	$+9.14^{+}$	***
Ages 65 Years And Older	_	57.65%	73.75%	$+16.10^{+}$	***
Total	_	74.68%	84.31%	+9.63+	*
Obesity					
Weight Assessment and Coun	seling for Nu	trition and Ph	ysical Activity	for Children/Ad	olescents
Body Mass index (BMI) Percentile—Total ³	86.98%	86.98%	80.67%	-6.31	***
Counseling for Nutrition— Total	63.31%	63.31%	69.85%	+6.54	**

2021 HEDIS Aggregate Report for Michigan Medicaid State of Michigan





	HEDIS MY	HEDIS MY	HEDIS MY	MY 2019– MY 2020	MY 2020 Performance
Measure	2018	2019	2020	Comparison ¹	Level ²
Counseling for Physical Activity—Total	62.13%	62.13%	67.27%	+5.14	***
Pregnancy Care					
Prenatal and Postpartum Car	e ⁴				
Timeliness of Prenatal Care		90.12%	68.30%	-21.82 ⁺⁺	*
Postpartum Care	_	67.90%	52.68%	-15.22++	*
Living With Illness					
Comprehensive Diabetes Care	2				
Hemoglobin A1c (HbA1c) Testing ³	83.70%	88.32%	84.18%	-4.14	*
HbA1c Poor Control (>9.0%)* ³	40.15%	44.04%	46.96%	+2.92	*
<i>HbA1c Control (</i> <8.0%) ³	49.88%	49.88%	46.47%	-3.41	**
Eye Exam (Retinal) Performed ³	58.88%	56.93%	44.77%	-12.16++	*
Blood Pressure Control (<140/90 mm Hg)⁴	_	_	53.28%	NC	NC
Kidney Health Evaluation for	Patients With	n Diabetes ⁵			
Ages 18 to 64 Years	_	_	30.86%	NC	NC
Ages 65 to 74 Years	_	_	34.23%	NC	NC
Ages 75 to 85 Years	_	_	30.61%	NC	NC
Total	_	_	31.83%	NC	NC
Asthma Medication Ratio					
Total	37.68%	55.93%	46.27%	-9.66	*
Controlling High Blood Press	sure⁴	-			
Controlling High Blood Pressure	_	_	52.55%	NC	NC
Medical Assistance With Smo	king and Tob	acco Use Cess	ation		
Advising Smokers and Tobacco Users to Quit	83.23%	81.03%	76.13%	-4.90	**
Discussing Cessation Medications	65.69%	67.32%	59.35%	-7.97	***
Discussing Cessation Strategies	54.22%	55.47%	53.80%	-1.67	***
Antidepressant Medication M	anagement				
Effective Acute Phase Treatment	53.49%	53.00%	70.59%	+17.59+	****

Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Effective Continuation Phase Treatment	41.09%	42.00%	47.06%	+5.06	****
Diabetes Screening for People Medications	With Schizo	phrenia or Bij	oolar Disordei	• Who Are Using	Antipsychotic
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications	68.80%	73.36%	71.52%	-1.84	*
Diabetes Monitoring for Peop	le With Diabe	rtes and Schize	ophrenia		
Diabetes Monitoring for People With Diabetes and Schizophrenia	61.54%	64.58%	66.67%	+2.09	*
Cardiovascular Monitoring fo	or People With	h Cardiovascu	lar Disease an	d Schizophrenia	ı
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia	NA	NA	NA	NC	NC
Adherence to Antipsychotic M	edications for	r Individuals	With Schizopi	hrenia	
Adherence to Antipsychotic Medications for Individuals With Schizophrenia	69.31%	72.00%	65.04%	-6.96	***
Health Plan Diversity ⁵					
Race/Ethnicity Diversity of M	embership				
Total—White	56.78%	0.24%	39.22%	+38.98	NC
Total—Black or African American	23.97%	0.28%	46.62%	+46.34	NC
Total—American–Indian and Alaska Native	0.00%	0.00%	0.15%	+0.15	NC
Total—Asian	0.02%	0.03%	1.74%	+1.71	NC
Total—Native Hawaiian and Other Pacific Islander	0.02%	0.00%	0.04%	+0.04	NC
Total—Some Other Race	3.38%	0.02%	3.98%	+3.96	NC
Total—Two or More Races	0.00%	0.00%	0.00%	0.00	NC
Total—Unknown ³	15.83%	99.43%	8.24%	-91.19	NC
Total—Declined ³	0.00%	0.00%	0.00%	0.00	NC
Total—Hispanic or Latino ³	3.38%	0.01%	3.72%	+3.71	NC



	HEDIS MY	HEDIS MY	HEDIS MY	MY 2019– MY 2020	MY 2020 Performance
Measure	2018	2019	2020	Comparison ¹	Level ²
Language Diversity of Membe Spoken Language Preferred	rsnip				
for Health Care—English	97.26%	0.79%	90.36%	+89.57	NC
Spoken Language Preferred for Health Care—Non- English	0.18%	0.01%	0.74%	+0.73	NC
Spoken Language Preferred for Health Care—Unknown	2.55%	99.20%	8.91%	-90.29	NC
Spoken Language Preferred for Health Care—Declined	0.00%	0.00%	0.00%	0.00	NC
Language Preferred for Written Materials—English	97.26%	0.79%	90.36%	+89.57	NC
Language Preferred for Written Materials—Non- English	0.18%	0.01%	0.74%	+0.73	NC
Language Preferred for Written Materials— Unknown	2.55%	99.20%	8.91%	-90.29	NC
Language Preferred for Written Materials— Declined	0.00%	0.00%	0.00%	0.00	NC
Other Language Needs— English	97.26%	0.79%	90.36%	+89.57	NC
Other Language Needs— Non-English	0.18%	0.01%	0.74%	+0.73	NC
Other Language Needs— Unknown	2.55%	99.20%	8.91%	-90.29	NC
Other Language Needs— Declined	0.00%	0.00%	0.00%	0.00	NC
Utilization ⁶					
Ambulatory Care—Total (Per	1,000 Membe	er Months)			
Emergency Department Visits—Total*	66.17	66.59	50.14	-16.45	***
Outpatient Visits—Total	524.20	496.25	329.12	-167.13	NC
Inpatient Utilization—Genera	ıl Hospital/Ac	cute Care—To	tal		
Discharges per 1,000 Member Months—Total Inpatient—Total All Ages	12.01	13.93	10.20	-3.73	NC

Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Average Length of Stay— Total Inpatient—Total All Ages	5.15	5.97	5.95	-0.02	NC
Discharges per 1,000 Member Months— Maternity—Total All Ages	1.35	1.68	1.85	+0.17	NC
Average Length of Stay— Maternity—Total All Ages	2.54	2.79	2.57	-0.22	NC
Discharges per 1,000 Member Months— Surgery—Total All Ages	3.18	4.10	2.44	-1.66	NC
Average Length of Stay— Surgery—Total All Ages	7.45	9.24	9.44	+0.20	NC
Discharges per 1,000 Member Months— Medicine—Total All Ages	8.02	8.79	6.42	-2.37	NC
Average Length of Stay— Medicine—Total All Ages	4.51	4.82	5.33	+0.51	NC
Use of Opioids From Multiple	e Providers*3				
Multiple Prescribers	15.29%	15.83%	12.95%	-2.88	****
Multiple Pharmacies	3.51%	2.33%	3.34%	+1.01	***
Multiple Prescribers and Multiple Pharmacies	2.18%	1.23%	1.63%	+0.40	****
Use of Opioids at High Dosag	e* ^{,3}				
Use of Opioids at High Dosage*		2.84%	2.16%	-0.68	****
Risk of Continued Opioid Use	,*, ³				
At Least 15 Days Covered— Total	28.28%	13.47%	14.45%	+0.98	*
At Least 31 Days Covered— Total	11.52%	7.92%	9.91%	+1.99	*
Plan All-Cause Readmissions					
Observed Readmissions— Total*	_	NA	13.38%	NC	*
Expected Readmissions— Total*	_	NA	9.81%	NC	**
O/E Ratio—Total*		NA	1.36	NC	*

APPENDIX B. TREND TABLES



¹HEDIS MY 2019 to HEDIS MY 2020 comparisons were based on a Chi-square test of statistical significance with a p value of < 0.05. MY 2019–MY 2020 Comparisons shaded green with one cross (+) indicate significant improvement from the previous year. MY 2019–MY 2020 Comparisons shaded red with two crosses (++) indicate a significant decline in performance from the previous year.

²HEDIS MY 2020 Performance Levels were based on comparisons of the HEDIS MY 2020 measure indicator rates to national Medicaid Quality Compass HEDIS MY 2019 benchmarks, with the exception of the Plan All-Cause Readmissions measure indicator rates, which were compared to the national Medicaid NCQA Audit Means and Percentiles HEDIS MY 2019 benchmark.

³Due to changes in the technical specifications for this measure, NCQA recommends trending between MY 2020 and prior years be considered with caution.

⁴Due to changes in the technical specifications for this measure, NCQA recommends a break in trending between MY 2020 and prior years; therefore, prior years' rates are not displayed and comparisons to benchmarks are not performed for this measure.

⁵This measure is a first-year measure; therefore, the prior year's rates cannot be displayed and comparisons to benchmarks cannot be performed for this measure as benchmarks are not yet available. ⁶Significance testing was not performed for utilization-based or health plan description measure indicator rates and any Performance Levels for MY 2020 or MY 2019–MY 2020 Comparisons provided for these measures are for information purposes only.

* For this indicator, a lower rate indicates better performance.

— indicates that the rate is not presented in this report as the measure is a first-year measure; therefore, no trending information is available. This symbol may also indicate that NCQA recommended a break in trending; therefore, no prior year rates are displayed.

NC indicates that a comparison is not appropriate, or the measure did not have an applicable benchmark. NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

HEDIS MY 2020 Performance Levels represent the following percentile comparisons:

 $\star \star \star \star = 90$ th percentile and above

 $\star \star \star \star = 75$ th to 89th percentile

- $\star \star \star = 50$ th to 74th percentile
- $\star \star = 25$ th to 49th percentile
- \star = Below 25th percentile



Table B-4—MCL Trend Table

Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Child & Adolescent Care					
Childhood Immunization S	tatus				
Combination 2	70.56%	70.56%	65.94%	-4.62	*
Combination 3	63.99%	63.99%	63.26%	-0.73	*
Combination 4	62.77%	62.77%	61.56%	-1.21	*
Combination 5	53.77%	53.77%	52.55%	-1.22	*
Combination 6	33.09%	33.09%	37.23%	+4.14	**
Combination 7	52.80%	52.80%	51.34%	-1.46	*
Combination 8	32.85%	32.85%	36.74%	+3.89	**
Combination 9	27.98%	27.98%	31.87%	+3.89	**
Combination 10	27.74%	27.74%	31.39%	+3.65	**
Well-Child Visits in the Fir.	st 30 Months o	f Life		-	
Well-Child Visits in the First 15 Months—Six or More Well-Child Visits⁴	_	_	61.22%	NC	NC
Well-Child Visits for Age 15 Months to 30 Months—Two or More Well-Child Visits ⁵	_	_	67.44%	NC	NC
Lead Screening in Children	1				
Lead Screening in Children	82.73%	82.73%	74.21%	-8.52++	***
Child and Adolescent Well-	Care Visits⁴				
Ages 3 to 11 Years	_		48.09%	NC	NC
Ages 12 to 17 Years	_		37.63%	NC	NC
Ages 18 to 21 Years			21.68%	NC	NC
Total			40.50%	NC	NC
Immunizations for Adolesce	ents				
Combination 1 (Meningococcal, Tdap)	83.45%	86.37%	81.75%	-4.62	**
Combination 2 (Meningococcal, Tdap, HPV)	_	34.55%	30.90%	-3.65	*
Follow-Up Care for Childre	en Prescribed A	DHD Medicat	tion ³	•	
Initiation Phase	50.35%	47.72%	49.12%	+1.40	****

Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Continuation and Maintenance Phase	61.34%	57.74%	59.30%	+1.56	***
Women—Adult Care				• •	
Chlamydia Screening in Wo	men				
Ages 16 to 20 Years	54.65%	56.13%	53.49%	-2.64++	**
Ages 21 to 24 Years	65.24%	66.14%	61.32%	-4.82++	**
Total	59.23%	60.58%	57.22%	-3.36++	**
Cervical Cancer Screening ³					
Cervical Cancer Screening	65.21%	65.21%	59.85%	-5.36	**
Breast Cancer Screening ³					
Breast Cancer Screening	61.99%	60.82%	56.20%	-4.62 ⁺⁺	**
Access to Care					
Adults' Access to Preventive	Ambulatory A	Tealth Services	5		
Ages 20 to 44 Years	77.87%	78.10%	73.17%	-4.93 ⁺⁺	**
Ages 45 to 64 Years	86.81%	86.53%	83.28%	-3.25++	**
65 Years and Older	83.33%	86.07%	72.67%	-13.40++	*
Total	81.45%	81.33%	76.67%	-4.66++	*
Avoidance of Antibiotic Tre	atment for Acu	te Bronchitis/	Bronchiolitis		
Ages 3 Months to 17 Years	_	58.97%	61.39%	+2.42	***
Ages 18 to 64 Years		38.43%	39.96%	+1.53	***
Ages 65 Years And Older		NA	NA	NC	NC
Total	_	47.71%	50.05%	+2.34+	**
Appropriate Testing for Pha	ryngitis ³				
Ages 3 to 17 Years		82.55%	81.62%	-0.93	**
Ages 18 to 64 Years		69.16%	67.58%	-1.58	***
Ages 65 Years And Older		NA	NA	NC	NC
Total		77.73%	76.36%	-1.37**	**
Appropriate Treatment for U	Upper Respirat	ory Infection			
Ages 3 Months to 17 Years	_	90.12%	90.52%	+0.40	**
Ages 18 to 64 Years		77.09%	79.90%	$+2.81^{+}$	***
Ages 65 Years And Older		NA	NA	NC	NC
Total		85.77%	86.88%	+1.11+	**



ObesityImage: Constraint of the second s	xvel² 5 ★ ★ ★
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/AdolescentsBody Mass index (BMI) Percentile—Total³79.32%79.32%65.21%-14.11**9Counseling for Nutrition—Total66.67%66.67%53.53%-13.14**9Counseling for Physical Activity—Total63.26%63.26%53.77%-9.49**9Pregnancy Care9Prenatal and Postpartum Care³88.32%78.59%-9.73**9Postpartum Care74.45%70.32%4.139Living With Illness9	*
Body Mass index (BMI) Percentile—Total ³ 79.32% 79.32% 65.21% -14.11 ⁺⁺ Counseling for Nutrition—Total 66.67% 63.53% -13.14 ⁺⁺ 9 Counseling for Physical Activity—Total 63.26% 63.26% 53.77% -9.49 ⁺⁺ 9 Pregnancy Care	*
Percentile—Total ³ 79.32% 79.32% 65.21% -14.11" 9 Counseling for Nutrition—Total 66.67% 66.67% 53.53% -13.14" 9 Counseling for Physical Activity—Total 63.26% 63.26% 53.77% -9.49" 9 Pregnancy Care	*
Nutrition—Total 66.67% 66.67% 53.53% -13.14** 9 Counseling for Physical Activity—Total 63.26% 63.26% 53.77% -9.49** 9 Pregnancy Care Prenatal and Postpartum Care ³ 5 5 7 9 9 Timeliness of Prenatal Care — 88.32% 78.59% -9.73** 9 Postpartum Care — 74.45% 70.32% -4.13 9 Living With Illness — 74.45% 70.32% -4.13 9	
Activity—Total 63.26% 63.26% 53.71% -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.49 -9.43 -9.49 -9.41	<u>ـ</u>
Prenatal and Postpartum Care ³ Timeliness of Prenatal Care 88.32% 78.59% -9.73 ⁺⁺ 9 Postpartum Care 74.45% 70.32% -4.13 9 Living With Illness 9 9 9 9	*
Timeliness of Prenatal Care — 88.32% 78.59% -9.73 ⁺⁺ • Postpartum Care — 74.45% 70.32% -4.13 • Living With Illness — 74.45% 70.32% -4.13 •	
Care 88.32% 78.39% -9.73 9 Postpartum Care 74.45% 70.32% 4.13 9 Living With Illness 74.45% 70.32% 4.13 9	
Living With Illness	*
0	*
Comprehensive Diabetes Care	
Comprenensive Diabetes Care	
Hemoglobin A1c (HbA1c) 87.83% 87.83% 77.86% -9.97 ⁺⁺	*
HbA1c Poor Control 42.58% 42.58% 56.45% +13.87 ⁺⁺	*
	*
<i>Eye Exam (Retinal)</i> <i>Performed</i> ³ 58.64% 58.64% 54.74% -3.90 ★	r x
Blood Pressure Control $(<140/90 mm Hg)^4$ —50.85%NCN	NC
Kidney Health Evaluation for Patients With Diabetes ⁵	
Ages 18 to 64 Years — 26.56% NC N	NC
Ages 65 to 74 Years — — 27.87% NC N	NC
Ages 75 to 85 Years — — NA NC N	NC
<i>Total</i> — — 26.57% NC N	NC
Asthma Medication Ratio	
Total 66.58% 57.20% 53.48% -3.72 ⁺⁺	*
Controlling High Blood Pressure ⁴	
Controlling High Blood 47.20% NC N	
Medical Assistance With Smoking and Tobacco Use Cessation	NC
Advising Smokers and Tobacco Users to Quit 79.45% 79.01% 72.51% -6.50	NC

Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²		
Discussing Cessation Medications	58.23%	56.67%	51.79%	-4.88	**		
Discussing Cessation Strategies	45.20%	50.28%	47.31%	-2.97	**		
Antidepressant Medication	Management						
Effective Acute Phase Treatment	56.77%	63.61%	63.95%	+0.34	****		
Effective Continuation Phase Treatment	40.88%	49.09%	48.85%	-0.24	****		
Diabetes Screening for Peop Medications	Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications						
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications	79.10%	83.12%	74.61%	-8.51**	*		
Diabetes Monitoring for Pe	ople With Diab	etes and Schiz	zophrenia				
Diabetes Monitoring for People With Diabetes and Schizophrenia	73.23%	67.20%	60.37%	-6.83	*		
Cardiovascular Monitoring	for People Wit	h Cardiovasci	ular Disease an	d Schizophrenia			
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia	82.22%	70.59%	51.11%	-19.48	*		
Adherence to Antipsychotic	Medications fo	or Individuals	With Schizoph	renia			
Adherence to Antipsychotic Medications for Individuals With Schizophrenia	66.40%	69.10%	71.26%	+2.16	****		
Health Plan Diversity ⁵							
Race/Ethnicity Diversity of	Membership						
Total—White	64.93%	63.10%	64.38%	+1.28	NC		
Total—Black or African American	19.55%	20.19%	20.63%	+0.44	NC		
Total—American–Indian and Alaska Native	0.51%	0.52%	0.55%	+0.03	NC		





Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Total—Asian	0.63%	1.45%	0.80%	-0.65	NC
Total—Native Hawaiian and Other Pacific Islander	0.07%	0.08%	0.09%	+0.01	NC
Total—Some Other Race	5.59%	5.82%	6.06%	+0.24	NC
Total—Two or More Races	0.00%	0.00%	0.00%	0.00	NC
Total—Unknown ³	8.72%	8.84%	7.48%	-1.36	NC
Total—Declined ³	0.00%	0.00%	0.00%	0.00	NC
Total—Hispanic or Latino ³	5.59%	5.82%	6.06%	+0.24	NC
Language Diversity of Mem	bership				
Spoken Language Preferred for Health Care—English	76.22%	60.94%	52.87%	-8.07	NC
Spoken Language Preferred for Health Care—Non-English	0.60%	0.46%	0.40%	-0.06	NC
Spoken Language Preferred for Health Care—Unknown	23.18%	38.60%	46.73%	+8.13	NC
Spoken Language Preferred for Health Care—Declined	0.00%	0.00%	0.00%	0.00	NC
Language Preferred for Written Materials— English	0.00%	0.00%	0.00%	0.00	NC
Language Preferred for Written Materials—Non- English	0.00%	0.00%	0.00%	0.00	NC
Language Preferred for Written Materials— Unknown	100.00%	100.00%	100.00%	0.00	NC
Language Preferred for Written Materials— Declined	0.00%	0.00%	0.00%	0.00	NC
Other Language Needs— English	0.00%	0.00%	0.00%	0.00	NC
Other Language Needs— Non-English	0.00%	0.00%	0.00%	0.00	NC

Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Other Language Needs— Unknown	100.00%	100.00%	100.00%	0.00	NC
Other Language Needs— Declined	0.00%	0.00%	0.00%	0.00	NC
Utilization ⁶					
Ambulatory Care—Total (P	er 1,000 Memb	er Months)			
ED Visits—Total*	65.51	70.40	51.72	-18.68	***
Outpatient Visits—Total	577.22	552.68	447.82	-104.86	NC
Inpatient Utilization—Gene	eral Hospital/A	cute Care—T	otal		
Total Inpatient— Discharges per 1,000 Member Months—Total	7.80	9.14	8.31	-0.83	NC
Total Inpatient—Average Length of Stay—Total	3.38	3.87	3.87	0.00	NC
Maternity—Discharges per 1,000 Member Months—Total	2.57	2.77	2.61	-0.16	NC
Maternity—Average Length of Stay—Total	2.01	1.77	1.69	-0.08	NC
Surgery—Discharges per 1,000 Member Months— Total	1.99	2.24	2.07	-0.17	NC
Surgery—Average Length of Stay—Total	5.15	5.81	6.00	+0.19	NC
Medicine—Discharges per 1,000 Member Months—Total	3.91	4.82	4.28	-0.54	NC
Medicine—Average Length of Stay—Total	3.14	3.86	3.86	0.00	NC
Use of Opioids From Multip	ole Providers* ³				
Multiple Prescribers	21.41%	14.91%	14.77%	-0.14	****
Multiple Pharmacies	7.02%	3.48%	2.60%	-0.88+	****
Multiple Prescribers and Multiple Pharmacies	3.76%	1.65%	1.21%	-0.44+	****
Use of Opioids at High Dosd	Ige*,3				
Use of Opioids at High Dosage*		2.95%	2.65%	-0.30	****



Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Risk of Continued Opioid U	/se* ^{,3}				
At Least 15 Days Covered—Total	13.49%	19.36%	12.40%	-6.96 ⁺	*
At Least 31 Days Covered—Total	5.97%	11.64%	6.36%	-5.28+	*
Plan All-Cause Readmissio	ns ⁴				
Observed Readmissions— Total*		8.50%	9.63%	+1.13**	***
Expected Readmissions— Total*		9.55%	9.76%	+0.21	**
O/E Ratio—Total*	_	0.89	0.99	+0.10++	***

¹HEDIS MY 2019 to HEDIS MY 2020 comparisons were based on a Chi-square test of statistical significance with a p value of < 0.05. MY 2019–MY 2020 Comparisons shaded green with one cross (+) indicate significant improvement from the previous year. MY 2019–MY 2020 Comparisons shaded red with two crosses (++) indicate a significant decline in performance from the previous year.

²HEDIS MY 2020 Performance Levels were based on comparisons of the HEDIS MY 2020 measure indicator rates to national Medicaid Quality Compass HEDIS MY 2019 benchmarks, with the exception of the Plan All-Cause Readmissions measure indicator rates, which were compared to the national Medicaid NCQA Audit Means and Percentiles HEDIS MY 2019 benchmark.

³Due to changes in the technical specifications for this measure, NCQA recommends trending between MY 2020 and prior years be considered with caution.

⁴Due to changes in the technical specifications for this measure, NCQA recommends a break in trending between MY 2020 and prior years; therefore, prior years' rates are not displayed and comparisons to benchmarks are not performed for this measure.

⁵This measure is a first-year measure; therefore, the prior year's rates cannot be displayed and comparisons to benchmarks cannot be performed for this measure as benchmarks are not yet available. ⁶Significance testing was not performed for utilization-based or health plan description measure indicator rates and any Performance Levels for MY 2020 or MY 2019–MY 2020 Comparisons provided for these measures are for information purposes only.

* For this indicator, a lower rate indicates better performance.

— indicates that the rate is not presented in this report as the measure is a first-year measure; therefore, no trending information is available. This symbol may also indicate that NCQA recommended a break in trending; therefore, no prior year rates are displayed.

NC indicates that a comparison is not appropriate, or the measure did not have an applicable benchmark. NA indicates that the MHP followed the specifications, but the denominator was too small (\leq 30) to report a valid rate HEDIS MY 2020 Performance Levels represent the following percentile comparisons:

 $\star \star \star \star \star = 90$ th percentile and above

 $\star \star \star \star = 75$ th to 89th percentile

 $\star \star \star = 50$ th to 74th percentile

 $\star \star = 25$ th to 49th percentile

 \star = Below 25th percentile



Table B-5—MER Trend Table

				MY 2019–	MY 2020
	HEDIS MY	HEDIS MY	HEDIS MY	MY 2020	Performance
Measure	2018	2019	2020	Comparison ¹	Level ²
Child & Adolescent Care					
Childhood Immunization Stat	1				
Combination 2	72.02%	71.33%	64.72%	-6.61++	*
Combination 3	67.40%	67.60%	62.53%	-5.07**	*
Combination 4	66.91%	66.75%	62.04%	-4.71 ⁺⁺	*
Combination 5	56.93%	58.46%	56.69%	-1.77	**
Combination 6	40.39%	36.53%	35.77%	-0.76	**
Combination 7	56.45%	57.79%	56.20%	-1.59	**
Combination 8	40.39%	36.30%	35.77%	-0.53	**
Combination 9	34.79%	32.54%	32.85%	+0.31	**
Combination 10	34.79%	32.34%	32.85%	+0.51	**
Well-Child Visits in the First 3	80 Months of	^r Life			
Well-Child Visits in the First 15 Months—Six or More Well-Child Visits ⁴	_		63.12%	NC	NC
Well-Child Visits for Age 15 Months to 30 Months—Two or More Well-Child Visits ⁵	_	_	68.93%	NC	NC
Lead Screening in Children					
Lead Screening in Children	78.42%	77.51%	73.87%	-3.64++	***
Child and Adolescent Well-Car	re Visits⁴				
Ages 3 to 11 Years			52.28%	NC	NC
Ages 12 to 17 Years	_	_	42.30%	NC	NC
Ages 18 to 21 Years		_	26.22%	NC	NC
Total			45.63%	NC	NC
Immunizations for Adolescent	s		-		
Combination 1 (Meningococcal, Tdap)	86.37%	84.43%	82.73%	-1.70	***
Combination 2 (Meningococcal, Tdap, HPV)		38.44%	36.50%	-1.94	**
Follow-Up Care for Children	Prescribed A	DHD Medice	ation ³		
Initiation Phase	44.78%	45.12%	44.59%	-0.53	***
Continuation and Maintenance Phase	56.86%	56.80%	55.18%	-1.62	***

Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Women—Adult Care					
Chlamydia Screening in Wom	en				
Ages 16 to 20 Years	63.13%	61.42%	55.53%	-5.89++	***
Ages 21 to 24 Years	69.90%	69.18%	62.83%	-6.35++	**
Total	66.33%	64.92%	58.84%	-6.08++	***
Cervical Cancer Screening ³					
Cervical Cancer Screening	64.59%	67.64%	59.41%	-8.23++	**
Breast Cancer Screening ³					
Breast Cancer Screening	64.00%	63.17%	56.65%	-6.52++	**
Access to Care					
Adults' Access to Preventive/A	mbulatory H	lealth Servic	es		
Ages 20 to 44 Years	80.18%	80.91%	76.20%	-4.71++	**
Ages 45 to 64 Years	88.46%	88.76%	84.67%	-4.09++	**
65 Years and Older	96.22%	95.43%	88.91%	-6.52++	**
Total	83.40%	84.02%	79.18%	-4.84++	**
Avoidance of Antibiotic Treat	ment for Acu	te Bronchiti	s/Bronchioli	tis	
Ages 3 Months to 17 Years		61.92%	60.82%	-1.10	***
Ages 18 to 64 Years	_	37.45%	39.00%	+1.55	***
Ages 65 Years And Older	_	29.27%	31.25%	+1.98	**
Total	_	49.29%	50.08%	+0.79	**
Appropriate Testing for Phary	ngitis ³				
Ages 3 to 17 Years	_	78.99%	77.32%	-1.67**	**
Ages 18 to 64 Years	_	63.96%	60.88%	-3.08++	**
Ages 65 Years And Older	_	NA	NA	NC	NC
Total	_	73.82%	71.39%	-2.43++	**
Appropriate Treatment for Up	per Respirat	ory Infection			
Ages 3 Months to 17 Years	_	91.15%	91.71%	$+0.56^{+}$	***
Ages 18 to 64 Years	_	75.27%	78.27%	$+3.00^{+}$	***
Ages 65 Years And Older	_	75.65%	88.33%	+12.68+	****
Total	_	86.80%	87.84%	$+1.04^{+}$	***
Obesity	-				
Weight Assessment and Coun	seling for Nu	trition and	Physical Acti	vity for Childrer	n/Adolescents
Body Mass index (BMI) Percentile—Total ³	83.70%	83.70%	78.59%	-5.11	**
Counseling for Nutrition— Total	72.99%	72.99%	69.83%	-3.16	**



Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Counseling for Physical Activity—Total	69.59%	69.59%	68.13%	-1.46	***
Pregnancy Care					
Prenatal and Postpartum Care	y ³				
Timeliness of Prenatal Care	_	79.81%	79.08%	-0.73	*
Postpartum Care	_	69.59%	67.88%	-1.71	*
Living With Illness					
Comprehensive Diabetes Care					
Hemoglobin A1c (HbA1c) Testing ³	88.08%	88.08%	85.89%	-2.19	*
HbA1c Poor Control (>9.0%)* ³	40.88%	40.88%	44.04%	+3.16	**
<i>HbA1c Control</i> (<8.0%) ³	49.15%	49.15%	47.45%	-1.70	**
Eye Exam (Retinal) Performed ³	67.61%	67.61%	50.17%	-17.44++	*
Blood Pressure Control (<140/90 mm Hg) ⁴			56.45%	NC	NC
Kidney Health Evaluation for	Patients Wit	h Diabetes ⁵			
Ages 18 to 64 Years	_		31.06%	NC	NC
Ages 65 to 74 Years	_	_	36.07%	NC	NC
Ages 75 to 85 Years	_	_	35.43%	NC	NC
Total	_		31.21%	NC	NC
Asthma Medication Ratio					
Total	62.95%	63.10%	60.15%	-2.95++	**
Controlling High Blood Press	ure⁴				
Controlling High Blood Pressure			51.82%	NC	NC
Medical Assistance With Smo	king and Tol	oacco Use Ce	ssation		
Advising Smokers and Tobacco Users to Quit	80.83%	78.06%	75.72%	-2.34	**
Discussing Cessation Medications	56.05%	55.05%	56.12%	+1.07	***
Discussing Cessation Strategies	47.62%	46.86%	46.81%	-0.05	**
Antidepressant Medication Mo	inagement				
Effective Acute Phase Treatment	53.57%	52.58%	50.48%	-2.10++	**

Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Effective Continuation Phase Treatment	37.03%	35.43%	33.33%	-2.10++	*
Diabetes Screening for People Antipsychotic Medications	With Schizo	ophrenia or 1	Bipolar Disoi	der Who Are U	sing
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications	86.06%	86.14%	81.52%	-4.62++	**
Diabetes Monitoring for People	e With Diab	etes and Sch	izophrenia		
Diabetes Monitoring for People With Diabetes and Schizophrenia	71.46%	73.60%	61.17%	-12.43**	*
Cardiovascular Monitoring for	r People Wit	h Cardiovas	cular Disease	e and Schizophr	enia
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia	72.06%	79.55%	61.90%	-17.65**	*
Adherence to Antipsychotic Me	edications fo	r Individual	ls With Schiz	ophrenia	
Adherence to Antipsychotic Medications for Individuals With Schizophrenia	69.06%	69.10%	68.04%	-1.06	****
Health Plan Diversity ⁵					
Race/Ethnicity Diversity of Me	mhershin				
Total—White	54.61%	59.99%	59.95%	-0.04	NC
Total—Black or African American	18.96%	21.94%	22.36%	+0.42	NC
Total—American—Indian and Alaska Native	0.37%	0.47%	0.48%	+0.01	NC
Total—Asian	0.66%	3.04%	2.43%	-0.61	NC
Total—Native Hawaiian and Other Pacific Islander	0.05%	0.07%	0.08%	+0.01	NC
Total—Some Other Race	0.19%	0.02%	0.00%	-0.02	NC
Total—Two or More Races	0.00%	0.00%	0.00%	0.00	NC
Total—Unknown ³	5.12%	6.70%	14.70%	+8.00	NC
Total—Declined ³	20.05%	7.76%	0.00%	-7.76	NC
Total—Hispanic or Latino ³	5.10%	6.40%	0.00%	-6.40	NC





Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²				
Language Diversity of Membership									
Spoken Language Preferred for Health Care—English	98.62%	98.53%	98.48%	-0.05	NC				
Spoken Language Preferred for Health Care—Non- English	1.38%	1.44%	0.67%	-0.77	NC				
Spoken Language Preferred for Health Care—Unknown	0.00%	0.04%	0.84%	+0.80	NC				
Spoken Language Preferred for Health Care—Declined	0.00%	0.00%	0.00%	0.00	NC				
Language Preferred for Written Materials—English	98.62%	98.53%	98.48%	-0.05	NC				
Language Preferred for Written Materials—Non- English	1.38%	1.44%	0.67%	-0.77	NC				
Language Preferred for Written Materials— Unknown	0.00%	0.04%	0.84%	+0.80	NC				
Language Preferred for Written Materials—Declined	0.00%	0.00%	0.00%	0.00	NC				
Other Language Needs— English	98.62%	98.53%	98.48%	-0.05	NC				
Other Language Needs— Non-English	1.38%	1.44%	0.67%	-0.77	NC				
Other Language Needs— Unknown	0.00%	0.04%	0.84%	+0.80	NC				
Other Language Needs— Declined	0.00%	0.00%	0.00%	0.00	NC				
Utilization ⁶									
	Ambulatory Care—Total (Per 1,000 Member Months)								
Emergency Department Visits—Total*	68.41	64.84	45.54	-19.30	****				
Outpatient Visits—Total	396.93	389.60	397.73	+8.13	NC				
Inpatient Utilization—General	l Hospital/A	cute Care—2	Total						
Discharges per 1,000 Member Months—Total Inpatient—Total All Ages	7.59	7.44	6.67	-0.77	NC				

Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Average Length of Stay— Total Inpatient—Total All Ages	3.98	4.05	4.30	+0.25	NC
Discharges per 1,000 Member Months— Maternity—Total All Ages	2.99	2.88	2.63	-0.25	NC
Average Length of Stay— Maternity—Total All Ages	2.54	2.53	2.67	+0.14	NC
Discharges per 1,000 Member Months—Surgery— Total All Ages	1.76	1.76	1.52	-0.24	NC
Average Length of Stay— Surgery—Total All Ages	6.45	6.56	7.18	+0.62	NC
Discharges per 1,000 Member Months— Medicine—Total All Ages	3.69	3.62	3.25	-0.37	NC
Average Length of Stay— Medicine—Total All Ages	3.64	3.70	3.91	+0.21	NC
Use of Opioids From Multiple	Providers*,3				
Multiple Prescribers	18.12%	15.44%	14.84%	-0.60	****
Multiple Pharmacies	5.64%	3.73%	3.78%	+0.05	***
Multiple Prescribers and Multiple Pharmacies	3.10%	2.08%	2.59%	+0.51++	***
Use of Opioids at High Dosage	* ,3				
Use of Opioids at High Dosage*	_	3.31%	2.65%	-0.66+	****
Risk of Continued Opioid Use	*,3				
At Least 15 Days Covered— Total	15.52%	13.21%	9.38%	-3.83+	**
At Least 31 Days Covered— Total	6.76%	6.70%	5.91%	-0.79 ⁺	*
Plan All-Cause Readmissions					
Observed Readmissions— Total*	_	8.21%	8.60%	+0.39	***
Expected Readmissions— Total*		10.28%	9.60%	-0.68+	***
O/E Ratio—Total*	_	0.80	0.90	+0.10**	****



¹HEDIS MY 2019 to HEDIS MY 2020 comparisons were based on a Chi-square test of statistical significance with a p value of <0.05. MY 2019–MY 2020 Comparisons shaded green with one cross (+) indicate significant improvement from the previous year. MY 2019–MY 2020 Comparisons shaded red with two crosses (++) indicate a significant decline in performance from the previous year. ²HEDIS MY 2020 Performance Levels were based on comparisons of the HEDIS MY 2020 measure indicator rates to national Medicaid Quality Compass HEDIS MY 2019 benchmarks, with the exception of the Plan All-Cause Readmissions measure indicator rates, which were compared to the national Medicaid NCQA Audit Means and Percentiles HEDIS MY 2019 benchmark.

³Due to changes in the technical specifications for this measure, NCQA recommends trending between MY 2020 and prior years be considered with caution.

⁴Due to changes in the technical specifications for this measure, NCQA recommends a break in trending between MY 2020 and prior years; therefore, prior years' rates are not displayed and comparisons to benchmarks are not performed for this measure.

⁵This measure is a first-year measure; therefore, the prior year's rates cannot be displayed and comparisons to benchmarks cannot be performed for this measure as benchmarks are not yet available. ⁶Significance testing was not performed for utilization-based or health plan description measure indicator rates and any Performance Levels for MY 2020 or MY 2019–MY 2020 Comparisons provided for these measures are for information purposes only.

* For this indicator, a lower rate indicates better performance.

— indicates that the rate is not presented in this report as the measure is a first-year measure; therefore, no trending information is available. This symbol may also indicate that NCQA recommended a break in trending; therefore, no prior year rates are displayed.

NC indicates that a comparison is not appropriate, or the measure did not have an applicable benchmark. *HEDIS MY 2020 Performance Levels represent the following percentile comparisons:*

 $\star \star \star \star \star = 90$ th percentile and above

- $\star \star \star \star = 75$ th to 89th percentile
- $\star \star \star = 50$ th to 74th percentile
- $\star \star = 25$ th to 49th percentile
- \star = Below 25th percentile



Table B-6—MOL Trend Table

Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Child & Adolescent Care					
Childhood Immunization Stat	tus				
Combination 2	75.91%	75.91%	71.29%	-4.62	**
Combination 3	71.29%	71.29%	67.15%	-4.14	**
Combination 4	70.32%	70.32%	66.18%	-4.14	**
Combination 5	61.80%	61.80%	59.37%	-2.43	**
Combination 6	38.93%	38.93%	37.23%	-1.70	**
Combination 7	61.07%	61.07%	58.64%	-2.43	**
Combination 8	38.93%	38.93%	36.98%	-1.95	**
Combination 9	33.82%	33.82%	34.06%	+0.24	**
Combination 10	33.82%	33.82%	33.82%	0.00	**
Well-Child Visits in the First	30 Months of	Life			
Well-Child Visits in the First 15 Months—Six or More Well-Child Visits⁴	_	_	59.93%	NC	NC
Well-Child Visits for Age 15 Months to 30 Months—Two or More Well-Child Visits ⁵	_	_	67.01%	NC	NC
Lead Screening in Children					
Lead Screening in Children	78.83%	78.83%	72.14%	-6.69++	**
Child and Adolescent Well-Ca	re Visits ⁴				
Ages 3 to 11 Years	_	_	51.03%	NC	NC
Ages 12 to 17 Years	_	_	45.06%	NC	NC
Ages 18 to 21 Years	_	_	29.85%	NC	NC
Total	_	_	45.75%	NC	NC
Immunizations for Adolescen	ts				
Combination 1 (Meningococcal, Tdap)	88.56%	87.59%	83.70%	-3.89	***
Combination 2 (Meningococcal, Tdap, HPV)		42.09%	42.34%	+0.25	***
Follow-Up Care for Children	Prescribed Al	DHD Medicati	on ³		
Initiation Phase	54.32%	43.00%	51.67%	$+8.67^{+}$	****
Continuation and Maintenance Phase	68.20%	47.17%	65.49%	+18.32+	****

	HEDIS MY	HEDIS MY	HEDIS MY	MY 2019– MY 2020	MY 2020 Performance
Measure	2018	2019	2020	Comparison ¹	Level ²
Women—Adult Care					
Chlamydia Screening in Wom					
Ages 16 to 20 Years	66.65%	65.32%	59.09%	-6.23++	***
Ages 21 to 24 Years	70.08%	71.11%	65.40%	-5.71**	***
Total	68.09%	67.64%	61.79%	-5.85**	***
Cervical Cancer Screening ³		-	-		
Cervical Cancer Screening	67.40%	67.40%	63.99%	-3.41	***
Breast Cancer Screening ³					
Breast Cancer Screening	59.49%	59.27%	55.52%	-3.75**	**
Access to Care					
Adults' Access to Preventive/A	mbulatory He	ealth Services			
Ages 20 to 44 Years	78.52%	78.91%	75.54%	-3.37**	**
Ages 45 to 64 Years	87.40%	87.19%	85.30%	-1.89++	**
65 Years and Older	94.07%	93.18%	90.28%	-2.90++	***
Total	82.47%	82.61%	79.57%	-3.04++	**
Avoidance of Antibiotic Treat	ment for Acut	e Bronchitis/I	Bronchiolitis		
Ages 3 Months to 17 Years	_	56.03%	58.59%	+2.56+	**
Ages 18 to 64 Years		37.43%	38.65%	+1.22	***
Ages 65 Years And Older	_	38.14%	22.73%	-15.41++	*
Total	_	47.10%	48.76%	$+1.66^{+}$	**
Appropriate Testing for Phary	ngitis ³				
Ages 3 to 17 Years		72.02%	70.08%	-1.94++	*
Ages 18 to 64 Years		54.73%	52.12%	-2.61++	*
Ages 65 Years And Older		41.67%	24.00%	-17.67	***
Total		66.65%	63.70%	-2.95**	*
Appropriate Treatment for Up	per Resnirato		05.7070		0
Ages 3 Months to 17 Years		88.42%	89.18%	$+0.76^{+}$	**
Ages 18 to 64 Years		73.82%	76.95%	$+3.13^{+}$	***
Ages 65 Years And Older		65.93%	61.31%	-4.62	*
Total		84.57%	85.63%	+1.02	**
Obesity		07.770	05.0570	1.00	~~~
Weight Assessment and Count	aling for Nut	rition and PL	vsical Activity	for Children / Ad	alascants
Body Mass index (BMI) Percentile—Total ³	81.27%	85.67%	76.89%	-8.78 ⁺⁺	**
Counseling for Nutrition— Total	75.18%	74.63%	70.80%	-3.83	**





Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Counseling for Physical Activity—Total	72.02%	74.33%	67.64%	-6.69++	***
Pregnancy Care					
Prenatal and Postpartum Car	e ³				
Timeliness of Prenatal Care	_	97.81%	81.27%	-16.54**	*
Postpartum Care	_	77.86%	70.32%	-7.54++	*
Living With Illness					
Comprehensive Diabetes Care	2				
Hemoglobin A1c (HbA1c) Testing ³	87.10%	89.29%	82.73%	-6.56++	*
HbA1c Poor Control (>9.0%)* ³	41.36%	37.23%	44.77%	+7.54**	**
<i>HbA1c Control</i> (<8.0%) ³	49.15%	52.07%	43.31%	-8.76++	*
Eye Exam (Retinal) Performed ³	59.37%	58.88%	53.28%	-5.60	**
Blood Pressure Control (<140/90 mm Hg) ⁴	_	_	56.93%	NC	NC
Kidney Health Evaluation for	Patients With	Diabetes ⁵			
Ages 18 to 64 Years			30.64%	NC	NC
Ages 65 to 74 Years	_	_	33.74%	NC	NC
Ages 75 to 85 Years	_	_	34.29%	NC	NC
Total			30.94%	NC	NC
Asthma Medication Ratio					
Total	60.16%	55.87%	52.96%	-2.91++	*
Controlling High Blood Press	sure				
Controlling High Blood Pressure ³			50.85%	NC	NC
Medical Assistance With Smo	king and Tob	acco Use Cess	ation		
Advising Smokers and Tobacco Users to Quit	80.00%	77.25%	73.80%	-3.45	*
Discussing Cessation Medications	56.54%	58.59%	58.38%	-0.21	***
Discussing Cessation Strategies	45.59%	49.61%	51.35%	+1.74	***
Antidepressant Medication M	anagement				
Effective Acute Phase Treatment	57.07%	43.73%	61.61%	+17.88+	****

Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Effective Continuation Phase Treatment	40.40%	26.47%	43.83%	+17.36+	****
Diabetes Screening for People Medications	With Schizop	ohrenia or Bip	olar Disorder	Who Are Using	Antipsychotic
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications	85.98%	84.56%	78.55%	-6.01**	*
Diabetes Monitoring for Peopl	e With Diabe	tes and Schizo	phrenia		
Diabetes Monitoring for People With Diabetes and Schizophrenia	71.26%	69.18%	62.18%	-7.00**	*
Cardiovascular Monitoring for	r People With	Cardiovascul	lar Disease an	d Schizophrenia	!
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia	76.74%	71.67%	67.27%	-4.40	*
Adherence to Antipsychotic M	edications for	Individuals V	Vith Schizoph	renia	
Adherence to Antipsychotic Medications for Individuals With Schizophrenia	64.60%	41.22%	71.35%	+30.13+	****
Health Plan Diversity ⁵					
Race/Ethnicity Diversity of Me	mbership				
Total—White	45.40%	45.25%	45.74%	+0.49	NC
Total—Black or African American	34.44%	34.24%	34.04%	-0.20	NC
Total—American–Indian and Alaska Native	0.26%	0.27%	0.27%	0.00	NC
Total—Asian	0.30%	0.29%	0.30%	+0.01	NC
Total—Native Hawaiian and Other Pacific Islander	0.00%	0.00%	0.00%	0.00	NC
Total—Some Other Race	0.00%	0.00%	0.00%	0.00	NC
Total—Two or More Races	0.00%	0.00%	0.00%	0.00	NC
Total—Unknown ³	19.60%	19.95%	19.64%	-0.31	NC
Total—Declined ³	0.00%	0.00%	0.00%	0.00	NC
Total—Hispanic or Latino ³	6.76%	6.90%	6.92%	+0.02	NC





	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY	MY 2019– MY 2020	MY 2020 Performance Level ²
Measure Language Diversity of Membe		2019	2020	Comparison ¹	Lever
Spoken Language Preferred for Health Care—English	98.64%	98.52%	98.51%	-0.01	NC
Spoken Language Preferred for Health Care—Non- English	1.32%	1.43%	1.47%	+0.04	NC
Spoken Language Preferred for Health Care—Unknown	0.04%	0.05%	0.02%	-0.03	NC
Spoken Language Preferred for Health Care—Declined	0.00%	0.00%	0.00%	0.00	NC
Language Preferred for Written Materials—English	98.64%	98.52%	98.51%	-0.01	NC
Language Preferred for Written Materials—Non- English	1.32%	1.43%	1.47%	+0.04	NC
Language Preferred for Written Materials— Unknown	0.04%	0.05%	0.02%	-0.03	NC
Language Preferred for Written Materials— Declined	0.00%	0.00%	0.00%	0.00	NC
Other Language Needs— English	98.64%	98.52%	98.51%	-0.01	NC
Other Language Needs— Non-English	1.32%	1.43%	1.47%	+0.04	NC
Other Language Needs— Unknown	0.04%	0.05%	0.02%	-0.03	NC
Other Language Needs— Declined	0.00%	0.00%	0.00%	0.00	NC
Utilization ⁶					
Ambulatory Care—Total (Per	1,000 Membe	r Months)			
Emergency Department Visits—Total*	68.48	66.87	47.07	-19.80	****
Outpatient Visits—Total	418.38	429.45	340.07	-89.38	NC
Inpatient Utilization—Genera	ıl Hospital/Ac	ute Care—To	tal		
Discharges per 1,000 Member Months—Total Inpatient—Total All Ages	7.34	7.20	5.99	-1.21	NC

Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Average Length of Stay— Total Inpatient—Total All Ages	4.57	4.80	5.13	+0.33	NC
Discharges per 1,000 Member Months— Maternity—Total All Ages	2.62	2.69	2.44	-0.25	NC
Average Length of Stay— Maternity—Total All Ages	2.78	2.85	2.83	-0.02	NC
Discharges per 1,000 Member Months— Surgery—Total All Ages	1.72	1.70	1.35	-0.35	NC
Average Length of Stay— Surgery—Total All Ages	7.41	8.16	9.18	+1.02	NC
Discharges per 1,000 Member Months— Medicine—Total All Ages	3.73	3.56	2.86	-0.70	NC
Average Length of Stay— Medicine—Total All Ages	4.16	4.25	4.65	+0.40	NC
Use of Opioids From Multiple	e Providers* ³				
Multiple Prescribers	18.63%	14.07%	13.36%	-0.71	*****
Multiple Pharmacies	5.64%	3.84%	2.75%	-1.09+	****
Multiple Prescribers and Multiple Pharmacies	3.37%	2.06%	1.70%	-0.36+	***
Use of Opioids at High Dosag	e*,3	-	-		
Use of Opioids at High Dosage*	_	2.29%	2.15%	-0.14	****
Risk of Continued Opioid Use	*,3				-
At Least 15 Days Covered— Total	19.29%	12.76%	9.82%	-2.94+	*
At Least 31 Days Covered— Total	7.93%	6.62%	6.95%	+0.33	*
Plan All-Cause Readmissions					
Observed Readmissions— Total*	_	8.87%	9.43%	+0.56	***
Expected Readmissions— Total*	_	9.56%	9.90%	+0.34	**
O/E Ratio—Total*		0.93	0.95	+0.02++	***



¹HEDIS MY 2019 to HEDIS MY 2020 comparisons were based on a Chi-square test of statistical significance with a p value of < 0.05. MY 2019–MY 2020 Comparisons shaded green with one cross (+) indicate significant improvement from the previous year. MY 2019–MY 2020 Comparisons shaded red with two crosses (++) indicate a significant decline in performance from the previous year.

²HEDIS MY 2020 Performance Levels were based on comparisons of the HEDIS MY 2020 measure indicator rates to national Medicaid Quality Compass HEDIS MY 2019 benchmarks, with the exception of the Plan All-Cause Readmissions measure indicator rates, which were compared to the national Medicaid NCQA Audit Means and Percentiles HEDIS MY 2019 benchmark.

³Due to changes in the technical specifications for this measure, NCQA recommends trending between MY 2020 and prior years be considered with caution.

⁴Due to changes in the technical specifications for this measure, NCQA recommends a break in trending between MY 2020 and prior years; therefore, prior years' rates are not displayed and comparisons to benchmarks are not performed for this measure.

⁵This measure is a first-year measure; therefore, the prior year's rates cannot be displayed and comparisons to benchmarks cannot be performed for this measure as benchmarks are not yet available. ⁶Significance testing was not performed for utilization-based or health plan description measure indicator rates and any Performance Levels for MY 2020 or MY 2019–MY 2020 Comparisons provided for these measures are for information purposes only.

* For this indicator, a lower rate indicates better performance.

— indicates that the rate is not presented in this report as the measure is a first-year measure; therefore, no trending information is available. This symbol may also indicate that NCQA recommended a break in trending; therefore, no prior year rates are displayed.

NC indicates that a comparison is not appropriate, or the measure did not have an applicable benchmark. *HEDIS MY 2020 Performance Levels represent the following percentile comparisons:*

 $\star \star \star \star \star = 90$ th percentile and above

- $\star \star \star \star = 75$ th to 89th percentile
- $\star \star \star = 50$ th to 74th percentile
- $\star \star = 25$ th to 49th percentile
- \star = Below 25th percentile



Table B-7—PRI Trend Table

Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Child & Adolescent Care					
Childhood Immunization Stat	tus				
Combination 2	80.05%	80.05%	75.91%	-4.14	***
Combination 3	76.89%	76.89%	74.70%	-2.19	***
Combination 4	76.40%	76.40%	73.72%	-2.68	****
Combination 5	69.10%	69.10%	66.67%	-2.43	****
Combination 6	51.82%	51.82%	53.53%	+1.71	****
Combination 7	68.86%	68.86%	65.94%	-2.92	****
Combination 8	51.82%	51.82%	53.04%	+1.22	****
Combination 9	47.93%	47.93%	48.42%	+0.49	****
Combination 10	47.93%	47.93%	47.93%	0.00	****
Well-Child Visits in the First .	30 Months of	Life			
Well-Child Visits in the First 15 Months—Six or More Well-Child Visits ⁴	_	_	65.77%	NC	NC
Well-Child Visits for Age 15 Months to 30 Months—Two or More Well-Child Visits ⁵	_	_	75.71%	NC	NC
Lead Screening in Children			-		
Lead Screening in Children	82.00%	82.00%	78.35%	-3.65	***
Child and Adolescent Well-Ca	re Visits⁴		-		
Ages 3 to 11 Years			55.86%	NC	NC
Ages 12 to 17 Years			46.32%	NC	NC
Ages 18 to 21 Years	_	_	28.87%	NC	NC
Total		_	49.14%	NC	NC
Immunizations for Adolescent	ts				
Combination 1 (Meningococcal, Tdap)	83.70%	87.35%	87.59%	+0.24	****
Combination 2 (Meningococcal, Tdap, HPV)		50.85%	45.99%	-4.86	****
Follow-Up Care for Children	Prescribed Al	OHD Medicati	on ³		
Initiation Phase	26.15%	36.56%	37.07%	+0.51	**
Continuation and Maintenance Phase	26.23%	40.30%	42.59%	+2.29	*

HEDIS MY Neasure HEDIS MY 2018 HEDIS MY 2019 HEDIS MY 2020 MY 2020 Comparison ¹ Perfor Lev Women—Adult Care	el ²
Women—Adult Care International Content of Conten	
Chlamydia Screening in Women Ages 16 to 20 Years 68.22% 67.87% 58.78% -9.09** ★★ Ages 21 to 24 Years 70.23% 68.88% 63.95% 4.93** ★ Total 69.06% 68.30% 61.05% -7.25** ★★ Cervical Cancer Screening ³	
Ages 16 to 20 Years 68.22% 67.87% 58.78% 9.09^{++} $\star\star$ Ages 21 to 24 Years 70.23% 68.88% 63.95% 4.93^{++} $\star\star$ Total 69.06% 68.30% 61.05% -7.25^{++} $\star\star$ Cervical Cancer Screening ³ $Cervical Cancer Screening^3$ -7.25^{++} $\star\star$ Breast Cancer Screening 68.61% 73.24% 67.88% -5.36 $\star\star$ Access to Care $Adults' Access to Preventive/Ambulatory Health Services Ages 20 to 44 Years 81.39\% 81.45\% 76.55\% 4.90^{++} \star\star Ages 45 to 64 Years 88.98\% 89.15\% 85.47\% -3.68^{++} \star\star Ages 45 to 64 Years 88.98\% 89.15\% 80.06\% 4.66^{++} \star\star Ages 3 Months to 17 Years -69.89\% 71.56\% +1.67 \star\star Ages 65 Years And Older 45.63\% 48.74\% +3.11 \star\star Ages 64 Years 45.63\% 48.74\% +3.11 \star\star Ages 65 Years And Older - NA $	
Ages 21 to 24 Years 70.23% 68.88% 63.95% 4.93 ⁺⁺ ** Total 69.06% 68.30% 61.05% -7.25 ⁺⁺ ** Cervical Cancer Screening ³ Cervical Cancer Screening ³ 67.88% -5.36 ** Breast Cancer Screening ³ Breast Cancer Screening ³ 67.88% -5.36 ** Access to Care Access to Care Adults' Access to Preventive/Ambulatory Health Services 4.90 ⁺⁺ * Ages 20 to 44 Years 81.39% 81.45% 76.55% 4.90 ⁺⁺ * Ages 45 to 64 Years 88.98% 89.15% 85.47% -3.68 ⁺⁺ * Total 84.69% 84.72% 80.06% 4.66 ⁺⁺ * Ages 3 Months to 17 Years — 69.89% 71.56% +1.67 * Ages 65 Years And Older — NA NA NC Ni Ages 65 Years And Older — 45.63% 48.74% +3.11 * Ages 65 Years And Older — NA NA NC Ni	
Total 0.060° 0.010° 0.010° 0.010° 0.010° Total 0.060° 68.00° 61.05° -7.25° $\star \star$ Cervical Cancer Screening ³ $Cervical Cancer Screening^3$ $\star \star$ Breast Cancer Screening 64.48° 66.04° 64.51° -1.53 $\star \star \star$ Access to Care $Adults'$ Access to Preventive/Ambulatory Health Services $Ages 20 to 44$ Years 81.39° 81.45° 76.55° $-4.90^{\circ +}$ $\star \star$ Ages 45 to 64 Years 88.98° 89.15° 85.47° $-3.68^{\circ +}$ $\star \star$ Ages 45 to 64 Years 88.98° 89.15° 85.47° $-3.68^{\circ +}$ $\star \star$ Ages 45 to 64 Years 88.98° 89.15° 85.47° $-3.68^{\circ +}$ $\star \star$ Ages 45 to 64 Years 88.98° 89.15° 85.47° $-3.68^{\circ +}$ $\star \star$ Ages 3 Months to 17 Years - 69.89° 71.56° $+1.67^{\circ}$ $\star \star$ Ages 65 Years And Older - NA	*
Cervical Cancer Screening 68.61% 73.24% 67.88% -5.36 *** Breast Cancer Screening 64.48% 66.04% 64.51% -1.53 *** Access to Care	r
Cervical Cancer Screening 68.61% 73.24% 67.88% -5.36 *** Breast Cancer Screening 64.48% 66.04% 64.51% -1.53 *** Access to Care *** *** *** *** Ages 20 to 44 Years 81.39% 81.45% 76.55% 4.90** *** Ages 45 to 64 Years 88.98% 89.15% 85.47% -3.68** *** G5 Years and Older 94.70% 94.82% 91.77% -3.05** *** Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis 80.06% 4.66** *** Ages 3 Months to 17 Years - 69.89% 71.56% +1.67 *** Ages 65 Years And Older - NA NA NC Ni Ages 3 to 17 Years - 82.40% 81.08% -1.32 *** Ages 65 Years And Older - NA NA NC Ni Ages 16 to 64 Years - 72.26% 68.19% -1.32 *** Ages 16 Years An	*
Original Contents Breast Cancer Screening 64.48% 66.04% Breast Cancer Screening 64.48% 66.04% Adults' Access to Preventive/Ambulatory Health Services Ages 20 to 44 Years 81.39% 81.45% 76.55% Ages 20 to 44 Years 88.98% 89.15% Ages 45 to 64 Years 88.98% 89.15% Assume to 44 Years 88.98% 89.15% Ages 3 to 64 Years A feed of Artibiotic Treatment for Acute Bronchitis/Bronchiolitis Ages 3 Months to 17 Years — Ages 3 Months to 17 Years — Ages 3 to 17 Years — Ages 18 to 64 Years — Ages 18 to 64 Years — NA <td></td>	
Breast Cancer Screening 64.48% 66.04% 64.51% -1.53 ★★★ Access to Care Adults' Access to Preventive/Ambulatory Health Services Ages 20 to 44 Years 81.39% 81.45% 76.55% 4.90 ⁺⁺ ★★ Ages 45 to 64 Years 88.98% 89.15% 85.47% -3.68 ⁺⁺ ★★ 65 Years and Older 94.70% 94.82% 91.77% -3.05 ⁺⁺ ★★ Total 84.69% 84.72% 80.06% 4.66 ⁺⁺ ★★ Ages 3 Months to 17 Years — 69.89% 71.56% +1.67 ★★ Ages 65 Years And Older — NA NA NC Ni Total — 55.95% 59.51% +3.56 ⁺ ★★ Ages 18 to 64 Years — 45.63% 48.74% +3.11 ★★ Ages 65 Years And Older — NA NA NC Ni Total — 55.95% 59.51% +3.56 ⁺ ★★ Ages 18 to 64 Years — 72.26% 68.19% -1.32 ★ Ages 18 to 64 Years — <	r *
Access to Care Adults' Access to Preventive/Ambulatory Health Services Ages 20 to 44 Years 81.39% 81.45% 76.55% 4.90 ⁺⁺ ** Ages 45 to 64 Years 88.98% 89.15% 85.47% -3.68 ⁺⁺ ** 65 Years and Older 94.70% 94.82% 91.77% -3.05 ⁺⁺ ** Total 84.69% 84.72% 80.06% 4.66 ⁺⁺ ** Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis # ** ** Ages 3 Months to 17 Years 69.89% 71.56% +1.67 *** Ages 65 Years And Older NA NA NC Nu Total 55.95% 59.51% +3.56 ⁺ *** Ages 65 Years And Older NA NA NC Nu Total 52.95% 59.51% +3.56 ⁺ *** Ages 18 to 64 Years 72.26% 68.19% -1.32 *** Ages 65 Years And Older NA NA NC Nu Ages 65 Y	
Adults' Access to Preventive/Ambulatory Health Services Ages 20 to 44 Years 81.39% 81.45% 76.55% 4.90 ⁺⁺ ** Ages 45 to 64 Years 88.98% 89.15% 85.47% -3.68 ⁺⁺ ** 65 Years and Older 94.70% 94.82% 91.77% -3.05 ⁺⁺ ** Total 84.69% 84.72% 80.06% 4.66 ⁺⁺ ** Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis 4.66 ⁺⁺ ** Ages 18 to 64 Years 69.89% 71.56% +1.67 ** Ages 65 Years And Older NA NA NC Nu Total 55.95% 59.51% +3.56 ⁺ ** Ages 65 Years And Older NA NA NC Nu Total 55.95% 59.51% +3.56 ⁺ ** Ages 18 to 64 Years 72.26% 68.19% -1.32 ** Ages 65 Years And Older NA NA NC Nu Ages 65 Years And Older 78.75% 76.32%	r *
Ages 20 to 44 Years 81.39% 81.45% 76.55% 4.90 ⁺⁺ ★ Ages 45 to 64 Years 88.98% 89.15% 85.47% -3.68 ⁺⁺ ★ 65 Years and Older 94.70% 94.82% 91.77% -3.05 ⁺⁺ ★ Total 84.69% 84.72% 80.06% 4.66 ⁺⁺ ★ Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis 4.66 ⁺⁺ ★ ★ Ages 18 to 64 Years 69.89% 71.56% +1.67 ★ ★ Ages 18 to 64 Years 45.63% 48.74% +3.11 ★ ★ Ages 65 Years And Older NA NA NC Nu Total 55.95% 59.51% +3.56 ⁺⁺ ★ ★ Ages 3 to 17 Years 82.40% 81.08% -1.32 ★ ★ Ages 65 Years And Older NA NA NC Nu Ages 65 Years And Older 72.26% 68.19% 4.07 ⁺⁺ ★ ★ Ages 65 Years And Older NA NA NC Nu Tot	
Ages 45 to 64 Years 88.98% 89.15% 85.47% -3.68 ⁺⁺ ★ 65 Years and Older 94.70% 94.82% 91.77% -3.05 ⁺⁺ ★ Total 84.69% 84.72% 80.06% 44.66 ⁺⁺ ★ Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis Ages 3 Months to 17 Years — 69.89% 71.56% +1.67 ★ Ages 18 to 64 Years — 45.63% 48.74% +3.11 ★ ★ Ages 65 Years And Older — NA NA NC Ni Total — 55.95% 59.51% +3.56 ⁺ ★ ★ Ages 3 to 17 Years — 82.40% 81.08% -1.32 ★ ★ Ages 65 Years And Older — NA NA NC Ni Ages 65 Years And Older — 72.26% 68.19% 4.07 ⁺⁺ ★ Ages 65 Years And Older — NA NA NC Ni Ages 65 Years And Older — 78.75% 76.32% -2.43 ⁺⁺ ★ Ages 3 Months to 17 Ye	
65 Years and Older 94.70% 94.82% 91.77% -3.05 ⁺⁺ ★★ Total 84.69% 84.72% 80.06% 4.66 ⁺⁺ ★★ Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis Ages 3 Months to 17 Years 69.89% 71.56% +1.67 ★★ Ages 18 to 64 Years 45.63% 48.74% +3.11 ★★ Ages 65 Years And Older NA NA NC Ni Total 55.95% 59.51% +3.56 ⁺ ★★ Ages 3 to 17 Years 82.40% 81.08% -1.32 ★ Ages 18 to 64 Years 72.26% 68.19% -4.07 ⁺⁺ ★ Ages 65 Years And Older NA NA NC Ni Ages 18 to 64 Years 72.26% 68.19% -4.07 ⁺⁺ ★ Ages 65 Years And Older NA NA NC Ni Total 78.75% 76.32% -2.43 ⁺⁺ ★ Ages 3 Months to 17 Years 94.65% 95.1	۲
Total 84.69% 84.72% 80.06% 44.66 ⁺⁺ *** Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis Ages 3 Months to 17 Years — 69.89% 71.56% +1.67 *** Ages 18 to 64 Years — 45.63% 48.74% +3.11 *** Ages 65 Years And Older — NA NA NC Ni Total — 55.95% 59.51% +3.56 ⁺ *** Ages 3 to 17 Years — 82.40% 81.08% -1.32 ** Ages 18 to 64 Years — 72.26% 68.19% 4.07 ⁺⁺ ** Ages 65 Years And Older — NA NA NC Ni Ages 18 to 64 Years — 72.26% 68.19% -4.07 ⁺⁺ ** Ages 65 Years And Older — NA NA NC Ni Ages 65 Years And Older — NA NA NC Ni Ages 65 Years And Older — NA NA NC Ni Ages 65 Years And Older — NA NA NC Ni	r
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis Ages 3 Months to 17 Years — 69.89% 71.56% +1.67 ★★★ Ages 18 to 64 Years — 45.63% 48.74% +3.11 ★★★ Ages 65 Years And Older — NA NA NC Ni Total — 55.95% 59.51% +3.56 ⁺ ★★★ Ages 18 to 64 Years — 82.40% 81.08% -1.32 ★★ Ages 3 to 17 Years — 82.40% 81.08% -1.32 ★★ Ages 18 to 64 Years — 72.26% 68.19% -4.07 ⁺⁺ ★★ Ages 65 Years And Older — NA NA NC Ni Total — 78.75% 76.32% -2.43 ⁺⁺ ★ Ages 3 Months to 17 Years — 94.65% 95.18% +0.53 ★ ★	*
Ages 3 Months to 17 Years — 69.89% 71.56% +1.67 ★★★ Ages 18 to 64 Years — 45.63% 48.74% +3.11 ★★★ Ages 65 Years And Older — NA NA NC Ni Total — 55.95% 59.51% +3.56 ⁺ ★★★ Appropriate Testing for Pharyngitis ³ — 82.40% 81.08% -1.32 ★★ Ages 18 to 64 Years — 72.26% 68.19% 4.07⁺⁺ ★★ Ages 65 Years And Older — NA NA NC Ni Ages 65 Years And Older — 78.75% 76.32% 2.43⁺⁺ ★ Ages 3 Months to 17 Years — 94.65% 95.18% +0.53 ★★	۲
Ages 18 to 64 Years — 45.63% 48.74% +3.11 ★★★ Ages 65 Years And Older — NA NA NC NK Total — 55.95% 59.51% +3.56 ⁺ ★★★ Appropriate Testing for Pharyngitis ³ — 82.40% 81.08% -1.32 ★★ Ages 18 to 64 Years — 72.26% 68.19% 4.07⁺⁺ ★★ Ages 65 Years And Older — NA NA NC NK Ages 65 Years And Older — 78.75% 76.32% 2.43⁺⁺ ★★ Appropriate Treatment for Upper Respiratory Infection — 94.65% 95.18% +0.53 ★★	
Ages 65 Years And Older - NA NA NC NN Total - 55.95% 59.51% +3.56 ⁺ ★★★ Appropriate Testing for Pharyngitis ³ - 82.40% 81.08% -1.32 ★★ Ages 18 to 64 Years - 72.26% 68.19% 4.07 ⁺⁺ ★★ Ages 65 Years And Older - NA NA NC NK Total - 78.75% 76.32% -2.43 ⁺⁺ ★ Appropriate Treatment for Upper Respiratory Infection - 94.65% 95.18% +0.53 ★★	r *
Total 55.95% 59.51% +3.56 ⁺ ★★ Appropriate Testing for Pharyngitis ³ 3 Ages 3 to 17 Years 82.40% 81.08% -1.32 ★ Ages 18 to 64 Years 72.26% 68.19% 4.07 ⁺⁺ ★ Ages 65 Years And Older NA NA NC NM Total 78.75% 76.32% -2.43 ⁺⁺ ★ Appropriate Treatment for Upper Respiratory Infection Ages 3 Months to 17 Years 94.65% 95.18% +0.53 ★ ★	r *
Appropriate Testing for Pharyngitis ³ Ages 3 to 17 Years — 82.40% 81.08% -1.32 ★ Ages 18 to 64 Years — 72.26% 68.19% 4.07 ⁺⁺ ★ Ages 65 Years And Older — NA NA NC N Total — 78.75% 76.32% -2.43 ⁺⁺ ★ Appropriate Treatment for Upper Respiratory Infection	2
Ages 3 to 17 Years — 82.40% 81.08% -1.32 *** Ages 18 to 64 Years — 72.26% 68.19% -4.07** ** Ages 65 Years And Older — NA NA NC NK Total — 78.75% 76.32% -2.43** *** Appropriate Treatment for Upper Respiratory Infection — 94.65% 95.18% +0.53 ***	r *
Ages 18 to 64 Years — 72.26% 68.19% 4.07 ⁺⁺ ★★ Ages 65 Years And Older — NA NA NC Nu Total — 78.75% 76.32% -2.43 ⁺⁺ ★★ Appropriate Treatment for Upper Respiratory Infection — 94.65% 95.18% +0.53 ★★	
Ages 65 Years And OlderNANANCNuTotal78.75%76.32%-2.43*****Appropriate Treatment for Upper Respiratory InfectionAges 3 Months to 17 Years94.65%95.18%+0.53****	r
Total — 78.75% 76.32% -2.43 ⁺⁺ * Appropriate Treatment for Upper Respiratory Infection	*
Appropriate Treatment for Upper Respiratory Infection Ages 3 Months to 17 Years — 94.65% 95.18% +0.53 ★★	2
Ages 3 Months to 17 Years - 94.65% 95.18% +0.53 **	۲
	r *
<i>Ages 18 to 64 Years</i> — 86.80% 87.57% +0.77 ★★★	**
Ages 65 Years And Older — 83.33% 89.74% +6.41 ★★	r *
<i>Total</i> − 92.45% 93.04% +0.59 ★★	r *
Obesity	
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents	
Body Mass index (BMI) 91.48% 93.43% 90.02% -3.41 Percentile—Total ³ 91.48% 93.43% 90.02% -3.41	r *
Counseling for Nutrition— 79.32% 85.16% 81.75% -3.41	r *





Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Counseling for Physical Activity—Total	79.32%	84.43%	80.29%	-4.14	****
Pregnancy Care					
Prenatal and Postpartum Car	e ³				
Timeliness of Prenatal Care		92.21%	86.37%	-5.84**	**
Postpartum Care	_	80.05%	79.56%	-0.49	***
Living With Illness					
Comprehensive Diabetes Care	2				
Hemoglobin A1c (HbA1c) Testing ³	93.43%	92.70%	90.51%	-2.19	***
HbA1c Poor Control (>9.0%)* ³	28.47%	26.28%	28.47%	+2.19	****
<i>HbA1c Control (</i> <8.0%) ³	61.50%	65.94%	60.58%	-5.36	****
Eye Exam (Retinal) Performed ³	69.53%	72.75%	63.02%	-9.73**	***
Blood Pressure Control (<140/90 mm Hg)⁴	_		75.91%	NC	NC
Kidney Health Evaluation for	Patients With	Diabetes ⁵			
Ages 18 to 64 Years	_		38.84%	NC	NC
Ages 65 to 74 Years	_		31.63%	NC	NC
Ages 75 to 85 Years	_		36.36%	NC	NC
Total	_		38.23%	NC	NC
Asthma Medication Ratio					
Total	70.40%	71.70%	73.36%	+1.66	****
Controlling High Blood Press	sure ³				
Controlling High Blood Pressure	_		74.94%	NC	NC
Medical Assistance With Smo	king and Tob	acco Use Cess	ntion		
Advising Smokers and Tobacco Users to Quit	81.94%	81.78%	79.39%	-2.39	***
Discussing Cessation Medications	57.42%	58.88%	56.29%	-2.59	***
Discussing Cessation Strategies	50.16%	55.14%	51.22%	-3.92	***
Antidepressant Medication M	anagement				
Effective Acute Phase Treatment	79.84%	74.59%	62.76%	-11.83++	****

Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Effective Continuation Phase Treatment	66.67%	55.74%	45.30%	-10.44++	****
Diabetes Screening for People Medications	With Schizop	ohrenia or Bip	olar Disorder	Who Are Using A	Intipsychotic
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications	85.12%	84.17%	80.64%	-3.53	**
Diabetes Monitoring for Peopl	e With Diabe	tes and Schizo	phrenia		
Diabetes Monitorin <u>g f</u> or People With Diabetes and Schizophrenia	54.84%	57.69%	61.00%	+3.31	*
Cardiovascular Monitoring fo	r People With	Cardiovascul	lar Disease an	d Schizophrenia	
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia	NA	NA	NA	NC	NC
Adherence to Antipsychotic M	edications for	Individuals V	Vith Schizoph	renia	
Adherence to Antipsychotic Medications for Individuals With Schizophrenia	65.24%	75.11%	72.27%	-2.84	****
Health Plan Diversity ⁵					
Race/Ethnicity Diversity of Me	mbership				
Total—White	60.16%	58.71%	59.62%	+0.91	NC
Total—Black or African American	14.30%	14.63%	15.20%	+0.57	NC
Total—American–Indian and Alaska Native	0.53%	0.55%	0.55%	0.00	NC
Total—Asian	0.77%	1.81%	0.97%	-0.84	NC
Total—Native Hawaiian and Other Pacific Islander	0.05%	0.07%	0.08%	+0.01	NC
Total—Some Other Race	0.00%	0.00%	0.00%	0.00	NC
Total—Two or More Races	0.00%	0.00%	0.00%	0.00	NC
Total—Unknown ³	24.18%	24.23%	23.58%	-0.65	NC
Total—Declined ³	0.00%	0.00%	0.00%	0.00	NC
Total—Hispanic or Latino ³	10.53%	10.98%	11.27%	+0.29	NC



	HEDIS MY	HEDIS MY	HEDIS MY	MY 2019– MY 2020	MY 2020 Performance					
Measure	2018	2019	2020	Comparison ¹	Level ²					
00 11	Language Diversity of Membership									
Spoken Language Preferred for Health Care—English	0.00%	0.00%	0.00%	0.00	NC					
Spoken Language Preferred for Health Care—Non- English	0.00%	0.00%	0.00%	0.00	NC					
Spoken Language Preferred for Health Care—Unknown	100.00%	100.00%	100.00%	0.00	NC					
Spoken Language Preferred for Health Care—Declined	0.00%	0.00%	0.00%	0.00	NC					
Language Preferred for Written Materials—English	0.00%	0.00%	0.00%	0.00	NC					
Language Preferred for Written Materials—Non- English	0.00%	0.00%	0.00%	0.00	NC					
Language Preferred for Written Materials— Unknown	100.00%	100.00%	100.00%	0.00	NC					
Language Preferred for Written Materials— Declined	0.00%	0.00%	0.00%	0.00	NC					
Other Language Needs— English	0.00%	0.00%	0.00%	0.00	NC					
Other Language Needs— Non-English	0.00%	0.00%	0.00%	0.00	NC					
Other Language Needs— Unknown	100.00%	100.00%	100.00%	0.00	NC					
Other Language Needs— Declined	0.00%	0.00%	0.00%	0.00	NC					
Utilization ⁶										
Ambulatory Care—Total (Per	1,000 Membe	r Months)								
Emergency Department Visits—Total*	65.22	65.08	49.54	-15.54	***					
Outpatient Visits—Total	368.60	379.56	294.42	-85.14	NC					
Inpatient Utilization—Genera	ıl Hospital/Ac	ute Care—To	tal							
Discharges per 1,000 Member Months—Total Inpatient—Total All Ages	6.48	6.33	5.35	-0.98	NC					

Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Average Length of Stay— Total Inpatient—Total All Ages	3.91	3.85	4.27	+0.42	NC
Discharges per 1,000 Member Months— Maternity—Total All Ages	2.92	3.07	2.72	-0.35	NC
Average Length of Stay— Maternity—Total All Ages	2.85	2.94	3.01	+0.07	NC
Discharges per 1,000 Member Months— Surgery—Total All Ages	1.71	1.64	1.30	-0.34	NC
Average Length of Stay— Surgery—Total All Ages	5.62	5.41	6.23	+0.82	NC
Discharges per 1,000 Member Months— Medicine—Total All Ages	2.72	2.56	2.13	-0.43	NC
Average Length of Stay— Medicine—Total All Ages	3.62	3.61	4.21	+0.60	NC
Use of Opioids From Multiple	Providers*3				
Multiple Prescribers	21.61%	19.47%	18.70%	-0.77	***
Multiple Pharmacies	4.24%	2.39%	2.23%	-0.16	****
Multiple Prescribers and Multiple Pharmacies	2.43%	1.43%	1.21%	-0.22	****
Use of Opioids at High Dosag	e* ^{,3}				
Use of Opioids at High Dosage*	_	3.20%	3.04%	-0.16	***
Risk of Continued Opioid Use	*, ³			•	
At Least 15 Days Covered— Total	12.41%	9.87%	10.85%	+0.98	*
At Least 31 Days Covered— Total	5.45%	4.62%	5.88%	+1.26**	*
Plan All-Cause Readmissions					
Observed Readmissions— Total*	_	6.34%	7.75%	+1.41**	****
Expected Readmissions— Total*	_	9.97%	9.61%	-0.36	***
O/E Ratio—Total*	_	0.64	0.81	+0.17**	*****



¹HEDIS MY 2019 to HEDIS MY 2020 comparisons were based on a Chi-square test of statistical significance with a p value of < 0.05. MY 2019–MY 2020 Comparisons shaded green with one cross (+) indicate significant improvement from the previous year. MY 2019–MY 2020 Comparisons shaded red with two crosses (++) indicate a significant decline in performance from the previous year.

²HEDIS MY 2020 Performance Levels were based on comparisons of the HEDIS MY 2020 measure indicator rates to national Medicaid Quality Compass HEDIS MY 2019 benchmarks, with the exception of the Plan All-Cause Readmissions measure indicator rates, which were compared to the national Medicaid NCQA Audit Means and Percentiles HEDIS MY 2019 benchmark.

³Due to changes in the technical specifications for this measure, NCQA recommends trending between MY 2020 and prior years be considered with caution.

⁴Due to changes in the technical specifications for this measure, NCQA recommends a break in trending between MY 2020 and prior years; therefore, prior years' rates are not displayed and comparisons to benchmarks are not performed for this measure.

⁵This measure is a first-year measure; therefore, the prior year's rates cannot be displayed and comparisons to benchmarks cannot be performed for this measure as benchmarks are not yet available. ⁶Significance testing was not performed for utilization-based or health plan description measure indicator rates and any Performance Levels for MY 2020 or MY 2019–MY 2020 Comparisons provided for these measures are for information purposes only.

* For this indicator, a lower rate indicates better performance.

— indicates that the rate is not presented in this report as the measure is a first-year measure; therefore, no trending information is available. This symbol may also indicate that NCQA recommended a break in trending; therefore, no prior year rates are displayed.

NC indicates that a comparison is not appropriate, or the measure did not have an applicable benchmark. NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

HEDIS MY 2020 Performance Levels represent the following percentile comparisons:

 $\star \star \star \star = 90$ th percentile and above

 $\star \star \star \star = 75$ th to 89th percentile

- $\star \star \star = 50$ th to 74th percentile
- $\star \star = 25$ th to 49th percentile
- \star = Below 25th percentile



Table B-8—THC Trend Table

Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Child & Adolescent Care					
Childhood Immunization Stat	tus				
Combination 2	64.46%	64.46%	60.34%	-4.12	*
Combination 3	58.94%	58.94%	53.04%	-5.90	*
Combination 4	58.94%	58.94%	53.04%	-5.90	*
Combination 5	49.23%	49.23%	44.53%	-4.70	*
Combination 6	25.83%	25.83%	28.47%	+2.64	*
Combination 7	49.23%	49.23%	44.53%	-4.70	*
Combination 8	25.83%	25.83%	28.47%	+2.64	*
Combination 9	21.85%	21.85%	24.57%	+2.72	*
Combination 10	21.85%	21.85%	24.57%	+2.72	*
Well-Child Visits in the First	30 Months of	Life			
Well-Child Visits in the First 15 Months—Six or More Well-Child Visits ⁴		_	48.82%	NC	NC
Well-Child Visits for Age 15 Months to 30 Months—Two or More Well-Child Visits ⁵	_	_	57.20%	NC	NC
Lead Screening in Children					
Lead Screening in Children	68.43%	68.43%	67.64%	-0.79	**
Child and Adolescent Well-Ca	re Visits ⁴				
Ages 3 to 11 Years	_	_	48.36%	NC	NC
Ages 12 to 17 Years	_		43.70%	NC	NC
Ages 18 to 21 Years	_	_	38.72%	NC	NC
Total	_	_	45.02%	NC	NC
Immunizations for Adolescen	ts		-	· · · ·	
Combination 1 (Meningococcal, Tdap)	84.55%	86.62%	81.75%	-4.87	**
Combination 2 (Meningococcal, Tdap, HPV)	_	38.69%	36.98%	-1.71	***
Follow-Up Care for Children	Prescribed Al	DHD Medicati	on ³		
Initiation Phase	51.78%	56.41%	55.50%	-0.91	*****
Continuation and Maintenance Phase	65.45%	53.66%	62.50%	+8.84	****

Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Women—Adult Care					
Chlamydia Screening in Wom	en				
Ages 16 to 20 Years	67.78%	66.64%	69.37%	+2.73	****
Ages 21 to 24 Years	70.09%	70.60%	72.69%	+2.09	****
Total	68.69%	68.18%	70.82%	+2.64	****
Cervical Cancer Screening ³					
Cervical Cancer Screening	60.89%	65.69%	61.56%	-4.13	***
Breast Cancer Screening ³					
Breast Cancer Screening	54.44%	54.60%	50.62%	-3.98**	*
Access to Care	-	-	•		
Adults' Access to Preventive/A	mbulatory He	ealth Services			
Ages 20 to 44 Years	73.35%	74.44%	69.67%	-4.77**	*
Ages 45 to 64 Years	83.46%	85.45%	82.94%	-2.51++	*
65 Years and Older	87.69%	90.82%	81.87%	-8.95++	*
Total	77.65%	79.31%	74.97%	-4.34**	*
Avoidance of Antibiotic Treat	ment for Acut	e Bronchitis/I	Bronchiolitis		
Ages 3 Months to 17 Years	_	58.75%	64.79%	$+6.04^{+}$	***
Ages 18 to 64 Years		35.71%	39.51%	+3.80	***
Ages 65 Years And Older		NA	NA	NC	NC
Total		45.23%	49.92%	+4.69+	**
Appropriate Testing for Phary	ngitis ³				
Ages 3 to 17 Years	_	67.37%	65.71%	-1.66	*
Ages 18 to 64 Years		47.19%	45.57%	-1.62	*
Ages 65 Years And Older		NA	NA	NC	NC
Total		59.36%	56.49%	-2.87	*
Appropriate Treatment for Up	per Respirato	ry Infection		• •	
Ages 3 Months to 17 Years		90.53%	91.99%	$+1.46^{+}$	***
Ages 18 to 64 Years		71.68%	75.58%	$+3.90^{+}$	***
Ages 65 Years And Older		NA	NA	NC	NC
Total	_	83.99%	86.44%	+2.45+	**
Obesity			•		
Weight Assessment and Coun	seling for Nut	rition and Ph	ysical Activity	for Children/Ad	olescents
Body Mass index (BMI) Percentile—Total ³	86.31%	86.31%	75.91%	-10.40**	**
Counseling for Nutrition— Total	77.26%	77.26%	69.10%	-8.16++	**

2021 HEDIS Aggregate Report for Michigan Medicaid State of Michigan





Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Counseling for Physical Activity—Total	75.28%	75.28%	66.91%	-8.37++	***
Pregnancy Care					
Prenatal and Postpartum Car	e ³				
Timeliness of Prenatal Care	_	85.64%	64.72%	-20.92**	*
Postpartum Care	_	65.94%	53.53%	-12.41**	*
Living With Illness					
Comprehensive Diabetes Care					
Hemoglobin A1c (HbA1c) Testing ³	88.30%	88.30%	77.62%	-10.68++	*
HbA1c Poor Control (>9.0%)* ³	35.10%	35.10%	52.31%	+17.21**	*
<i>HbA1c Control</i> (<8.0%) ³	49.67%	49.67%	40.39%	-9.28++	*
Eye Exam (Retinal) Performed ³	55.85%	55.85%	41.85%	-14.00++	*
Blood Pressure Control (<140/90 mm Hg) ⁴	_	_	47.45%	NC	NC
Kidney Health Evaluation for	Patients With	Diabetes ⁵			
Ages 18 to 64 Years	_	_	28.22%	NC	NC
Ages 65 to 74 Years	_	_	22.95%	NC	NC
Ages 75 to 85 Years	_	_	NA	NC	NC
Total	_	_	28.03%	NC	NC
Asthma Medication Ratio					
Total	51.33%	51.18%	45.68%	-5.50++	*
Controlling High Blood Press	sure⁴				
Controlling High Blood Pressure	_		45.26%	NC	NC
Medical Assistance With Smo	king and Tobe	acco Use Cess	ation		
Advising Smokers and Tobacco Users to Quit	80.43%	86.01%	88.84%	+2.83	*****
Discussing Cessation Medications	60.11%	65.02%	69.51%	+4.49	*****
Discussing Cessation Strategies	47.54%	53.90%	60.09%	+6.19	****
Antidepressant Medication M	anagement				
Effective Acute Phase Treatment	69.46%	73.08%	69.08%	-4.00	*****

Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Effective Continuation Phase Treatment	56.57%	59.50%	56.84%	-2.66	*****
Diabetes Screening for People Medications	With Schizop	ohrenia or Bip	olar Disorder	Who Are Using	Antipsychotic
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications	87.68%	85.33%	82.53%	-2.80	***
Diabetes Monitoring for Peopl	e With Diabe	tes and Schizo	phrenia		
Diabetes Monitoring for People With Diabetes and Schizophrenia	65.43%	61.90%	58.33%	-3.57	*
Cardiovascular Monitoring for	r People With	Cardiovascul	lar Disease an	d Schizophrenia	ı
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia	NA	NA	NA	NC	NC
Adherence to Antipsychotic M	edications for	Individuals V	Vith Schizoph	renia	
Adherence to Antipsychotic Medications for Individuals With Schizophrenia	57.43%	61.02%	53.40%	-7.62	*
Health Plan Diversity ⁵					
Race/Ethnicity Diversity of Me	embership				
Total—White	30.67%	29.70%	29.57%	-0.13	NC
Total—Black or African American	54.84%	53.20%	50.92%	-2.28	NC
Total—American–Indian and Alaska Native	0.25%	0.24%	0.22%	-0.02	NC
Total—Asian	1.12%	0.00%	0.00%	0.00	NC
Total—Native Hawaiian and Other Pacific Islander	0.06%	0.06%	0.08%	+0.02	NC
Total—Some Other Race	2.86%	0.00%	0.00%	0.00	NC
Total—Two or More Races	0.00%	0.00%	0.00%	0.00	NC
Total—Unknown ³	10.19%	4.81%	6.28%	+1.47	NC
Total—Declined ³	0.00%	11.99%	12.94%	+0.95	NC
Total—Hispanic or Latino ³	2.86%	3.05%	3.41%	+0.36	NC



	HEDIS MY	HEDIS MY	HEDIS MY	MY 2019– MY 2020	MY 2020 Performance			
Measure	2018	2019	2020	Comparison ¹	Level ²			
Language Diversity of Membership								
Spoken Language Preferred for Health Care—English	99.10%	82.52%	57.53%	-24.99	NC			
Spoken Language Preferred for Health Care—Non- English	0.89%	0.17%	0.11%	-0.06	NC			
Spoken Language Preferred for Health Care—Unknown	0.01%	17.31%	42.36%	+25.05	NC			
Spoken Language Preferred for Health Care—Declined	0.00%	0.00%	0.00%	0.00	NC			
Language Preferred for Written Materials—English	99.10%	82.52%	57.53%	-24.99	NC			
Language Preferred for Written Materials—Non- English	0.89%	0.17%	0.11%	-0.06	NC			
Language Preferred for Written Materials— Unknown	0.01%	17.31%	42.36%	+25.05	NC			
Language Preferred for Written Materials— Declined	0.00%	0.00%	0.00%	0.00	NC			
Other Language Needs— English	99.10%	82.52%	57.53%	-24.99	NC			
Other Language Needs— Non-English	0.89%	0.17%	0.11%	-0.06	NC			
Other Language Needs— Unknown	0.01%	17.31%	42.36%	+25.05	NC			
Other Language Needs— Declined	0.00%	0.00%	0.00%	0.00	NC			
Utilization ⁶	Utilization ⁶							
Ambulatory Care—Total (Per	1,000 Membe	r Months)						
Emergency Department Visits—Total*	68.80	69.38	47.79	-21.59	***			
Outpatient Visits—Total	339.74	373.79	287.21	-86.58	NC			
Inpatient Utilization—Genera	ıl Hospital/Ac	cute Care—To	tal					
Total Inpatient—Discharges per 1,000 Member Months—Total	9.33	10.34	8.36	-1.98	NC			

Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Total Inpatient—Average Length of Stay—Total	4.41	3.56	3.85	+0.29	NC
Maternity—Discharges per 1,000 Member Months— Total	2.32	2.43	2.16	-0.27	NC
Maternity—Average Length of Stay—Total	2.71	1.86	1.91	+0.05	NC
Surgery—Discharges per 1,000 Member Months— Total	2.12	2.18	1.78	-0.40	NC
Surgery—Average Length of Stay—Total	7.82	6.98	7.01	+0.03	NC
Medicine—Discharges per 1,000 Member Months— Total	5.44	6.29	4.89	-1.40	NC
Medicine—Average Length of Stay—Total	3.63	2.88	3.36	+0.48	NC
Use of Opioids From Multiple	Providers *,3				
Multiple Prescribers	16.77%	15.42%	12.71%	-2.71+	*****
Multiple Pharmacies	6.23%	5.07%	2.48%	-2.59+	****
Multiple Prescribers and Multiple Pharmacies	3.33%	2.37%	1.29%	-1.08+	****
Use of Opioids at High Dosage	9** ³				
Use of Opioids at High Dosage*	_	11.83%	10.57%	-1.26	*
Risk of Continued Opioid Use	*3				
At Least 15 Days Covered— Total	31.83%	29.40%	28.78%	-0.62	*
At Least 31 Days Covered— Total	19.28%	20.95%	19.19%	-1.76	*
Plan All-Cause Readmissions					
Observed Readmissions— Total*	_	10.13%	10.48%	+0.35	**
Expected Readmissions— Total*	—	10.00%	10.01%	+0.01	**
O/E Ratio—Total*	_	1.01	1.05	+0.04**	**



¹HEDIS MY 2019 to HEDIS MY 2020 comparisons were based on a Chi-square test of statistical significance with a p value of < 0.05. MY 2019–2020 Comparisons shaded green with one cross (+) indicate significant improvement from the previous year. MY 2019–2020 Comparisons shaded red with two crosses (++) indicate a significant decline in performance from the previous year.

²*HEDIS MY 2020 Performance Levels were based on comparisons of the HEDIS MY 2020 measure indicator rates to national Medicaid Quality Compass HEDIS MY 2019 benchmarks, with the exception of the Plan All-Cause Readmissions measure indicator rates, which were compared to the national Medicaid NCQA Audit Means and Percentiles HEDIS MY 2019 benchmark.*

³Due to changes in the technical specifications for this measure, NCQA recommends trending between MY 2020 and prior years be considered with caution.

⁴Due to changes in the technical specifications for this measure, NCQA recommends a break in trending between MY 2020 and prior years; therefore, prior years' rates are not displayed and comparisons to benchmarks are not performed for this measure.

⁵This measure is a first-year measure; therefore, the prior year's rates cannot be displayed and comparisons to benchmarks cannot be performed for this measure as benchmarks are not yet available. ⁶Significance testing was not performed for utilization-based or health plan description measure indicator rates and any Performance Levels for MY 2020 or MY 2019–MY 2020 Comparisons provided for these measures are for information purposes only.

* For this indicator, a lower rate indicates better performance.

— indicates that the rate is not presented in this report as the measure is a first-year measure; therefore, no trending information is available. This symbol may also indicate that NCQA recommended a break in trending; therefore, no prior year rates are displayed.

NC indicates that a comparison is not appropriate, or the measure did not have an applicable benchmark. NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

HEDIS MY 2020 Performance Levels represent the following percentile comparisons:

 $\star \star \star \star = 90$ th percentile and above

 $\star \star \star \star = 75$ th to 89th percentile

- $\star \star \star = 50$ th to 74th percentile
- $\star \star = 25$ th to 49th percentile
- \star = Below 25th percentile



Table B-9—UNI Trend Table

Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Child & Adolescent Care					
Childhood Immunization Stat	tus				
Combination 2	71.05%	71.78%	65.21%	-6.57**	*
Combination 3	66.42%	68.13%	61.80%	-6.33	*
Combination 4	63.99%	67.40%	61.07%	-6.33	*
Combination 5	58.15%	57.91%	55.47%	-2.44	*
Combination 6	33.58%	37.71%	32.85%	-4.86	*
Combination 7	56.20%	57.18%	54.74%	-2.44	*
Combination 8	32.36%	37.23%	32.85%	-4.38	*
Combination 9	30.41%	32.85%	29.68%	-3.17	*
Combination 10	29.44%	32.36%	29.68%	-2.68	*
Well-Child Visits in the First	30 Months of	Life			
Well-Child Visits in the First 15 Months—Six or More Well-Child Visits⁴		_	61.25%	NC	NC
Well-Child Visits for Age 15 Months to 30 Months—Two or More Well-Child Visits ⁵			65.10%	NC	NC
Lead Screening in Children					
Lead Screening in Children	75.91%	78.35%	74.70%	-3.65	***
Child and Adolescent Well-Ca	re Visits ^₄				
Ages 3 to 11 Years	_	_	50.09%	NC	NC
Ages 12 to 17 Years	_	_	42.31%	NC	NC
Ages 18 to 21 Years		_	29.19%	NC	NC
Total		_	44.24%	NC	NC
Immunizations for Adolescen	ts				
Combination 1 (Meningococcal, Tdap)	85.16%	85.16%	80.78%	-4.38	**
Combination 2 (Meningococcal, Tdap, HPV)	_	42.34%	38.20%	-4.14	***
Follow-Up Care for Children	Prescribed Al	DHD Medicati	on ³		
Initiation Phase	42.41%	BR	41.20%	NC	**
Continuation and Maintenance Phase	57.02%	BR	54.09%	NC	**

	HEDIS MY	HEDIS MY	HEDIS MY	MY 2019– MY 2020	MY 2020 Performance
Measure	2018	2019	2020	Comparison ¹	Level ²
Women—Adult Care					
Chlamydia Screening in Wom		(1 500/	50.050/	1.00++	
Ages 16 to 20 Years	67.63%	64.73%	59.85%	-4.88**	***
Ages 21 to 24 Years	71.25%	69.61%	64.95%	-4.66**	**
Total	69.09%	66.70%	62.06%	-4.64**	***
Cervical Cancer Screening ³					
Cervical Cancer Screening	64.48%	68.37%	57.66%	-10.71**	**
Breast Cancer Screening ³					
Breast Cancer Screening	61.31%	59.73%	54.30%	-5.43**	**
Access to Care					
Adults' Access to Preventive/A	mbulatory He	ealth Services			
Ages 20 to 44 Years	77.98%	77.80%	73.73%	-4.07**	**
Ages 45 to 64 Years	87.95%	87.89%	84.72%	-3.17++	**
65 Years and Older	95.08%	92.43%	88.25%	-4.18**	**
Total	81.97%	81.79%	77.79%	-4.00++	**
Avoidance of Antibiotic Treat	ment for Acut	e Bronchitis/I	Bronchiolitis		
Ages 3 Months to 17 Years	_	59.47%	60.54%	+1.07	***
Ages 18 to 64 Years	_	36.88%	38.84%	+1.96	***
Ages 65 Years And Older		NA	31.25%	NC	**
Total	_	48.09%	49.38%	+1.29	**
Appropriate Testing for Phar	ngitis ³				
Ages 3 to 17 Years		76.94%	73.31%	-3.63++	*
Ages 18 to 64 Years		52.83%	51.63%	-1.20	*
Ages 65 Years And Older	_	NA	NA	NC	NC
Total		68.81%	65.10%	-3.71**	*
Appropriate Treatment for Up	ner Resnirato		05.1070	-0,71	<u> </u>
Ages 3 Months to 17 Years		90.70%	91.43%	$+0.73^{+}$	**
Ages 18 to 64 Years		72.60%	75.01%	+0.73	**
Ages 65 Years And Older		72.0076 NA	67.80%	+2.41 NC	**
Total		86.03%	86.75%	$+0.72^{+}$	**
		00.0370	00./370	+0.72	× ×
Obesity Weight Assessment and Court	a din a fan N	uition and DI.	union Anticita	for Children / A 1	alasaants
Weight Assessment and Coun	seung jor Nut	rition and Ph	vsical Activity	for Children/Add	viescents
Body Mass index (BMI) Percentile—Total ³	86.37%	89.29%	82.48%	-6.81**	***
Counseling for Nutrition— Total	81.27%	81.27%	73.72%	-7.55**	***

2021 HEDIS Aggregate Report for Michigan Medicaid State of Michigan





Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Counseling for Physical Activity—Total	77.13%	79.81%	71.29%	-8.52++	***
Pregnancy Care					
Prenatal and Postpartum Car	e ³				
Timeliness of Prenatal Care	_	86.86%	78.83%	-8.03++	*
Postpartum Care	_	75.18%	71.78%	-3.40	**
Living With Illness					
Comprehensive Diabetes Care					
Hemoglobin A1c (HbA1c) Testing ³	91.51%	91.51%	83.21%	-8.30++	*
HbA1c Poor Control (>9.0%)* ³	29.63%	29.63%	34.79%	+5.16	***
<i>HbA1c Control</i> (<8.0%) ³	60.80%	60.80%	54.26%	-6.54++	***
Eye Exam (Retinal) Performed ³	61.27%	61.27%	55.23%	-6.04	**
Blood Pressure Control (<140/90 mm Hg)⁴	_	_	63.75%	NC	NC
Kidney Health Evaluation for	Patients With	Diabetes ⁵			
Ages 18 to 64 Years	—	_	35.65%	NC	NC
Ages 65 to 74 Years	_		35.70%	NC	NC
Ages 75 to 85 Years	_		40.96%	NC	NC
Total	_	_	35.69%	NC	NC
Asthma Medication Ratio					
Total	62.94%	62.58%	61.08%	-1.50	**
Controlling High Blood Press	sure ³				
Controlling High Blood Pressure	_		62.53%	NC	NC
Medical Assistance With Smo	king and Tobe	acco Use Cess	ntion		
Advising Smokers and Tobacco Users to Quit	84.33%	85.02%	80.79%	-4.23	***
Discussing Cessation Medications	63.16%	63.05%	60.12%	-2.93	****
Discussing Cessation Strategies	55.30%	57.14%	52.02%	-5.12	***
Antidepressant Medication M	anagement				
Effective Acute Phase Treatment	52.99%	56.04%	54.48%	-1.56	***

Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Effective Continuation Phase Treatment	36.51%	39.44%	38.21%	-1.23	***
Diabetes Screening for People Medications	With Schizop	ohrenia or Bip	oolar Disorder	Who Are Using	Antipsychotic
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications	86.71%	87.12%	80.12%	-7.00**	**
Diabetes Monitoring for Peopl	e With Diabe	tes and Schizo	phrenia		
Diabetes Monitoring for People With Diabetes and Schizophrenia	74.24%	69.46%	61.61%	-7.85**	*
Cardiovascular Monitoring fo	r People With	Cardiovascu	lar Disease an	d Schizophrenia	1
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia	79.69%	73.21%	67.86%	-5.35	*
Adherence to Antipsychotic M	edications for	Individuals	With Schizoph	renia	
Adherence to Antipsychotic Medications for Individuals With Schizophrenia	60.25%	57.61%	65.78%	+8.17+	***
Health Plan Diversity ⁵					
Race/Ethnicity Diversity of Me	embership				
Total—White	51.15%	50.75%	50.57%	-0.18	NC
Total—Black or African American	30.36%	30.35%	29.76%	-0.59	NC
Total—American–Indian and Alaska Native	0.28%	0.31%	0.30%	-0.01	NC
Total—Asian	1.89%	2.23%	3.38%	+1.15	NC
Total—Native Hawaiian and Other Pacific Islander	0.08%	0.08%	0.08%	0.00	NC
Total—Some Other Race	0.00%	0.00%	0.00%	0.00	NC
Total—Two or More Races	0.00%	0.00%	0.00%	0.00	NC
Total—Unknown ³	16.24%	16.28%	15.90%	-0.38	NC
Total—Declined ³	0.00%	0.00%	0.00%	0.00	NC
Total—Hispanic or Latino ³	5.90%	6.14%	6.34%	+0.20	NC



	HEDIS MY	HEDIS MY	HEDIS MY	MY 2019– MY 2020	MY 2020 Performance				
Measure	2018	2019	2020	Comparison ¹	Level ²				
Language Diversity of Membership									
Spoken Language Preferred for Health Care—English	95.23%	96.02%	96.13%	+0.11	NC				
Spoken Language Preferred for Health Care—Non- English	4.71%	3.94%	3.86%	-0.08	NC				
Spoken Language Preferred for Health Care—Unknown	0.06%	0.04%	0.01%	-0.03	NC				
Spoken Language Preferred for Health Care—Declined	0.00%	0.00%	0.00%	0.00	NC				
Language Preferred for Written Materials—English	95.23%	96.02%	96.13%	+0.11	NC				
Language Preferred for Written Materials—Non- English	4.71%	3.94%	3.86%	-0.08	NC				
Language Preferred for Written Materials— Unknown	0.06%	0.04%	0.01%	-0.03	NC				
Language Preferred for Written Materials— Declined	0.00%	0.00%	0.00%	0.00	NC				
Other Language Needs— English	95.23%	96.02%	96.13%	+0.11	NC				
Other Language Needs— Non-English	4.71%	3.94%	3.86%	-0.08	NC				
Other Language Needs— Unknown	0.06%	0.04%	0.01%	-0.03	NC				
Other Language Needs— Declined	0.00%	0.00%	0.00%	0.00	NC				
Utilization ⁶									
Ambulatory Care—Total (Per	1,000 Membe	er Months)	-	-					
Emergency Department Visits—Total*	66.48	65.10	46.01	-19.09	****				
Outpatient Visits—Total	371.07	374.36	315.19	-59.17	NC				
Inpatient Utilization—Genera	ıl Hospital/Ac	cute Care—To	tal						
Total Inpatient—Discharges per 1,000 Member Months—Total	5.62	5.68	5.29	-0.39	NC				

Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²				
Total Inpatient—Average Length of Stay—Total	4.56	4.63	4.70	+0.07	NC				
Maternity—Discharges per 1,000 Member Months— Total	2.51	2.53	2.27	-0.26	NC				
Maternity—Average Length of Stay—Total	2.63	2.60	2.46	-0.14	NC				
Surgery—Discharges per 1,000 Member Months— Total	1.30	1.40	1.19	-0.21	NC				
Surgery—Average Length of Stay—Total	7.42	7.61	8.02	+0.41	NC				
Medicine—Discharges per 1,000 Member Months— Total	2.50	2.44	2.41	-0.03	NC				
Medicine—Average Length of Stay—Total	4.46	4.45	4.61	+0.16	NC				
Use of Opioids From Multiple	Providers *,3								
Multiple Prescribers	18.82%	15.67%	14.38%	-1.29+	****				
Multiple Pharmacies	4.88%	3.21%	2.00%	-1.21+	****				
Multiple Prescribers and Multiple Pharmacies	2.58%	1.64%	1.17%	-0.47*	****				
Use of Opioids at High Dosage	9* ³								
Use of Opioids at High Dosage*	—	3.60%	2.90%	-0.70+	****				
Risk of Continued Opioid Use	*3								
At Least 15 Days Covered— Total	20.54%	15.82%	9.87%	-5.95 ⁺	*				
At Least 31 Days Covered— Total	7.88%	7.14%	6.80%	-0.34	*				
Plan All-Cause Readmissions									
Observed Readmissions— Total*	_	11.39%	12.05%	+0.66	*				
Expected Readmissions— Total*	_	10.69%	10.77%	+0.08	*				
O/E Ratio—Total*		1.06	1.12	+0.06++	*				



¹HEDIS MY 2020 to HEDIS MY 2019 comparisons were based on a Chi-square test of statistical significance with a p value of < 0.05. MY 2019–MY 2020 Comparisons shaded green with one cross (+) indicate significant improvement from the previous year. MY 2019–MY 2020 Comparisons shaded red with two crosses (++) indicate a significant decline in performance from the previous year.

²HEDIS MY 2020 Performance Levels were based on comparisons of the HEDIS MY 2020 measure indicator rates to national Medicaid Quality Compass HEDIS MY 2019 benchmarks, with the exception of the Plan All-Cause Readmissions measure indicator rates, which were compared to the national Medicaid NCQA Audit Means and Percentiles HEDIS MY 2019 benchmark.

³Due to changes in the technical specifications for this measure, NCQA recommends trending between MY 2020 and prior years be considered with caution.

⁴Due to changes in the technical specifications for this measure, NCQA recommends a break in trending between MY 2020 and prior years; therefore, prior years' rates are not displayed and comparisons to benchmarks are not performed for this measure.

⁵This measure is a first-year measure; therefore, the prior year's rates cannot be displayed and comparisons to benchmarks cannot be performed for this measure as benchmarks are not yet available. ⁶Significance testing was not performed for utilization-based or health plan description measure indicator rates and any Performance Levels for MY 2020 or MY 2019–MY 2020 Comparisons provided for these measures are for information purposes only.

* For this indicator, a lower rate indicates better performance.

— indicates that the rate is not presented in this report as the measure is a first-year measure; therefore, no trending information is available. This symbol may also indicate that NCQA recommended a break in trending; therefore, no prior year rates are displayed.

NC indicates that a comparison is not appropriate, or the measure did not have an applicable benchmark. NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

BR indicates that the *MHP*'s reported rate was invalid; therefore, the rate is not presented. *HEDIS MY 2020 Performance Levels represent the following percentile comparisons:*

 $\star \star \star \star \star = 90$ th percentile and above

 $\star \star \star \star = 75$ th to 89th percentile

 $\star \star \star = 50$ th to 74th percentile

- $\star \star = 25$ th to 49th percentile
- \star = Below 25th percentile



Table B-10—UPP Trend Table MY 2019-MY 2020 HEDIS MY HEDIS MY MY 2020 HEDIS MY Performance Measure 2018 2019 2020 **Comparison**¹ Level² Child & Adolescent Care **Childhood Immunization Status** 71.93% 75.43% Combination 2 68.36% -7.07+ * Combination 3 69.23% 70.07% 66.08% -3.99 * Combination 4 67.78% 68.86% 64.52% -4.34 * Combination 5 55.30% 58.88% 55.08% -3.80 * Combination 6 44.91% 46.23% 45.02% -1.21 *** * Combination 7 54.68% 57.91% 53.94% -3.97 Combination 8 44.70% 45.74% 44.40% -1.34 *** *** Combination 9 37.94% 40.88% 39.83% -1.05 Combination 10 37.84% 40.63% -1.42 *** 39.21% Well-Child Visits in the First 30 Months of Life Well-Child Visits in the First 15 Months—Six or 70.27% NC NC ____ ____ More Well-Child Visits⁴ Well-Child Visits for Age 15 Months to 30 Months—Two 73.13% NC NC ____ ____ or More Well-Child Visits⁵ Lead Screening in Children Lead Screening in Children 82.00% 79.23% 74.48% -4.75⁺ *** Child and Adolescent Well-Care Visits⁴ Ages 3 to 11 Years 50.87% NC NC ____ ____ Ages 12 to 17 Years 43.87% NC NC Ages 18 to 21 Years 22.41% NC NC ____ _ Total 44.29% NC NC Immunizations for Adolescents Combination 1 80.97% 77.32% 80.72% +3.40** (Meningococcal, Tdap) Combination 2 35.07% 34.93% (Meningococcal, Tdap, ____ -0.14 ** HPV) Follow-Up Care for Children Prescribed ADHD Medication³ Initiation Phase 49.62% 47.77% 50.42% +2.65**** Continuation and 53.92% 58.76% 62.20% +3.44**** Maintenance Phase

	HEDIS MY	HEDIS MY	HEDIS MY	MY 2019– MY 2020	MY 2020 Performance
Measure	2018	2019	2020	Comparison ¹	Level ²
Women—Adult Care					
Chlamydia Screening in Wom	en				
Ages 16 to 20 Years	43.19%	46.00%	41.01%	-4.99**	*
Ages 21 to 24 Years	53.78%	55.87%	49.82%	-6.05++	*
Total	47.86%	50.29%	44.89%	-5.40++	*
Cervical Cancer Screening ³					
Cervical Cancer Screening	65.21%	64.96%	58.15%	-6.81 ⁺⁺	**
Breast Cancer Screening ³					
Breast Cancer Screening	65.42%	64.85%	61.87%	-2.98++	***
Access to Care					
Adults' Access to Preventive/A	mbulatory He	ealth Services			
Ages 20 to 44 Years	82.16%	81.08%	78.29%	-2.79**	**
Ages 45 to 64 Years	88.60%	87.99%	85.12%	-2.87**	**
65 Years and Older	94.91%	94.93%	92.68%	-2.25++	****
Total	85.65%	84.69%	81.72%	-2.97**	***
Avoidance of Antibiotic Treat	ment for Acut	e Bronchitis/I	Bronchiolitis		
Ages 3 Months to 17 Years	_	58.03%	64.64%	+6.61	***
Ages 18 to 64 Years	_	31.94%	36.47%	+4.53	**
Ages 65 Years And Older		NA	NA	NC	NC
Total	_	42.62%	47.53%	$+4.91^{+}$	**
Appropriate Testing for Phary	ngitis ³			1	
Ages 3 to 17 Years		78.22%	79.18%	+0.96	**
Ages 18 to 64 Years		68.24%	71.84%	+3.60	***
Ages 65 Years And Older		NA	NA	NC	NC
Total		74.41%	76.40%	+1.99	**
Appropriate Treatment for Up	per Respirato				
Ages 3 Months to 17 Years	_	89.64%	91.43%	$+1.79^{+}$	**
Ages 18 to 64 Years		83.16%	83.13%	-0.03	****
Ages 65 Years And Older		80.00%	NA	NC	NC
Total		87.63%	88.72%	+1.09	***
Obesity		0,.0070	00.7270	1109	000
Weight Assessment and Coun	seling for Nut	rition and Ph	vsical Activity	for Children/Ad	olescents
BMI Percentile Documentation—Total ³	92.21%	89.29%	88.08%	-1.21	****
Counseling for Nutrition— Total	69.83%	69.59%	72.99%	+3.40	***

APPENDIX B. TREND TABLES





Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Counseling for Physical Activity—Total	66.42%	69.10%	69.59%	+0.49	***
Pregnancy Care					
Prenatal and Postpartum Car	e ³				
Timeliness of Prenatal Care	_	92.46%	91.24%	-1.22	***
Postpartum Care	_	90.27%	87.59%	-2.68	*****
Living With Illness					
Comprehensive Diabetes Care	!				
Hemoglobin A1c (HbA1c) Testing ³	92.21%	92.70%	87.59%	-5.11++	**
HbA1c Poor Control (>9.0%)* ³	21.90%	24.57%	29.93%	+5.36	****
<i>HbA1c Control (</i> <8.0%) ³	63.50%	61.07%	57.42%	-3.65	****
Eye Exam (Retinal) Performed ³	70.32%	70.56%	61.07%	-9.49++	***
Blood Pressure Control (<140/90 mm Hg) ³	_		78.35%	NC	NC
Kidney Health Evaluation for	Patients With	Diabetes ⁵			
Ages 18 to 64 Years	_		34.80%	NC	NC
Ages 65 to 74 Years	_	_	38.66%	NC	NC
Ages 75 to 85 Years	_	_	27.78%	NC	NC
Total	_		34.97%	NC	NC
Asthma Medication Ratio					
Total	63.06%	62.33%	58.42%	-3.91	**
Controlling High Blood Press	sure ³				
Controlling High Blood Pressure	_		73.24%	NC	NC
Medical Assistance With Smo	king and Tob	acco Use Cess	ation		
Advising Smokers and Tobacco Users to Quit	77.22%	79.96%	76.50%	-0.46	***
Discussing Cessation Medications	56.42%	59.96%	63.00%	+3.04	****
Discussing Cessation Strategies	49.09%	54.65%	56.03%	+1.38	****
Antidepressant Medication M	anagement				
Effective Acute Phase Treatment	59.54%	55.85%	62.13%	+6.28+	****

Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Effective Continuation Phase Treatment	44.15%	40.30%	44.50%	+4.20	****
Diabetes Screening for People Medications	With Schizop	ohrenia or Bip	olar Disorder	Who Are Using	Antipsychotic
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications	88.87%	87.08%	85.06%	-2.02	****
Diabetes Monitoring for Peopl	e With Diabe	tes and Schizo	phrenia		
Diabetes Monitoring for People With Diabetes and Schizophrenia	84.15%	81.25%	82.35%	+1.10	*****
Cardiovascular Monitoring fo	r People With	Cardiovascul	lar Disease an	d Schizophrenia	ı
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia	NA	NA	NA	NC	NC
Adherence to Antipsychotic M	edications for	Individuals V	Vith Schizoph	renia	
Adherence to Antipsychotic Medications for Individuals With Schizophrenia	83.38%	81.84%	84.72%	+2.88	*****
Health Plan Diversity ⁵		-	-		
Race/Ethnicity Diversity of Me	embership				
Total—White	87.85%	86.34%	87.12%	+0.78	NC
Total—Black or African American	1.48%	1.46%	1.66%	+0.20	NC
Total—American–Indian and Alaska Native	2.43%	2.34%	2.67%	+0.33	NC
Total—Asian	0.24%	2.07%	0.44%	-1.63	NC
Total—Native Hawaiian and Other Pacific Islander	0.07%	0.11%	0.13%	+0.02	NC
Total—Some Other Race	1.68%	1.92%	2.08%	+0.16	NC
Total—Two or More Races	0.00%	0.00%	0.00%	0.00	NC
Total—Unknown ³	0.00%	0.00%	0.00%	0.00	NC
Total—Declined ³	6.25%	5.76%	5.90%	+0.14	NC
Total—Hispanic or Latino ³	1.68%	1.92%	2.08%	+0.16	NC



Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²				
Language Diversity of Membership									
Spoken Language Preferred for Health Care—English	99.93%	99.90%	99.90%	0.00	NC				
Spoken Language Preferred for Health Care—Non- English	0.04%	0.07%	0.07%	0.00	NC				
Spoken Language Preferred for Health Care—Unknown	0.02%	0.02%	0.03%	+0.01	NC				
Spoken Language Preferred for Health Care—Declined	0.00%	0.00%	0.00%	0.00	NC				
Language Preferred for Written Materials—English	99.93%	99.90%	99.90%	0.00	NC				
Language Preferred for Written Materials—Non- English	0.04%	0.07%	0.07%	0.00	NC				
Language Preferred for Written Materials— Unknown	0.02%	0.02%	0.03%	+0.01	NC				
Language Preferred for Written Materials— Declined	0.00%	0.00%	0.00%	0.00	NC				
Other Language Needs— English	0.00%	0.00%	0.00%	0.00	NC				
Other Language Needs— Non-English	0.00%	0.00%	0.00%	0.00	NC				
Other Language Needs— Unknown	100.00%	100.00%	100.00%	0.00	NC				
Other Language Needs— Declined	0.00%	0.00%	0.00%	0.00	NC				
Utilization ⁶									
Ambulatory Care—Total (Per	1,000 Membe	er Months)	I.						
Emergency Department Visits—Total*	52.04	54.01	42.87	-11.14	****				
Outpatient Visits—Total	307.10	351.79	317.54	-34.25	NC				
Inpatient Utilization—Genera	ıl Hospital/Ac	cute Care—To	tal						
Total Inpatient—Discharges per 1,000 Member Months—Total	5.34	7.06	6.20	-0.86	NC				

Measure	HEDIS MY 2018	HEDIS MY 2019	HEDIS MY 2020	MY 2019– MY 2020 Comparison ¹	MY 2020 Performance Level ²
Total Inpatient—Average Length of Stay—Total	3.80	4.08	4.41	+0.33	NC
Maternity—Discharges per 1,000 Member Months— Total	2.22	2.13	2.01	-0.12	NC
Maternity—Average Length of Stay—Total	2.93	2.80	2.75	-0.05	NC
Surgery—Discharges per 1,000 Member Months— Total	1.65	2.25	1.83	-0.42	NC
Surgery—Average Length of Stay—Total	5.60	5.71	6.46	+0.75	NC
Medicine—Discharges per 1,000 Member Months— Total	2.08	3.26	2.88	-0.38	NC
Medicine—Average Length of Stay—Total	3.05	3.56	3.96	+0.40	NC
Use of Opioids From Multiple	Providers *,3	-			
Multiple Prescribers	15.85%	15.76%	16.04%	+0.28	****
Multiple Pharmacies	6.53%	6.33%	6.41%	+0.08	**
Multiple Prescribers and Multiple Pharmacies	4.16%	4.24%	4.77%	+0.53	*
Use of Opioids at High Dosage	9** ³				
Use of Opioids at High Dosage*	_	3.51%	3.33%	-0.18	***
Risk of Continued Opioid Use	*3				
At Least 15 Days Covered— Total	13.07%	7.95%	9.27%	+1.32	**
At Least 31 Days Covered— Total	5.72%	4.38%	5.43%	+1.05++	*
Plan All-Cause Readmissions					
Observed Readmissions— Total*	_	8.40%	9.38%	+0.98	***
Expected Readmissions— Total*	_	9.82%	9.97%	+0.15	**
O/E Ratio—Total*		0.86	0.94	+0.08++	***



¹HEDIS MY 2019 to HEDIS MY 2020 comparisons were based on a Chi-square test of statistical significance with a p value of < 0.05. MY 2019–MY 2020 Comparisons shaded green with one cross (+) indicate significant improvement from the previous year. MY 2019–MY 2020 Comparisons shaded red with two crosses (++) indicate a significant decline in performance from the previous year.

²HEDIS MY 2020 Performance Levels were based on comparisons of the HEDIS MY 2020 measure indicator rates to national Medicaid Quality Compass HEDIS MY 2019 benchmarks, with the exception of the Plan All-Cause Readmissions measure indicator rates, which were compared to the national Medicaid NCQA Audit Means and Percentiles HEDIS MY 2019 benchmark.

³Due to changes in the technical specifications for this measure, NCQA recommends trending between MY 2020 and prior years be considered with caution.

⁴Due to changes in the technical specifications for this measure, NCQA recommends a break in trending between MY 2020 and prior years; therefore, prior years' rates are not displayed and comparisons to benchmarks are not performed for this measure.

⁵This measure is a first-year measure; therefore, the prior year's rates cannot be displayed and comparisons to benchmarks cannot be performed for this measure as benchmarks are not yet available. ⁶Significance testing was not performed for utilization-based or health plan description measure indicator rates and any Performance Levels for MY 2020 or MY 2019–MY 2020 Comparisons provided for these measures are for information purposes only.

* For this indicator, a lower rate indicates better performance.

— indicates that the rate is not presented in this report as the measure is a first-year measure; therefore, no trending information is available. This symbol may also indicate that NCQA recommended a break in trending; therefore, no prior year rates are displayed.

NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

NC indicates that a comparison is not appropriate, or the measure did not have an applicable benchmark. *HEDIS MY 2020 Performance Levels represent the following percentile comparisons:*

 $\star \star \star \star = 90$ th percentile and above

 $\star \star \star \star = 75$ th to 89th percentile

- $\star \star \star = 50$ th to 74th percentile
- $\star \star = 25$ th to 49th percentile
- \star = Below 25th percentile



Appendix C. Performance Summary Stars

Introduction

This section presents the MHPs' performance summary stars for each measure within the following measure domains:

- Child & Adolescent Care
- Women—Adult Care
- Access to Care
- Obesity
- Living With Illness
- Utilization

Performance ratings were assigned by comparing the MHPs' HEDIS MY 2020 rates to the HEDIS MY 2019 MWA Quality Compass national Medicaid benchmarks (from ***** representing *Poor Performance* to ******** representing *Excellent Performance*). Please note, HSAG assigned performance ratings to all but one measure in the Utilization measure domain, *Plan All-Cause Readmissions*. Please refer to Appendix B for comparisons to national percentiles for *Plan All-Cause Readmissions*. Measures in the Health Plan Diversity domain and the remaining utilization-based measure rates were not evaluated based on comparisons to national benchmarks; however, rates for these measure indicators are presented in Appendix B. Due to changes in the technical specifications for Well-Child Visits in the First 30 Months of Life—Six or More Well-Child Visits, Child and Adolescent Well-Care Visits, Comprehensive Diabetes Care—Blood Pressure Control (<140/90 mm Hg), Controlling High Blood Pressure in HEDIS MY 2020, NCQA does not recommend comparing these measures' rates to national Medicaid benchmarks; therefore, these measures are not displayed in this appendix. Additional details about the performance comparisons and star ratings are found in Section 2.



Child & Adolescent Care Performance Summary Stars

МНР	Childhood Immunization Status— Combination 2	Childhood Immunization Status— Combination 3	Childhood Immunization Status— Combination 4	Childhood Immunization Status— Combination 5	Childhood Immunization Status— Combination 6	Childhood Immunization Status— Combination 7
AET	*	*	*	*	*	*
BCC	*	*	*	*	**	*
HAP	*	*	*	*	*	*
MCL	*	*	*	*	**	*
MER	*	*	*	**	**	**
MOL	**	**	**	**	**	**
PRI	***	***	****	****	****	****
THC	*	*	*	*	*	*
UNI	*	*	*	*	*	*
UPP	*	*	*	*	***	*

Table C-1—Child & Adolescent Care Performance Summary Stars (Table 1 of 3)



мнр	Childhood Immunization Status— Combination 8	Childhood Immunization Status— Combination 9	Childhood Immunization Status— Combination 10	Lead Screening in Children	Immunizations for Adolescents— Combination 1 (Meningococcal, Tdap)	Immunizations for Adolescents— Combination 2 (Meningococcal, Tdap, HPV)
AET	*	*	*	*	**	***
BCC	**	**	**	**	**	**
НАР	*	*	*	*	*	*
MCL	**	**	**	***	**	*
MER	**	**	**	***	***	**
MOL	**	**	**	**	***	***
PRI	****	****	****	***	****	****
THC	*	*	*	**	**	***
UNI	*	*	*	***	**	***
UPP	***	***	***	***	**	**

Table C-2—Child & Adolescent Care Performance Summary Stars (Table 2 of 3)



МНР	Follow-Up Care for Children Prescribed ADHD Medication— Initiation Phase	Follow-Up Care for Children Prescribed ADHD Medication— Continuation and Maintenance Phase
AET	*	*
BCC	****	****
HAP	NA	NA
MCL	****	***
MER	***	***
MOL	****	****
PRI	**	*
THC	****	****
UNI	**	**
UPP	****	****

Table C-3—Child & Adolescent Care Performance Summary Stars (Table 3 of 3)

NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.





Women—Adult Care Performance Summary Stars

МНР	Chlamydia Screening in Women—Ages 16 to 20 Years	Chlamydia Screening in Women—Ages 21 to 24 Years	Chlamydia Screening in Women—Total	Cervical Cancer Screening	Breast Cancer Screening
AET	***	**	***	*	*
BCC	***	**	***	**	**
НАР	**	**	**	*	**
MCL	**	**	**	**	**
MER	***	**	***	**	**
MOL	***	***	***	***	**
PRI	***	**	***	****	****
THC	****	****	****	***	*
UNI	***	**	***	**	**
UPP	*	*	*	**	***

Table C-4—Women—Adult Care Performance Summary Stars



Access to Care Performance Summary Stars

МНР	Adults' Access to Preventive⁄ Ambulatory Health Services—Ages 20 to 44 Years	Adults' Access to Preventive/ Ambulatory Health Services—Ages 45 to 64 Years	Adults' Access to Preventive⁄ Ambulatory Health Services—Ages 65 Years and Older	Adults' Access to Preventive⁄ Ambulatory Health Services—Total	Avoidance of Antibiotic Treatment for Acute Bronchitis Bronchiolitis—Ages 3 Months to 17 Years	Avoidance of Antibiotic Treatment for Acute Bronchitis Bronchiolitis—Ages 18 to 64 Years
AET	*	*	**	*	***	****
BCC	**	*	*	**	***	***
HAP	*	*	**	*	****	***
MCL	**	**	*	*	***	***
MER	**	**	**	**	***	***
MOL	**	**	***	**	**	***
PRI	**	**	***	**	****	****
THC	*	*	*	*	***	***
UNI	**	**	**	**	***	***
UPP	**	**	****	***	***	**

Table C-5—Access to Care Performance Summary Stars (Table 1 of 3)



МНР	Avoidance of Antibiotic Treatment for Acute Bronchitis Bronchiolitis—Ages 65 Years And Older	Avoidance of Antibiotic Treatment for Acute Bronchitis Bronchiolitis — Total	Appropriate Testing for Pharyngitis—Ages 3 to 17 Years	Appropriate Testing for Pharyngitis—Ages 18 to 64 Years	Appropriate Testing for Pharyngitis—Ages 65 Years And Older	Appropriate Testing for Pharyngitis—Total
AET	**	**	*	*	NA	*
BCC	NA	**	*	*	NA	*
HAP	**	**	*	*	NA	*
MCL	NA	**	**	***	NA	**
MER	**	**	**	**	NA	**
MOL	*	**	*	*	***	*
PRI	NA	****	**	***	NA	**
THC	NA	**	*	*	NA	*
UNI	**	**	*	*	NA	*
UPP	NA	**	**	***	NA	**

Table C-6—Access to Care Performance Summary Stars (Table 2 of 3)

NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.



МНР	Appropriate Treatment for Upper Respiratory Infection—Ages 3 Months to 17 Years	Appropriate Treatment for Upper Respiratory Infection—Ages 18 to 64 Years	Appropriate Treatment for Upper Respiratory Infection—Ages 65 Years And Older	Appropriate Treatment for Upper Respiratory Infection—Total
AET	**	***	**	**
BCC	***	***	NA	**
НАР	***	***	***	*
MCL	**	***	NA	**
MER	***	***	****	***
MOL	**	***	*	**
PRI	****	****	****	****
THC	***	***	NA	**
UNI	**	**	**	**
UPP	**	****	NA	***

Table C-7—Access to Care Performance Summary Stars (Table 3 of 3)

NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.



Obesity Performance Summary Stars

МНР	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents— BMI Percentile Documentation— Total	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents— Counseling for Nutrition—Total	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents— Counseling for Physical Activity—Total
AET	**	***	***
BCC	**	**	**
HAP	***	**	***
MCL	*	*	*
MER	**	**	***
MOL	**	**	***
PRI	****	****	****
THC	**	**	***
UNI	***	***	***
UPP	****	***	***

Table C-8—Obesity Performance Summary Stars



Pregnancy Care Performance Summary Stars

МНР	Prenatal and Postpartum Care— Timeliness of Prenatal Care	Prenatal and Postpartum Care— Postpartum Care
AET	*	*
BCC	*	*
HAP	*	*
MCL	*	*
MER	*	*
MOL	*	*
PRI	**	***
THC	*	*
UNI	*	**
UPP	***	****

Table C-9—Pregnancy Care Performance Summary Stars



Living With Illness Performance Summary Stars

МНР	Comprehensive Diabetes Care— Hemoglobin A1c (HbA1c) Testing	Comprehensive Diabetes Care— HbA1c Poor Control (>9.0%)	Comprehensive Diabetes Care— HbA1c Control (<8.0%)	Comprehensive Diabetes Care— Eye Exam (Retinal) Performed
AET	*	*	*	*
BCC	*	**	**	***
HAP	*	*	**	*
MCL	*	*	*	**
MER	*	**	**	*
MOL	*	**	*	**
PRI	***	****	****	***
THC	*	*	*	*
UNI	*	***	***	**
UPP	**	****	****	***

Table C-10—Living With Illness Performance Summary Stars (Table 1 of 3)



мнр	Asthma Medication Ratio—Total	Medical Assistance With Smoking and Tobacco Use Cessation— Advising Smokers and Tobacco Users to Quit	Medical Assistance With Smoking and Tobacco Use Cessation— Discussing Cessation Medications	Medical Assistance With Smoking and Tobacco Use Cessation— Discussing Cessation Strategies	Antidepressant Medication Management— Effective Acute Phase Treatment	Antidepressant Medication Management— Effective Continuation Phase Treatment
AET	*	***	***	***	**	**
BCC	*	***	***	***	****	****
НАР	*	**	***	***	****	****
MCL	*	*	**	**	****	****
MER	**	**	***	**	**	*
MOL	*	*	***	***	****	****
PRI	****	***	***	***	****	****
THC	*	****	****	****	****	****
UNI	**	***	****	***	***	***
UPP	**	***	****	****	****	****

Table C-11—Living With Illness Performance Summary Stars (Table 2 of 3)



МНР	Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications	Diabetes Monitoring for People With Diabetes and Schizophrenia	Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia	Adherence to Antipsychotic Medications for Individuals With Schizophrenia
AET	*	*	NA	***
BCC	**	*	NA	**
HAP	*	*	NA	***
MCL	*	*	*	****
MER	**	*	*	****
MOL	*	*	*	****
PRI	**	*	NA	****
THC	***	*	NA	*
UNI	**	*	*	***
UPP	****	****	NA	****

NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.



Utilization Performance Summary Stars

МНР	Ambulatory Care— Total (Per 1,000 Member Months)— Emergency Department Visits—Total	Use of Opioids From Multiple Providers— Multiple Prescribers	Use of Opioids From Multiple Providers— Multiple Pharmacies	Use of Opioids From Multiple Providers— Multiple Prescribers and Multiple Pharmacies	Use of Opioids at High Dosage	Risk of Continued Opioid Use—At Least 15 Days Covered—Total
AET	***	****	***	***	****	*
BCC	****	****	****	***	****	**
HAP	***	****	***	****	****	*
MCL	***	****	****	****	****	*
MER	****	****	***	***	****	**
MOL	****	****	****	***	****	*
PRI	***	***	****	****	***	*
THC	***	****	****	****	*	*
UNI	****	****	****	****	****	*
UPP	****	****	**	*	***	**

Table C-13—Utilization Performance Summary Stars (Table 1 of 2)¹

¹A lower rate may indicate more favorable performance for this measure indicator (i.e., low rates of ED services may indicate better utilization of services). Therefore, percentiles were reversed to align with performance (e.g., the 10th percentile [a lower rate] was inverted to become the 90th percentile, indicating better performance).



МНР	Risk of Continued Opioid Use—At Least 31 Days Covered—Total	Plan All-Cause Readmissions— Observed Readmissions— Total	Plan All-Cause Readmissions— Expected Readmissions— Total	Plan All-Cause Readmissions— O/E Ratio—Total
AET	*	*	**	*
BCC	*	**	**	**
HAP	*	*	**	*
MCL	*	***	**	***
MER	*	***	***	****
MOL	*	***	**	***
PRI	*	****	***	****
THC	*	**	**	**
UNI	*	*	*	*
UPP	*	***	**	***

Table C-14—Utilization Performance Summary Stars (Table 2 of 2)¹

¹A lower rate may indicate more favorable performance for this measure indicator (i.e., low rates of ED services may indicate better utilization of services). Therefore, percentiles were reversed to align with performance (e.g., the 10th percentile [a lower rate] was inverted to become the 90th percentile, indicating better performance).